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Résumé en français 
 
Contexte du projet et motivation 
La thrombine, aussi connue sous le nom  "facteur de coagulation II", est synthétisée 
dans le foie sous forme de zymogène: la prothrombine (ou FII), qui, une fois relâchée, est 
clivée, en exposant ses domaines et en activant ses fonctions (FIIa). Sa fonction la plus 
connue et la plus importante est celle de de catalyseur de la formation de fibrine qui 
constituera le caillot, d'activateur d'autres facteurs pro-coagulants mais également de 
déclencheur d'enzymes anti-coagulantes8. 
L'activation de la thrombine est le résultat de la cascade de coagulation à laquelle 
participent de nombreuses protéines (Tableau 1.1, page 6) s'activant les unes les autres 
(Figure 1.2., page 7). Le début de la coagulation a lieu quand le facteur tissulaire (TF) est 
exposé au sang, à cause d'une lésion des vaisseaux. Ensuite TF active le facteur VII (FVIIa, 
a pour activé) devenant le complexe TF-FVIIa qui active alors deux autres facteurs: le 
facteur IX et le facteur X. Le FXa seul est peu efficace et ne protéolyse qu’une petite quantité 
de prothrombine4. Cette petite, mais suffisante, quantité de thrombine activée (2 nmol / L) 
commence à interagir avec des cofacteurs et substrats en provoquant le début de réactions 
en chaîne menant à la coagulation1,3,4,9,15. La thrombine protéolyse le fibrinogène en formant 
des unités de fibrine (Figure 1.3., flèche 1, page 10) qui vont être assemblées en fibres à fin 
de stabiliser le caillot. En outre, elle protéolyse les facteurs V et VIII (Figure 1.3., flèche 4, 
page 10) qui vont aider à amplifier l'activation de la thrombine. La thrombine va également 
activer des facteurs anticoagulants qui vont aider à contrôler et finaliser la coagulation. 
La thrombine participe également, au-delà de l'hémostase, à d'autres systèmes 
physiologiques, comme par exemple les systèmes immunitaire, nerveux, gastro-intestinal, et 
musculo-squelettique. Elle interagit avec des protéines et des récepteurs, en activant les 
plaquettes et les cellules endothéliales, et en stimulant l'adhésion, l'angiogénèse, la 
croissance cellulaire, la différenciation, la prolifération, la vasoconstriction et l'inflammation. 
Tout ce large éventail de fonctions est modulé grâce à une combinaison complexe de 
substrats et de cofacteurs4 (Tableau 1.1. et 1.2., pages 6-7). 
Pour toutes les fonctions expliquées ci-dessus, la régulation de la thrombine est 
fondamentale pour une physiologie normale. Des niveaux déséquilibrés de thrombine se 
traduisent par différents types d'anomalies. Les plus connues et étudiées sont la 
thrombose/l'hémophilie, l'inflammation et l'athérosclérose. Il est alors essentiel de pouvoir 
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mesurer son activité aussi précisément que possible afin d'étudier et de comprendre les 
conséquences physiopathologiques et moléculaires de ses anomalies. Les tests classiques 
reflètent seulement 5% de l'ensemble du processus1 de l'activation et de l'activité de la 
thrombine. 
Le potentiel de génération de thrombine (TGP, en anglais) est un test qui a été mis à 
point pour mesurer la quantité potentielle de thrombine qui est capable d'être activée au 
moment de coagulation45. Il peut être vu comme un reflet l'ensemble du processus de la 
coagulation allant de son l'initiation, sa propagation et sa terminaison-amplification47. Il est 
plus sensible aux déficits de facteurs de coagulation: activateurs (FVII, FV, FX) et inhibiteurs 
(antithrombine, protéine C, protéine S) et à de nombreux troubles de la coagulation associés 
à une résistance à la protéine C activée (APC, en anglais). En outre, il est sensible à tous les 
types d'anticoagulants ou d'autres médicaments. 
Le TGP est mesuré à partir d'une méthode, communément appelée thrombogramme 
calibré automatisé (CAT, en anglais), qui consiste en deux mesures simultanées de 
l'activation de la thrombine avec un substrat fluorochromé pour un même échantillon de 
plasma. L'une mesure la génération de thrombine (TG) et l'autre sert de calibrage pour 
corriger le biais entre le signal fluorochrome et l'activation de la thrombine. Dans le test TG, 
la thrombine est produite dans une réaction de coagulation activée par du facteur tissulaire, 
des phospholipides et du calcium. La quantité de thrombine générée est alors mesurée en 
temps réel par la capture du signal de fluorescence qui émet le substrat consommé par la 
thrombine. Ce signal est capturé et corrigé simultanément pour être affiché sous la forme du 
courbe (appelée thrombogramme) (Figure 2.1., page 24). 
A partir de cette courbe, il est possible d'extraire plusieurs paramètres quantitatifs 
(Figure 2.2., page 25). Les plus utilisés sont : 1- le temps de latence (Lagtime en anglais) qui 
mesure le temps écoulé depuis le moment où la coagulation est déclenchée jusqu'à le début 
de formation du caillot; 2 - le potentiel endogène de thrombine (ETP pour Endogeneous 
Thrombin Potential en anglais) qui représente la totalité de thrombine activée (l'aire sous la 
courbe du thrombogramme) et permettant de représenter plus précisément l'état de 
coagulation et toute l'activée enzymatique autour la génération de la thrombine; 3- le hauteur 
du pic (Peak, P) qui mesure la quantité maximale de thrombine activée à un moment donné 
du processus de coagulation. 
Le test TGP est sensible aux variations des facteurs FX, FIX, FVII et FVIII, du 
fibrinogène, des D-dimères (produits de la formation des unités de fibrine à partir de 
fibrinogène) et de protéines anticoagulantes. Le TGP est également associé à l'indice de 
masse corporelle (IMC), l'âge et le sexe. En ce qui concerne les facteurs génétiques connus 
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pour influencer la variabilité interindividuelle du TGP, il en existait deux au moment où je 
commençais mon projet de thèse: les polymorphismes rs1799963 (20210G> A) et 
rs3136516 (19911A> G) du gène codant pour la prothrombine (F2). 
Des niveaux élevés de TGP, en particulier d' ETP, ont été associés au risque de 
thrombose veineuse80–82, aux accidents vasculaires cérébraux (AVC) ischémiques aigus223 et 
à l'infarctus du myocarde35. En revanche, des niveaux bas d'ETP sont associés à des 
troubles de la coagulation46,86 (Figure 2.6.). Le TGP a également été trouvé associé à 
diverses désordres cardiométaboliques comme l'athérosclérose87,224, l'obésité60, le diabète 
de type 288, la néphropathie diabétique89, et des troubles hépatiques comme la cirrhose225. 
Des troubles inflammatoires ont également été associés aux TGP tels que la maladie de 
Crohn91, la septicémie92 et la drépanocytose93. 
Objectifs: 
Comme mentionné ci-dessus, seuls deux polymorphismes génétiques, tous les deux 
situés dans le  gène F2, étaient connus pour influencer les taux plasmatiques de TGP. 
Cependant, ils n'expliquent que 11,3% de la variabilité interindividuelle de ce biomarqueur. 
Mon projet de thèse avait pour objectifs d'identifier de nouveaux facteurs génétiques et 
épigénétiques modulant ce phénotype et ses biomarqueurs associés. 
 
Partie I Identification de nouveaux déterminants génétiques contrôlant la 
variabilité interindividuelle plasmatique du potentiel de génération de thrombine 
Dans le cadre de mon projet de thèse, j'ai mené la toute première étude d'association 
génome-entier (GWAS pour Genome Wide Association Study en anglais) sur les 
biomarqueurs du TGP (à savoir ETP, Peak et Lagtime), afin d'identifier de nouveaux gènes 
participants à la variabilité du TGP. 
Dans une première étape de découverte, j'ai testé l'association entre 6 652 054 de 
polymorphismes génétiques, plus précisément des polymorphismes de substitution d'un seul 
nucléotide (SNP pour Single Nucleotide Polymorphism in anglais), et la variabilité 
plasmatique des trois biomarqueurs du TGP dans deux échantillons rassemblant 1967 
sujets. Outre les deux polymorphismes du gène F2 déjà connus et mentionnés ci-dessus, j'ai 
identifié un polymorphisme au sein du gène ORM1, rs150611042, montrant une association 
statistique très forte (p = 3.36 10-7) avec le temps de latence (Lagtime). J'ai ensuite cherché 
à répliquer cette association dans deux autres échantillons indépendants rassemblant 1254 
sujets. Dans cette deuxième étape de validation, le polymorphisme rs150611042 a été 
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retrouvé fortement associé (p = 6.07 10-9) à la variabilité interindividuelle du temps de 
latence. J'ai ensuite montré que, dans deux cohortes indépendantes, l'une de 745 sujets et 
l'autre de 1374 individus, l'allèle du polymorphisme rs150611042 qui diminuait le temps de 
latence était également associé à une diminution de l'expression monocytaire du gène 
ORM1 (p = 8.70 10-10 et p = 5.21 10-16, respectivement). Des expériences fonctionnelles ont 
été réalisées pour compléter ce travail et ont confirmé in vitro l'association entre la molécule 
codée par le gène ORM1 et la génération de thrombine. 
En conclusion, cette partie de mon travail de thèse a permis d'identifier un nouveau 
gène participant à la régulation de la production de thrombine. Les mécanismes précis de 
cette régulation restent cependant à élucider. 
 
Partie II Marques de méthylation d'ADN associées au potentiel de génération de 
thrombine 
La méthylation de l'ADN est une marque épigénétique qui consiste en l'addition 
enzymatique d'un groupement méthyle (CH3, une molécule de carbone et trois d'hydrogène) 
à la position 5 de carbone de la cytosine principalement dans le contexte de la séquence 5'-
cytosine-guanine (communément appelé dinucléotide CpG). Ce groupe méthyle est transféré 
par une ADN méthyltransférase à partir d'une autre molécule appelée S-
adenylmethylcisteine (SAM), qui devient une S-adenylhomocysteine (SAH). Dans le même 
temps, l'ADN méthyltransférase attire des protéines qui vont se lier l'ADN et réguler 
l'expression et la structure de la chromatine161. 
Ces dernières années, de plus en plus d'études ont démontré le rôle de la méthylation 
de l'ADN dans le développement des maladies humaines. Les premiers résultats ont été 
observés dans le domaine du cancer, mais étendus rapidement à d'autres maladies 
humaines complexes telles que la sclérose en plaques, le diabète, les maladies 
inflammatoires et cardiovasculaires166,175,176,226,227. 
Dans la deuxième partie de mon travail de thèse, j'ai utilisé des données de méthylation 
mesurées dans des échantillons d'ADN sanguin à partir d'une technologie haut-débit, la puce 
HumanMethylation450K développée par la société Illumina, pour rechercher des marques de 
méthylation associées à la variabilité plasmatique des mêmes 3 biomarqueurs du TGP que 
ceux utilisés dans mon projet GWAS (Partie I). Cette puce permet de mesurer les niveaux de 
méthylation de l'ADN d'environ 480 000 sites CpG répartis tout au long du génome. Son 
utilisation dans de grandes cohortes épidémiologiques fait l'objet d'un enthousiasme très 
important en raison des récents succès qu'elle a permis d'obtenir pour détecter des marques 
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de méthylation associés à des facteurs environnementaux, génétiques et biologiques185,228. 
Dans le cadre de mon projet, j'ai eu accès à deux échantillons, l'un de 238 sujets, l'autre de 
187, dans lesquels cette puce de méthylation avait été utilisée à partir de l'ADN issu du sang 
périphérique des sujets, et pour lesquels les biomarqueurs du TGP avaient aussi été 
mesurés. J'ai ainsi réalisé la première étude de recherche agnostique d'associations entre 
des niveaux de méthylation de sites CpG et la variabilité plasmatique du TGP. Ce type de 
recherche est communément appelée MWAS pour Methylome-Wide Association Study en 
anglais. J'ai suivi une stratégie de recherche assez similaire à celle que j'avais appliquée 
pour mon étude GWAS. Malheureusement, je n'ai identifié aucune association robuste entre 
des niveaux de méthylation de l'ADN sanguin et les biomarqueurs de la génération de 
thrombine.  
 
Conclusions 
L'étude GWAS que j'ai menée sur les taux plasmatiques de 3 marqueurs de la 
génération de thrombine a permis d'identifier un nouveau gène, ORM1, participant à la 
modulation du temps de latence. Le polymorphisme que j'ai identifié n'est vraisemblablement 
pas le variant fonctionnel et les mécanismes d'action d'ORM1 sur la génération de thrombine 
ne sont clairement pas caractérisés. Mon travail n'a donc ouvert qu'une petite porte vers un 
champ de recherches beaucoup plus vaste qui reste à explorer. D'autres pistes mériteraient 
d'être également explorées pour mieux disséquer les mécanismes génétiques associés à la 
génération de thrombine. La recherche que j'ai effectuée ne s'est concentrée que sur des 
associations univariées entre SNPs et TGP alors qu'il serait également intéressant d'étudier 
si des phénomènes d'interaction entre SNPs peuvent également contribuer à influencer la 
génération de thrombine. De plus, alors que je me suis concentrée sur 3 biomarqueurs du 
TGP, il existe d'autres biomarqueurs qu'il serait également possible d'étudier dans le 
contexte d'une étude GWAS, ce qui pourrait mener à l'identification d'autres mécanismes de 
régulation. 
L'étude MWAS que j'ai conduite sur les taux plasmatiques de TGP s'est avérée moins 
fructueuse que l'étude GWAS. Plusieurs explications peuvent être relevées. Tout d'abord, la 
taille des échantillons que j'ai analysés dans ce projet était relativement modeste par rapport 
à ceux dont je disposais pour mon étude GWAS. Je ne peux donc pas exclure un manque 
de puissance pour détecter des effets épigénétiques modérés, et disposer d'autres 
échantillons mesurés à la fois pour la méthylation de l'ADN et le TGP serait alors le 
bienvenu. De plus, cette étude MWAS a été réalisée à partir de l'ADN du sang périphérique 
qui n'est peut-être pas le bon modèle pour étudier des mécanismes de méthylation de l'ADN 
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de protéines principalement exprimées dans le foie. Il serait plus pertinent de pouvoir 
disposer de l'information sur la méthylation dans des cellules hépatocytaires mais à l'échelle 
épidémiologique, cela semble un peu plus compliqué. 
Enfin, j'ai mené de manière indépendante mon étude GWAS et mon étude MWAS sans 
avoir intégré les résultats de l'une pour augmenter la puissance de l'autre. De nombreux 
travaux indiquent que les niveaux de méthylation d'un site CpG peuvent également être sous 
le contrôle génétique de polymorphisme(s). Il serait donc tout à fait intéressant de combiner 
les résultats que j'ai obtenus dans mes 2 projets pour essayer d'identifier des 
polymorphismes génétiques influençant les taux de TGP via des mécanismes de régulation 
de la méthylation d'ADN. Affaire à suivre...  
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Introduction 
 
Thrombin is a crucial protein that is mostly known for its central role in the haemostasis 
but that also takes part in a wide variety of other physiological functions, such as 
inflammatory response, cell differentiation and proliferation, vasoconstriction and cell 
adhesion. Anomalies in its activity, due to either lost or excess of function, can onset 
different diseases. Thrombosis is one of the most important ones able to trigger myocardial 
infarction, atherosclerosis, inflammation or stroke. To study any disease, it is highly 
recommended to have access to a proper, reliable and easy method to measure and detect 
as many phenotypic and symptomatic shades as possible in order to use it in routine 
clinical practice. In case of thrombin-related anomalies, the used procedures are composite 
measurements of coagulation protein concentrations, of platelet counts and of 
function/activity assays (e.g., time to clot formation). However, the majority of those 
methods are not specifically measuring thrombin or they get a reduced information of its 
activity ("scratch the surface") because they do not measure the total amount of thrombin 
activated in the coagulation reaction. 
Recently, a measure called Thrombin Generation Potential (TGP) has been proposed 
to get a much closer representation of the in vivo thrombin activation all along the 
coagulation response of an individual. This measure brings the opportunity to better 
investigate the process of thrombin activation in plasma. TGP has already been used for 
studying thrombin-associated disorders in human and these works have confirmed that this 
measure is sensible to the already known thrombin-associated environmental and genetic 
factors. Being such a solid method, it is interesting to further study new factors that might 
influence thrombin generation and that could be later used in clinical diagnosis or 
prevention of diseases. 
To contextualize my research, I will first start reviewing what is known about the 
thrombin protein, its functions and implications in human physiology. As it is the protein that 
is assessed  by the TGP method, I want to stress its importance in human (also in animal) 
physiology and, hence, supporting the interest of the main subject of my PhD project: the 
identification of new genetic and epigenetic factors influencing the inter-individual plasma 
variability of TGP. I will also introduce some description about the technical method used 
for measuring TGP and summarize the main discoveries and works carried out so far on 
this subject. All along this document, I will refer to TGP as the measurement used for 
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investigating thrombin generation in a given individual. Hence, I might also define it as a 
phenotype because it characterizes a trait or state of the physiology of that individual. 
After introducing these general descriptions, my work will be divided in two main parts: 
first, I will focus on the search for new genetic factors associated to TGP I have conducted 
in the framework of a genome-wide association study; second, I will analyze epigenetic 
data with the aim of looking for DNA methylation patterns associated to the TGP inter-
individual variability in plasma. 
The result of these works constitute my PhD project entitled: Genetic and Epigenetic 
Determinants of Thrombin Generation Potential: an epidemiological approach. 
 
  
MOTIVATIONS 
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Chapter 1. Thrombin 
 
‘The living enzyme of my blood’ is how Walter Seegers, one of the pioneers studying 
thrombin, defined this protein ten years ago1. 
Thrombin, also known as coagulation factor II, is a 36000 Da serine protease 
composed of two chains: a light one (or A) and a heavy one (or B); unified by a covalent 
disulfide bound. His precursor, the zymogen Prothrombin (or FII), is synthesized in the liver 
and, once released, it is cleaved, exposing the domains and activating its functions (FIIa). 
Like others clotting factors, prothrombin is part of the vitamin K dependent family and is 
characterized by a γ-carboxyglutamic acid domain (Gla-domain) that depends on the union 
of the vitamin K and calcium (calcium-binding domain). Both molecules allow prothrombin 
to easily anchor into the cell membrane where it is functionally more active2,3. Other 
important domains for thrombin activities are the Sodium-binding site, and the exosites I 
and II3–5. The first is essential to modulate the ambivalent main functions. In normal 
physiological conditions, 60% of thrombin has this site occupied by Na+ making it more 
efficient to interact with pro-coagulation factors. On the other hand, without Na+, thrombin is 
more anti-coagulant. The two other thrombin epitopes are the binding sites of cofactors and 
proteins. In a general manner, the exosite I binds to fibrinogen, factor V, factor VIII, factor 
FXI, PAR1, thrombomodulin and protein C; while exosite II binds to heparin, glycoproteins 
and other cofactors that make thrombin more efficient in its functions4,6,7 (Table 1.1.). 
 
1.1. The functions of thrombin 
 
The most fundamental and studied function of thrombin is his central and pivotal role in 
haemostasis: catalyzing the formation of Fibrin that will form the thrombus (or fibrin clot), 
activating other pro-coagulant factors and also triggering anti-coagulation enzymes8. 
 
Thrombin also participates, beyond the haemostasis, in other physiological 
mechanisms , such as the immune, nervous, gastrointestinal, and musculoskeletal 
systems. Thrombin interacts with proteins and receptors, activating platelets and 
endothelial cells, and stimulating cell adhesion, angiogenesis, cell growth and 
differentiation, proliferation, vasoconstriction and inflammation. All this wide variety of 
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functions is modulated by a complex combination of substrates, cofactors and their plasma 
levels4 (Table 1.1. and 1.2.). 
 
Table 1.1. Thrombin actions and substrates
3–5
. 
Thrombin's substrate Cofactor 
Thrombin-
Domain 
Function Na
++
/Ca
++
 
Fibrinogen  - exosite I Activation of fibrinogen -> fibrin + 
FVIII  - exosite I & II Activation of FVIII -> FVIIIa + 
FV  - exosite I & II Activation of FV -> FVa + 
FXIII fibrin exosite I 
Plus fibrin activation of FXIII -> 
FXIIIa = stabilization of fibrin 
+ 
FXI  GpIbα exosite I 
Activation of FXI -> FXIa = 
activation of intrinsic pathway 
+ 
Thrombin activatable 
fibrinolysis inhibitor (TAFI) 
TM   
Activation of TAFI=TAFIa-> 
anti-fibrinolysis 
  
Glycoprotein V GpIbα_exositeII exosite I Activation of platelets 
 
Thrombomodulin (TM)   exosite I 
Physical inhibition to 
procoagulant actions 
- 
Protein C (PC) 
TM (exosite I and 
sometimes II) 
exosite I 
 Activation of PC resulting in: 
Inactivation of  Va ->Vi and 
VIIIa->VIIIi 
- 
Heparin cofactor II (HCII) glycosaminoglycans   Acts like antithrombin   
plasminogen activator 
inhibitor (PAI-1)  
    
Inhibition of plasmin formation; 
fibrinolysis 
  
Glycoprotein GpIb-IX-V 
platelet receptor complex  
exosite II 
Cofactor. Helps to cleavage 
PAR and glycoprotein V by 
thrombin, FXI,. 
 
protease activator inhibitor 
(PAR) receptor present in 
almost all cell types 
 
exosite I 
Healing tissue injuries    
Activates platelet activation 
factor (PAF) 
  
Cell growth and differentiation   
Smooth muscle, macrophage 
and endothelial cell 
proliferation 
  
Angiogenesis   
Pro-inflammatory   
Leukocyte adhesion   
Lymphocytes mitogenesis   
Activation: IL-6, IL-8   
Vasoconstriction and vascular 
permeability 
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  procoagulant  Anticoagulant 
  Activation thrombin  Thrombin-PAR functions 
 
Table 1.2. Interactions where thrombin is the substrate. 
Enzyme Cofactor 
Thrombin-
Domain 
Function 
FX 
 
- 
First activator of thrombin from 
prothrombin. Exposure active 
domains 
FVa-FXa complex 
 
- 
Activation of thrombin from 
prothrombin. Exposure active 
domains 
Thrombomodulin (TM) 
 
exosite I Cofactor 
Antithrombin (AT) 
Non or 
glycosaminoglycans: 
heparin, heparan 
sulfate 
proteoglycans-
(exosite II) 
- 
Without cofactor: AT inhibits 
thrombin reversibly. With a cofactor 
is irreversible. Also Inactivates of Xa 
-> Xi and IXa->Ixi; 
Heparin cofactor II (HCII) glycosaminoglycans 
 
Acts like AT 
Tissue factor pathway 
inhibitor (TFPI)   
Fibrinolysis-anticoagulant 
 
1.1.1. Thrombin in Haemostasis 
 
Haemostasis is the main physiological regulatory mechanism of the blood flow and of 
its integrity. It includes both the formation of the thrombus (i.e coagulation) and its 
dissolution (i.e fibrinolysis) 9. The dynamics of the coagulation can be explained in three 
phases10. 
1) The initiation of coagulation. 
2) The propagation and amplification. 
3) The termination. 
This last step and the fibrinolysis are both the other pan of the haemostasis balance, 
dissolving the formed thrombus. Thrombin is key for haemostasis balance due to its 
paradoxical main functions. First, it triggers the formation of clots when the vessels are 
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damaged and then helps to stop the process to avoid their progress into the normal 
vasculature4. 
 
 
 
Figure 1.1. Image of a vein section 
where a thrombus is being formed9. The 
collagen and the tissue factor are 
components of the vessel wall located 
under the first layer of cells (endothelium). 
When the vessel is injured, collagen 
(yellow arrows) and tissue factor (blue 
arrows) will get in the blood flow and 
trigger the coagulation. 
 
1.1.1.1. Blood coagulation: Initiation. Platelet plug formation 
 
At the beginning, when a vessel is damaged, collagen and von Willebrand factor 
become exposed to the blood (Figure 1.1.) and attract the platelets to the injured point 
starting to build the clot. Both collagen and vWF activate platelets through glycoprotein 
(GP) membrane receptors such as the GPIIb-V-IX and GP1bα respectively4,9, and that 
causes i.e. the releasing of P-selectins in the cell surface to help the cell-cell adhesion11. 
This step is called primary haemostasis. But this first plug of platelets is unstable and needs 
the fibrin fibbers to consolidate it. 
On the surface membrane of these first aggregated platelets takes place the thrombin 
production and then its activity will contribute to transform fibrinogen into fibrin4. That is why 
the anchoring of thrombin to the cell surface through the Gla-domain and calcium binding 
domain is very important (page 5). Thrombin activation is the result of the coagulation 
cascade, a mechanism very efficient where many proteins are involved (Table 1.3.) and 
ones activate the following others (Figure 1.2.). The cascade can also be described based 
on two pathways: the intrinsic and the extrinsic. At the beginning, they were considered as 
equal part of the initiation process of coagulation. Nowadays, it is suggested that the 
coagulation initiation step would correspond to the extrinsic pathway and the intrinsic one 
would be part of the amplification and prolongation12 (Figure 1.2.). 
The coagulation cascade is triggered by the tissue factor (TF), which is a membrane 
receptor. It is normally present in extravascular tissues but when it is exposed to blood, 
meaning there is some kind of vessel damage, the coagulation starts4. Its first action is to 
activate factor VII (FVIIa, activated) becoming the TF-FVIIa complex that then activates two 
other factors: factor IX and factor X. The extrinsic and intrinsic pathways both lead to the 
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activation of FX, reason why FX is established as the connection between the two 
pathways and thereafter the common coagulation pathway starts13. FXa alone is scarcely 
efficient and only proteolyses a small amount of prothrombin to its active state thrombin, 
plus other secondary fragments: fragment F1+2 and meizothrombin4. Together, the 
meizothrombin and thrombin join to adrenergic receptors in the nearby smooth muscle cells 
resulting in a vasoconstriction of the area of clotting helping to stop the bleeding7. 
Table 1.3 List of the principal coagulation factors14. 
 
 
Figure 1.2. Coagulation cascade (Adapted from Esmon 201315) and comparison of 
the two nomenclatures. The two different pathways, extrinsic and intrinsic, allow 
thrombin activation. Then, with dot-lined square (left) the initiation phase, which starts 
with the presence of tissue factor in the blood (possibly a vessel damage). Afterwards, 
with the apparition of the first amount of thrombin, the amplification phase (the right dot-
lined square) is activated and helps to amplify its own activation (positive feedback). 
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1.1.1.2. Blood coagulation: Propagation and amplification 
Once that small, but sufficient, amount of prothrombin is activated (2nmol/L), thrombin 
starts to interact with cofactors and substrates causing the burst of coagulation1,3,4,9,15. In 
this part of the process, the presence of sodium ions (Na++) is essential, as it will give to 
thrombin the suitable allosteric conformation to be bound easily with pro-coagulant 
substrates. Besides, calcium, also called coagulation factor IV, is important for the activity 
of thrombin and different proteic complexes. 
The most important thrombin's substrate is fibrinogen that is proteolysed to form fibrin 
units (Figure 1.3., arrow 1). These units are assembled in fibers that tangled the platelets 
and other necessary cells and molecules, and all together help to fix and stabilize the clot. 
Factor XIII is also activated (FXIIIa) by thrombin (Figure 1.3., arrow 2) and it acts cross-
linking the fibrin fibers and helping to form the net of the thrombus (Figure 1.3., arrow 3). 
Furthermore, thrombin proteolyses the factors V and VIII (Figure 1.3., arrows 4) that 
are both important to ameliorate the efficiency of the factors Xa and IXa, respectively. 
FVIIIa with FIXa form the IXa-VIIIa complex (tenasa complex) that activates more factor Xa. 
This conjugation makes FIXa 105-106 folds more active (Figure 1.3., arrow 5). Then, FXa 
combined with factor Va, become the Xa-Va complex (the prothrombinase complex). This 
complex also increases by 3·105 folds the thrombin activation1,16 (Figure 1.3., arrow 6). 
 
Figure 1.3. Amplification phase of coagulation. Scheme of the main thrombin activations 
to form fibrin and to increase its own formation (the burst). The 1st, 2nd and 3rd arrows are 
implicated in the fibrin formation; and the others arrows in the coagulation amplification. 
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Thrombin also activates factor XI, which becomes FXIa (Figure 1.3., arrow 7) helped by 
FXIIa whose activation in vivo is still controversial9,17. This part of the cascade is equivalent 
to the intrinsic pathway (Figure 1.2.), also known as the contact pathway (or even 
kallikrein/kinin system) because FXII in vitro is activated by the negative charges present in 
the surface of sampling tubes8. Once FXI is activated into FXIa, it triggers the coagulation 
activating even more FIXa (Figure 1.3., arrow 8). From here starts the common pathway 
again. FIXa complexes with FVIIIa to boost the activation of FXa and together activate more 
FXa (Figure 1.2., and 1.3.). This intrinsic pathway is very important to amplify the 
coagulation and the density of the fibrin. Deficiencies (mild or total) of FXI produce a very 
variable bleeding disease also called Haemophilia C18. Instead, FXII deficiencies are not 
associated to bleeding disorders, which makes it interesting as a possible anti-coagulation 
treatment17. 
Concurrently with all the reactions described above, thrombin activates more platelets 
and endothelial cells allowing increased cell aggregation by P-selectin and mobilization of 
more receptors to anchor more prothrombin3. 
 
1.1.1.3. Blood coagulation: Termination 
 
A tightly and accurate regulation of coagulation is very important to ensure that it do not 
pass beyond to a physiologically normal vessel. Antithrombin, tissue factor pathway 
inhibitor (TFPI) and protein C are the main proteins controlling the amounts of thrombin 
generated. In this situation, a lack of sodium ions gives thrombin the ability to attract more 
anti-coagulant factors and cofactors. 
There are two kinds of inhibitors: the indirect and the direct (Figure 1.4.). 
Indirect inhibitors 
 
The indirect inhibitors are those that cleave o inactivate the necessary proteins for the 
thrombin activation. These include TFPI, protein Z, ADAMTS13 and thrombomodulin. 
TFPI is one of the most important and principal inhibitors of the coagulation19 with big 
affinity for TF-FVIIa and FXa (Figure 1.3.). It is widely distributed in healthy arteries, in the 
endothelial cells, in smooth muscular cells and in macrophages, and is colocalized with 
TF8. It only takes place in early stages of the coagulation and TFPI inactivates the TF-VIIa 
complex and also the factor Xa (FXa) forming a TF-VIIa-Xa-TFPI complex. The latter blocks 
the formation of the efficient prothrombinase complex (FXa-FVa). TFPI has also been 
proposed to inhibit FXa, when it is complexed with protein S20. A dysfunction of TFPI 
Motivations and background 
 
12 
protein in the system is related to risk of thrombosis and disseminated intravascular 
coagulation19. 
 
Figure 1.4. Inhibitors of thrombin and its activation11. In the two panels are 
represented some of the coagulation inhibitors: antithrombin (AT), Heparin, tissue factor 
pathway inhibitor (TFPI), the Z-Z protein inhibitor (Z-ZPI), and protein C (PCI or APC). 
 
As an activator of thrombin, FXa is also the target of other inhibitor proteins such as 
antithrombin (see below) and serpin PZ-dependent protease inhibitor. PZ corresponds to 
protein Z, which is a member of the vitamin K-dependent family (FII, VII, IX, X, protein C 
and protein S) but has no proteolytic activity. However, it acts as a cofactor of the serpin 
PZ-dependent protein (Z-ZPI, or SERPINA)11. 
ADAMTS13 also acts as an indirect inhibitor in very early stages of coagulation. 
ADAMTS13 overbreaks von Willebrand factor and makes impossible its interaction with 
platelets, hence avoiding their aggregation. Mutations in vWF or ADAMTS13 genes that 
can modify the efficiency of ADAMT13 for easily tagging vWF are responsible for bleeding 
disorders known as von Willebrand disease (vWD). 
Finally, thrombomodulin (TM) is a protein located in the endothelium surface that 
connects to thrombin as a cofactor by the exosite I and anchors thrombin to the cell 
membranes. Therefore, it helps and increases the probability of union between thrombin 
(now T-TM) and the anticoagulant protein C (PC). PC also bound to endothelial cell protein 
C receptor (EPCR), making it easier the interaction4. The complex T-TM activates protein C 
(APC) and once liberated from its membrane receptor, APC can interact with its cofactor 
protein S, and together inactivate the factors Va and VIIIa to Vi and VIIIi (i for inactivate).  
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Direct inhibitors 
 
The direct inhibitors are those who bind "directly" to free activated thrombin and 
inactivate it. These include thrombomodulin, again, together with antithrombin, heparin 
cofactor II and alpha 2 macroglobulin. 
Thrombomodulin (TM) is additionally considered as direct inhibitor because it interacts 
with thrombin by the same domain as fibrinogen does, reducing the free thrombin. Hence, it 
is a physical inhibitor, avoiding the activation of fibrin, platelets and endothelial cells. 
Antithrombin (AT) inactivates thrombin by cleaving it. This action can be reversible if 
AT acts alone but if thrombin is bound to a glycosaminoglycan molecule, for instance 
heparin, the attraction between AT and thrombin increases and the inactivation is 
irreversible. AT also inhibits the coagulation factors IXa, Xa and XIa stopping the thrombin 
generation. From the same AT family, heparin cofactor II (HCII) acts similarly binding to 
thrombin when there are glycosaminoglycans acting as cofactors. 
Finally, alpha2 macroglobulin (a2M) is not really a specific thrombin inhibitor but better 
known for its relation with Alzheimer disease. It is a blood protease inhibitor that bounds to 
free thrombin that avoids thrombin functions21. 
 
1.1.1.4. Thrombin and (Anti-) Fibrinolysis 
 
Part of the haemostasis, the fibrinolysis is the process that dissolves the thrombus. It 
starts few days after the formation of the thrombus. One of the main proteins in this process 
is plasmin, which breaks the fibrin net connections. Plasmin is activated by tissue 
plasminogen activator (t-PA) from its precursor, the plasminogen. 
As already mentioned, thrombin also activates FXIII helping to stabilize the thrombus.  
Additionally, when thrombin is bound to thrombomodulin, it activates thrombin activatable 
fibrinolysis inhibitor (TAFI) that inhibits the t-PA, ergo TAFI inhibits the fibrinolysis3,11,22. 
However, when the complex thrombin-TM activates APC, it also promotes the fibrinolysis 
because APC inhibits the plasminogen activator inhibitor (PAI-1, SERPINE1). Thus it helps 
to produce plasmin, and that results with the dissolution of fibrin3. 
 
1.1.2. Thrombin and Inflammation 
 
Inflammation is part of the protective mechanisms of the body as a response of the 
immunity system to pathogens. The relation between thrombin and inflammation is very 
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tight, is a cross-talk where they activate each other (Figure 1.5.). Inﬂammation and sepsis 
are defence mechanisms against bacterial spreading and lead their destruction. 
Thrombin activates platelets by interacting with the protease-activated receptors (PAR). 
This stimulates the G-protein pathway which can result in the production of chemokines (as 
monocyte chemoattractant protein-1) that will attract leukocytes on platelets and endothelial 
cells. At the same time, platelets express protein P-selectin, CD40 ligands and binding 
receptors favoring the aggregation of those leukocytes. These cell-cell interactions produce 
the releasing of cytokines such as Interleukin-6 and 8 (IL-6, IL-8), tumour necrosis factor-α 
(TNFα) and growth factors (as vascular endothelial cell GF) by monocytes and endothelial 
cells. Thrombin also proteolyses complement components, e.g. activating C3 and C5. All 
these reactions together result in a inflammatory response11 by thrombin and normally, it 
can be stopped by the action of anticoagulant factors such TFPI, APC and AT and also 
TAFI11,23. 
 
 
 
Figure 1.5. The Cross 
talk between the 
coagulation, 
fibrinolysis and 
inflammation 
responses4. 
 
 
1.1.3. Other thrombin functions 
Since the discovery of PAR (PAR 1,3 and 4) in 1991 by Coughlin et al.24, thrombin 
started to be considered more than a coagulation protein. These receptors are membrane 
proteins present in many cell types not only from the vascular and immune systems but 
also from nervous, gastrointestinal, and musculoskeletal systems (Figure 1.6.). 
On the vascular cells, the thrombin-PAR (T-PAR) stimulus activates the protein G 
resulting in angiogenesis, cell growth and differentiation, and smooth muscle cell, 
macrophage and endothelial cell proliferation. T-PAR stimulates different growth factors 
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such as connective tissue growth factor (GTGF) and vascular endothelial GF (VEGF). 
GTGF stimulates the fibroblast mitogenesis and chemotaxis that produce procollagen and 
fibronectin3. VEGF affects the endothelial cells inducing cellular migration, endothelial cell 
proliferation, and vascular tube formation promoting angiogenesis. These responses permit 
to heal and repair the damaged tissue of the vessel. Besides, VEGF also promotes the 
generation of more thrombin. 
 
Figure 1.6. Thrombin physiology functions25. 
 
Additionally, T-PAR interaction stimulates the secretion of nitric oxide (NO). On one 
hand, NO produces vasoconstriction at the site of the injury contributing to stop the loss of 
blood. On the other hand, it leads to vasodilation of the normal endothelium to permit the 
blood flow beyond the injury3. 
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In the musculoskeletal system, T-PAR promotes osteoblasts, myoblasts and 
chondrocytes proliferation, which might be important in cases of bone injuries and fractures. 
Thrombin also has been found highly expressed in neonatals and embryos having 
important influences in muscle denervation and during brain development3. 
Neurons, astrocytes and olygodendrocytes express also PAR and release thrombin. 
Their interaction leads to brain development, synaptic plasticity and neuroprotection3,26. 
Every cell that express PAR, could be stimulated by thrombin, therefore there could be 
still many thrombin actions to investigate. Although PAR can be activated by other 
proteases (e.g. FVIIa or FXa), thrombin seems to be the most efficient one3. 
 
 
1.2. Related diseases and disorders 
For all the functions explained above, a careful thrombin regulation is fundamental for 
normal physiology and unbalanced levels of thrombin result in different kind of disorders. 
The most known and studied are: thrombosis, haemophilia, inflammation and 
atherosclerosis. 
1.2.1. Thrombosis and haemophilia 
 
Regarding the main functions of thrombin, two diseases are related to excess or 
deficiency of thrombin: thrombosis and haemophilia (respectively). 
Thrombosis is a very critical disorder that consists in a tendency to form thrombus, 
increasing the risk of vessel obstruction and interruption of the blood flow. There are two 
kinds of thrombosis: arterial and venous (Figure 1.7.). The arterial thrombosis is 
characterized by an excess of platelet activation, generally due to the rupture of an 
atherosclerotic plaque, whereas venous thrombosis is more related to an excess of 
activation of the clotting factors and/or decrease of the blood flow27. 
Therefore, all factors that increase the normal amount of thrombin in plasma may 
increase the risk of arterial and venous thrombosis when mutated8. Some of the most well 
known factors are blood group and the gene mutations: prothrombin G20210A or FV 
Leiden. However, the risk can be also caused by: up-regulation of FVII, FX, FV, FVIII, FXI, 
FXIII, TAFI and logically FII; and/or down-regulation of PC, PS, TM, AT, TFPI among 
others19,22,28,29. Total deficiencies in these latter proteins are either incompatible with life or 
cause bleeding disorders such as haemophilia30. 
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Haemophilia is a bleeding disease caused by a decreased capacity to form a 
thrombus. The most known causes are the decreased level of factors VIII (Haemophilia A) 
and FIX (Haemophilia B) in plasma. Additionally, deficiency of FXI (Haemophilia C) and von 
Willebrand disease (vWD) can also induce bleeding disease, however they are less known 
and also more variable in phenotype31. 
 
 
 
Figure 1.7. Arterial 
vs. venous 
thrombosis and 
their different 
possible causes18. 
a) is an example of 
arterial thrombosis 
and b) a case of 
venous thrombosis. 
1.2.2. Inflammation diseases 
 
As mentioned before, the relation between thrombin and inflammation is very tight. 
Actually they are mutually reinforcing processes9: increased thrombin plasma levels can 
produce inflammation, and decreased levels act as protective phenotype in inflammation. 
In turn, inflammatory cytokines and the TNFα are related to more platelet reactivity 
enhancing coagulation by stimulating the release of tissue factor. Additionally, TNFα 
downregulates the action of thrombomodulin and endothelial cell protein C receptor. In 
acute phase responses, the complement C4b binding protein (C4bBP) levels increase and 
it is very often found in complex with the protein S. That results in a PS deficiency and a 
decreased function of APC32,33. 
In some inflammatory diseases or infections (e.g. sepsis) there are symptoms of 
thrombosis. For instance in asthma, characterized by a reversible obstruction of the airflow, 
chest tightness, dyspnea and cough, coagulation in the airways is induced34. 
 
1.2.3. Atherosclerosis 
 
Atherosclerosis is a disorder characterized by the formation of cholesterol plaques in 
the vessels of the arteries. Besides the cholesterol, the plaque is composed by platelets, 
macrophages (which become foam cells after endocytosis of the deposited lipids), 
neutrophils, T and B cells, endothelial cells, and smooth muscle cells (SMC). All of them 
contribute to the development of the plate.  
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The components sensitive to thrombin are the platelets and macrophages, which 
express PAR in their membranes. These interactions reinforce the atherosclerotic plates, 
although the mechanism is unknown35. 
The different components of the atherosclerotic plaques have also an influence on 
thrombosis8. Actually, there is a close interaction between atherosclerosis, inflammation 
and thrombosis (Figure 1.8.), as thrombosis can stimulate both mechanisms. Inflammation 
contributes from early to final phases of the plaque: formation and rupture. Leukocytes and 
platelets express aggregation proteins and cytokines allowing both the accumulation of 
platelets and the production of tissue factor. The SMC inside the atherosclerosis plaque 
produce collagen. When plaque rupture occurs; TF and collagen are released into the 
vessel lumen, triggering thrombosis36. Additionally, the plaques in the vessels physically 
complicate the blood flow, occupying, in the worst case scenario, more than half of the 
lumen. 
 
 
Figure 1.8. 
Cross-talk between 
atherosclerosis, 
inflammation and 
thrombosis36. 
 
1.2.4. Cancer and other related disorders 
Besides the previous diseases, thrombin has been related to some other diseases, for 
instance cancer or central nervous system (CNS) anomalies. 
The capacity of thrombin to stimulate the proliferation, aggregation and mobilisation of 
cells, makes it a "potential collaborator" for tumours. Thrombin promotes angiogenesis by 
activating endothelial cells (T-PAR interaction) and stimulating the expression of growth 
factors. T-PAR also contributes to the expression of integrins (membrane proteins), 
influencing both the attachment and the mobilization of cells, hence in a cancer 
environment, to metastasis. For instance thrombin has been related with colon 
adenocarcinoma and up regulations of PAR with breast, prostate, melanoma and other 
cancers3. 
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In CNS, abnormal levels of thrombin seem to contribute through different mechanisms 
to stroke by: vascular disruption, inflammatory response, oxidative stress, and cellular 
toxicity26. Moreover, high levels of thrombin and PAR are related to low survival of 
astrocytes or neurons whereas low levels can be neuroprotective3. 
There are also disorders that contribute to thrombotic stages, e.g., obesity, liver 
diseases, diabetes and renal disorders. The first one it is also implicated in inflammation 
responses and probably atherosclerosis. The second one is related to haemostasis 
because the liver tissue synthesizes the majority of coagulation factors. Thus, in case of 
cirrhosis, infections or malfunctions, thrombin production and activity, thus hemostase, may 
be affected. Then, patients of type 2 of diabetes mellitus (T2DM) with insulin resistance 
tend to have enhanced coagulation activation and hypofibrinolysis. This may be due to a 
high plasma concentrations of procoagulant proteins and decreased anticoagulants ones in 
T2DM patients37. Finally, renal disorders have been shown to predispose to thrombotic 
disorders or uremic bleeding although the exact underlying mechanisms remain unknown38. 
 
1.3. Thrombin tests and measurements 
Given the importance of thrombin in coagulation and other physiological processes, it 
became essential to measure its activity as accurately as possible to study and understand 
the molecular and physiological consequences of its abnormalities. So far, the routine tests 
used are: 
 
1.3.1. The prothrombin time (PT) 
The prothrombin time is a measurement created by Quick in 1935 to fill the need for 
quantification of coagulation defects in new-borns and jaundice symptoms39. The test 
consists in the activation in vitro of coagulation system in a sample of plasma after 
incubation with thromboplastine reagent (tissue factor) and CaCl2. The time between the 
trigger and the clot formation is recorded in seconds. This measure permits to study the 
deficiency of factor II (prothrombin), V, VII, X and fibrinogen. Normally, this test is 
performed in combination with activated partial thromboplastine time. 
 
1.3.2. The activated partial thromboplastin time (aPTT) 
Langdell designed this coagulation measurement also in 1935, and modified it a 
posteriori in 196139. It consists in the induction of plasma coagulation by adding an activator 
of factor XII and a platelet substitute. Then the time that takes to get the clot is measured. 
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This test allows detecting abnormalities in factors XII, XI, IX, VIII, X, V, prothrombin and 
fibrinogen. 
Both aPTT and PT tests are regularly used to monitor the anticoagulant treatment. 
 
1.3.3. The activated clotting time (ACT) 
The ACT measurement uses whole blood samples taking into account the importance 
of platelets and phospholipids in the role of coagulation39. The triggering substance to 
activate the coagulation is a solution containing glass beads, celite or kaolin. All three have 
large contact surfaces allowing "the contact" pathway activation, thus the FXII activation. 
Then the time to form the clot is recorded. The test is also very easy and quick, it requires a 
small blood sample, and can be performed just before extraction by a non-trained person. 
 
1.3.4. Prothrombin fragment 
Prothrombin fragment 1+2 (F1+2) is a specific molecular marker of thrombin generation 
in the body. Circulating levels have previously been reported to be a marker of both acute 
venous and arterial thrombotic events and also to be a predictor for new thrombotic events 
and mortality40. 
 
These conventional coagulation tests just reflect 5% of the total process16,30,41 of 
thrombin activation and activity. Despite they are the affordable tests to measure this 
activity and informative for haemostasis defects, they may not be the best way to study 
thrombin activity, not detecting some dysfunctions and disorders as some kinds of 
thrombosis42,43. As Professor HC Hemker, one of the most important researchers in 
thrombin, wrote: "If you want to know about thrombin- measure thrombin"44. Fortunately 
since 2002-2003 there is an optimal model of haemostatic function which permits to 
measure the thrombin activity being the most closed to in vivo coagulation: the thrombin 
generation potential (TGP). 
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Chapter 2. Thrombin Generation Potential 
 
Thrombin generation potential (TGP) is a measure of the potential amount of thrombin 
that is possible to activate45 in a coagulation reaction, reflecting all the capacity46 rather 
than a normal coagulation30. Also, it can be expressed as the representation of the 
coagulation process from initiation, propagation-amplification and termination47. 
Depending on the interest of each study, it can be performed in platelet poor plasma 
(PPP) or platelet rich plasma (PRP). The first one reflects any coagulation factor deficiency 
except FXIII, activators (e.g., FIX, FV, FX) and inhibitors (antithrombin, protein C, protein 
S), thus many kinds of clotting disorders specially APC resistance. Additionally it is 
sensitive to all kind of anticoagulants or other drugs40. The second one adds the influence 
of platelets in the coagulation process, the vWF platelet-activation function, other 
thrombotic disorders and it is sensitive not just to anticoagulants but also to anti-platelet 
aggregation drugs45,48. 
 
2.1. Short history of the thrombin generation measurements 
 
The thrombin generation test is not a new technique although, it has been widely used 
in the last decade. The first reported experiments, in which TGP was studied, dated back to 
1901 by M. Arthur who tested dog defibrinated blood samples. The technique consisted in 
the incubation of the samples, then taking aliquots at regular intervals and introducing them 
into a known amount of fibrin to measure the time to clot formation. The more thrombin was 
activated, the less time to clot formation. Then, the data was plotted as "concentration of 
thrombin" versus the time49 obtaining a curve of thrombin generation. 
The first time this technique was applied using human blood was in 1939. However the 
protocol was still being modified (components and solutions), not finding a simple and 
reliable test50. The modifications continued like in the works of Pitney et al. 195351, 
Macfarlane et al 195349. In 1993, Hemker finally proposed a continuous registration of 
thrombin generation using optical lecture with a chromogenic thrombin substrate to 
measure the real time coagulation52. He proposed a continuous registration of thrombin 
generation using optical lecture with a chromogenic thrombin substrate to measure the real 
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time coagulation. Additionally, the substrate had to be slow-reactive to avoid his depletion 
before the end of the reaction. Before the use of the chromogenic components, the tests 
were applied in PPP, PRP or whole blood, defibrinated or just diluted. However, this new 
method reduced the option to PPP defribrinated samples without background noises 
caused by other bodies or molecules.  
Posteriorly, Ramjee proposed in 2000 to substitute the chromogenic substrate for a 
fluorogenic, permitting to test again all kinds of samples53. Besides, it brought the possibility 
of measure in 96-well plates, thus 96 samples at the same time that notably reduced the 
time of measure. 
Finally, in 2003, HC Hemker improved the protocol and the technique by developing 
the calibrated automated thrombogram (CAT)45 based on the fluorochrome substrate. The 
innovation was the additional calibration test measured with the sample at the same time, 
which consists in a known amount of thrombin consuming also the fluorogenic substrate. 
This complementary test permits to correct the bias between the fluorochrome signal and 
the thrombin activation, which are not constantly proportional as the fluorochrome signal 
increases. This correction permits to convert the fluorescence into thrombin concentration45. 
 
2.2. Method of measurement: calibrated automated 
thrombogram (CAT) 
 
As mentioned before, there are different approaches to assess the generation of 
thrombin. However, the most recently used, the one also used in this work, is the CAT, also 
called thrombin generation potential (TGP). The following description of the method is 
based on different reports: Hemker et al 200248, Hemker et al. 200345, Lavigne-Lasside et 
al. 201054 and Castoldi et al 201155. This method consists in two simultaneous 
measurements in the same plasma sample. One will be called the measurement or 
thrombin generation well (TG) and the other the calibration well (CL). The basic necessary 
solutions and components of this experiment are: 
- Plasma - As mentioned before, the plasma can be rich or poor in platelets. Generally, 
blood samples are extracted from antecubital venipuncture. Then a PRP is obtained 
from the supernatant (first visible liquid phase) of the sample after centrifugation at 
265g for 10 min. The platelets are counted to check that the sample has less than 
200.000 platelets/μL, the threshold for the method sensitivity. If needed, the sample 
has to be diluted with the corresponding PPP. For an optimal experiment, this type of 
plasma has to be used in no more than one hour after extraction to avoid biases 
Chapter 2. Thrombin generation potential 
 
 
23 
caused by the platelet "aging". For a PPP, the sample is centrifuged twice at 2900-
3000g for 10 min. All platelets precipitate in a pellet to the bottom. 
- Buffer base - The buffer base solution used to dilute and mix the other components. 
It is formed of: 20 mM Hepes, 140 mM NaCl, 5 g/l bovine serum albumin (BSA), in a 
pH = 7.35. 
- Trigger buffer - The triggering buffer is a solution that will activate the coagulation. It 
is composed by: in case of PRP: just 3 pM recombinant tissue factor (rTF) and buffer 
base, and in case of PPP:30 pM rTF and 24 μM phospholipid vesicles in the buffer 
base. 
- FluCa - It is the solution containing the fluorescent substrate: Z-Gly-Gly-Arg-AMC. 
Thrombin proteolyses this molecule releasing AMC, which will emit fluorescence at a 
390 nm wavelength of excitation and a 460 nm of emission. It is formed by: 2.5 mM of 
fluorescent substrate, 60 mg/mL of BSA and 0.1 M CaCl2 in buffer. 
- Calibrator solution - It is the solution used to calibrate and correct the TG 
measurement. It consists in thrombin complexed with the non-specific inhibitor α2-
macroglobulin (α2M-T), which will "protect" thrombin from specific anticoagulants and 
minimize thrombin activity. It is a mixture of prothrombin, α2-macroglobulin, FX, FV and 
phospholipids vesicles in Hepes buffer that will react and form the α2M-T. The amount 
used in the reaction is 600 nM of α2M-T. 
 
The support used is a 96-well specific fluorometer plate with 390/460 filters, excitation 
and emission wavelength respectively. That permits to test 48 samples in one plate. For 
each plasma sample, the two mixtures corresponding to TG measure and CL measure 
(Figure 2.1.). 
In the TG test, thrombin is generated in a coagulation reaction activated with the trigger 
buffer. This thrombin is measured at real time by capturing the fluorescence signal that 
emits the substrate consumed by thrombin. This signal is captured and displayed in a curve 
(Figure 2.1.). On the other hand, the calibration test has no coagulation reaction but just the 
activity of the α2M-thrombin consuming the fluorescent substrate. The resulting curve of the 
calibrator (from a known amount of thrombin) will correct the bias between the fluorescent 
curve and the thrombin curve. The dedicated software program used is the 
Thrombinoscope (Synapse BV, Maastricht, The Netherlands). The program reads the two 
tests at the same time and automatically corrects the thrombin generation measure. As a 
result it returns a TG curve of nM of thrombin per min called thrombogram. 
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Figure 2.1. Diagram 
of the CAT method 
measures for a 
plasma sample. 
Adapted from of 
Castoldi et al. 201155. 
The measurement or 
thrombin generation 
(TG) and the 
calibrator (CL) are 
simultaneously tested 
and combined to 
display the final 
corrected thrombin 
generation curve. 
 
Variations of the test 
Some variations can be applied changing or testing different concentrations of tissue 
factor and phospholipids in the reaction. Then, it is also possible to add to the mixture some 
anticoagulants such as APC with TM and AT to better study their pathways (Figure 2.3). 
Additionally, it is recommended for some studiesto inhibit the intrinsic pathway by inhibiting 
FXII with Corn trypsin inhibitor (CTI) and to just measure the intrinsic pathway and their 
coagulation factors. Finally, it seems that residual platelet can influence the measure; in 
order to avoid so Chantarangkul et al. proposed to use a greater concentration of 
phospholipids (> 1.5 nM)56. 
 
2.3. The parameters (biomarkers) 
From the thrombogram it is possible to extract several quantitative and biological 
parameters. In this work they are also referred as biomarkers (Figure 2.2.). 
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A  B  
Figure 2.2. Parameters of Thrombin Generation Potential measured by 
thrombogram. A- (L) is Lagtime (min), (P) is Peak height (nM), (E) is Endogenous 
thrombin potential (ETP) (nM x min), which are the main parameters used in this project. 
Then, (A) maximal rising slope (nM/min), (B) time to peak (min) and some also consider 
(C), start time of tail (min). B- the comparison of the thrombin generation curve with the 
coagulation cascade57. 
 
Although the most used are Lagtime, endogenous thrombin potential (ETP) and Peak, 
there are also other available parameters as: time to peak, velocity and start time of tail. 
The Lagtime (L)- It is an equivalent measure of clotting time, as it is the time passed 
from the moment that the coagulation is triggered until the clot start to form (fibrin). This last 
point has been arbitrarily proposed as the moment when 10 nM of thrombin are produced45. 
It is measured in minutes (min). 
Endogenous thrombin potential (ETP) (E)- It is the area under de curve (AUC) that 
represents all the potential enzymatic labour of thrombin when is activated. Therefore, it is 
the parameter that will better represent the state of coagulation. It is measured in units of 
nanomolar (NM = nmol/L) for the time in minutes (nM·min). 
Peak (P)- It is the maximum amount of thrombin activated in all the process. It is highly 
correlated with ETP. It is measured in units of nanomolar (nM or nmol/L). 
Time-to-peak (TTP) (B)- It represents the time that takes to get the peak of thrombin 
activity from the moment the coagulation started (by the trigger). It corresponds to the 
initiation phase plus the amplification phase of coagulation. It is also measured in minutes 
as Lagtime. 
Velocity (A)- It is the slope from the first thrombin activity until the peak, representing 
how fast the reaction reaches the maximum of thrombin activity (nM/min) 
Start time of tail (ST)(C)- It is the moment of time (in minutes) when the activation of 
thrombin decreases reflecting the start of termination phase and the activity of the 
anticoagulants. 
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As a general example, a hypercoagulation state is characterized by a small lagtime and 
large ETP and Peak. Conversely, hypocoagulation is association with delayed lagtime and 
decreased ETP and Peak. 
 
2.4. Known biological, environmental and genetic 
determinants of TGP 
TGP can also be defined as the collective activity of all components that participate in 
the coagulation cascade and the influencing pathways. Hence, it is suitable that this 
phenotype would be determined by different factors: genetic and environmental. Since the 
publication of this method, due to its close similarity to an in vivo coagulation and its 
medical relevance, numerous works have been conducted to detect its sensitivity to 
deficiencies, disorders, and mutations or to study its associations with other biological and 
clinical characteristics. 
Besides the levels of thrombin itself, the test is also sensitive to variations of the 
cascade factors: FX, FIX, FVII, FVIII, fibrinogen andD-dimer; and to anticoagulants: TFPI, 
AT, PS and PC20,21,54,58–60 (Figure 2.3.). Any mutation or disorder increasing or decreasing 
thrombin levels or functions influence the final curve of thrombin generation as an indirect 
implication. 
A  
B  
Figure 2.3. Comparison of thrombin generation curves of (left) controls, (right A) an 
individual with antithrombin deficiency and (right B) an individual with deficiency of 
protein C.A) In black the basic thrombin generation test, and in light grey, the test adding 
25 nM of active PC (APC). The differences between a healthy individual and an individual 
with deficiency of AT are visible. B) The grey line test with a variation, the addition of 10 nM 
of TM and the light grey the test with 25 nM of APC. The right curve, in comparison with 
controls, is a slight prolongation of the peak before decrease, whereas the controls quickly 
decrease. It displays also the method differences between the addition of TM or APC. 
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TGP is also associated to body mass index (BMI) presenting longer Lagtimes but also 
higher ETP60,61. Age can also be a determinant, presenting differences between children, 
young and old adults58,60–62 (Figure 2.4.). 
 
 
 
Figure 2.4.: Comparison of 
thrombin generation curves 
by sex (A), age (B), BMI (C) 
and oral contraceptives 
(D)61. 
 
Another major determinant of TGP variability observed is the gender63 (Figure 2.5.). 
Women are more prone to coagulate: lower Lagtimes and increased ETP and Peak. Also 
the levels of free PS and TFPI are lower in females, also reflected in higher ETP and Peak 
in the measurement with the addition of APC 58. There are also slight evidences of 
thrombotic changes reflected by TGP variability across the different phases of the 
menstruation cycle 64. Besides, women often have more risk to develop thrombopathologies 
due to the use of oral contraceptives or hormonal postmenopausal treatments21; always 
adding more risk when the treatments are based on estrogens and oral prophylaxis. TGP 
can be enhanced in women with treatments, and also in tests performed with the addition of 
APC45,61,65. 
Other studies have been made to search for environmental factors that could also 
modulate the TGP curve. For example, a small study investigated whether alcohol has any 
effect on TGP, but no associaiton was observed66. Additionally another study presented 
some preliminary experiments aiming at finding whether diet could influence TGP levels67. 
Last but not least, two genetic factors were known to influence TGP when I started my 
PhD project: the rs1799963 (20210G>A) and the rs3136516 (19911A>G) from the 
prothrombin gene (FII)68–70. The rs1799963-A is present in 2% of the population and well 
established as a mutation in the extreme 3'-UTR since 199671. It is located in the exact start 
point of the poli-A chain, of the gene and related to increased levels of prothrombin69,70,72. 
However the exact mechanism by which this mutation increases prothrombin levels 
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remains uncertain. It might be due to a better stability of the mRNA, a more efficient 
transcription or both. This mutation has been also related to risk of venous thrombosis, 
heterozygous carriers being at 2-371,72 and even a 769 fold increased risk and homozygous 
carriers at 11 fold risk73. 
 
 
Figure 2.5. Thrombin 
generation in females vs 
males63. In A thrombin 
generation curve from a 
family of individuals with a 
mutation in protein C 
(green) versus the non 
carriers (grey). In B with a 
prothrombin mutation (with 
the same colour code). In C 
individuals with a 
thrombosis history. 
 
The second F2 polymorphim known to influence TGP, rs3136516, is located in the last 
intron of the gene (the 13th intron). This polymorphism is very frequent in the population, 
with minor allele G frequency of almost 50%. This allele is associated with increased 
prothrombin levels (and then to TGP) in a dose-dependent manner68. The nucleotide 
change, originates an enhancer domain of splicing but has not been proved that is the 
cause of the increased levels69. The association of this polymorphism with the risk of 
venous thrombosis is still a matter of question. Some studies observed so74,75 whereas 
others did not find associations with this polymorphism76–79. 
TGP is sensible to these two genetic variations resulting in increased ETP and 
Peak6,54. Both polymorphisms explain an 11.3% of the variability of TGP (calculated with 
the populations used in this project, see Chapter 5, page 53). 
 
2.5. TGP related diseases 
The levels of TGP have also been related to some diseases or risks, accordingly to the 
previous section and the thrombin implications in some diseases (page 15). 
The levels of TGP, especially increased ETP, have been associated to venous 
thrombosis41,80–82, acute ischemic stroke83 and myocardial infarction35,84. It has also been 
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found very useful in monitoring anticoagulant treatment85, e.g. after an acute myocardial 
infarction40. In contrast, lower levels of ETP are associated with bleeding disorders41,46,86 
(Figure 2.6.). 
 
 
 
Figure 2.6. Thrombin 
generation curves 
from individuals with 
different levels of FXI 
deficiency86. Each 
line represents a 
different grade of 
heamophilia C 
indicated in the legend 
(top right corner). 
 
TGP has been related to other diseases as well including atherosclerosis87, obesity60, 
type 2 diabetes88, diabetic nephropathy89, or hepatic disorders as cirrhosis90. Inflamatory-
related disorders also have been associated to TGP as Crohn's disease91, sepsis 92and 
sickle cell disease93. 
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2.6. Main Objectives 
 
The thrombin generation potential has demonstrated so far its capacity to characterize 
the individual coagulation state and to detect possible disorders or deficiencies compared 
with other routine tests. TGP demonstrates a strong inter-individual variability that is mainly 
explained by environmental factors an, the main genetic factors observed to date are the 
mutations in the prothrombin gene in chromosome 11. This PhD project was proposed to 
identify more genetic factors that modulate this phenotype and its biomarkers. 
The aim of my PhD project was twofold: 
1 - To identify new genes that could influence plasma TGP variability. For this, I 
conducted a meta-analysis of two French genome-wide association studies (GWAS) on 
TGP biomarkers. 
2 - To investigate whether DNA methylation marks could also contribute to the inter-
individual variability of TGP plasma levels. For this, I conducted a meta-analysis of two 
methylome-wide association studies (MWAS) on TGP biomarkers from DNA methylation 
measured in peripheral blood DNA. 
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IDENTIFICATION OF NOVEL GENETIC DETERMINANTS 
CONTROLLING THE INTER-INDIVIDUAL PLASMA 
VARIABILITY OF THROMBIN GENERATION POTENTIAL 
 
 
This part contains the achievement of the first objective of my PhD project, the 
identification of new genetic determinants of the variability of Thrombin Generation Potential 
(TGP).  
The adopted strategy was to perform a genome-wide association study (GWAS) 
(definition in page 36) of three TGP biomarkers in two independent studies. Then the study-
specific results were combined into a meta-analysis to obtain candidate single nucleotide 
polymorphisms (SNPs) with strong statistical evidence for association with the biomarkers. 
These candidate SNPs were tested afterwards for replication in two additional independent 
cohorts.  
In the next pages, I will first describe the main principles and procedures underlying the 
application of a GWAS strategy and the different cohorts I have used for the main analysis. 
Then, I will describe the results I have obtained using this GWAS approach that are 
summarized in my first publication (Rocanin-Arjo et al. 201494) attached at the end of this 
chapter. 
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Chapter 3. Genome-Wide Association Studies: concepts 
 
The main objective of this project has been the study of inherited determinants that may 
influence thrombin generation potential in an epidemiological context. That means to study 
the trait (or disease) in human populations and find their genetic patterns and causes, 
occurrence and distribution to better understand and "control" the health of the population95. 
These traits can be quantitative such as: protein levels, weight or amount of adipose tissue; 
or discrete like: sick / healthy. For decades, there have been two main research strategies in 
the study of genetic factors: linkage and association analysis. 
 
 
Figure 3.1. Relation between the frequency of the alleles and 
their effect (or causal relation) upon the trait (adapted from of 
Manolio et al. 200996). 
 
The first method, linkage, is an approach that permits to identify and map regions of the 
genome that may contain causal genes, which in turn are transmitted to the offspring. 
Comparing members of families, it is possible to delimitate blocks of DNA, using known 
genetic variants (called markers) that have been transmitted together among affected 
members and where there might be a causal variant. This approach has been and still is 
very helpful in studies of Mendelian diseases, which are caused by "one" mutation, normally 
rare, but with a high effect on the phenotype or disease (Figure 3.1.). For that reason it is 
better to study them in families with affected members where their frequency would be 
increased compared to the general population (Figure 3.2.). 
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Figure 3.2. Linkage analysis vs. Association analysis97. Linkage 
analyses are performed in Family studies and association analysis 
are generally assessed in independent samples. 
 
On the other hand, association studies also test known genetic makers, generally SNPs 
(see in the following chapter 5), in association to a trait of interest and normally, in groups of 
independent individuals (Figure 3.2.). These kind of studies are based in the linkage 
disequilibrium, LD (not to confuse with the family linkage). Theoretically, when two 
polymorphisms, PA and PB, are biallelic, A/a and B/b (A and B being the most frequent 
alleles) and independent and from a panmictic population, they present the following 
haplotypes: AB, Ab, aB and ab, which are distributed randomly among the individuals. 
Hence the frequencies for PA and PB are: 
a) For allele A     and for the allele a:         
b) For allele B     and for the allele a:         
Then the frequencies of their combinations or haplotypes, are the product of their allelic 
frequencies. For example, AB would be the following in the population           and 
similarly for the other combinations. 
 
However, when the allele combinations are not aleatory, and for example the allele b is 
always transmitted together with allele A, then it exists a disequilibrium where this two alleles 
are linked. The haplotypes of the population would be: Ab, AB and aB. If, in addition,      , 
the distribution becomes: AB and ab, which represents a case of perfect LD. Therefore the 
frequencies are not based on the allelic frequencies but influenced by a disequilibrium with a 
value D (following the same example of AB) 
- The frequency of AB:             
- The frequency of Ab:             
- The frequency of aB:             (in this example, this one would be 0) 
- The frequency of ab:             
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The value D is the difference between the observed haplotypic frequencies and the 
expected ones (in equilibrium). This value depends on the allelic frequencies that are 
specific of each population, so, it cannot be used to compare. 
            
           
           
           
                 
The standardization of the D is called D': 
          
where Dmax is D in the case of complete LD 
                             
                            
D' is equal to 0 when there is equilibrium, and to 1 when there is complete LD where the 
alleles A and B are associated or -1 when A and b instead. 
Another normalized measure of LD is r 2, a correlation between A>a and B>b. It takes 
values between 0 and 1 where 0 again means equilibrium but 1 doesn't mean complete LD 
like in D'. The value increases when the linkage between the two polymorphisms is more 
important. 
   
  
           
 
Therefore, the more polymorphisms are used in an association study, the better to 
increase the power of detection and probabilities to find variants associated to the disease in 
LD with the markers. If an association is observed between a polymorphism and a 
phenotype, this could be because: the tested polymorphism is indeed a functional variant 
directly affecting the phenotype or the polymorphism is in "close proximity" with the 
underlying functional variant(s). This proximity is generally expressed in terms of linkage 
disequilibrium (LD). 
Even though this strategy is applicable in family studies, it has been mainly applied in 
designs of independent samples, such as case-control studies. It has also been very 
successful to investigate multifactorial traits, i.e., traits that are influenced by environmental 
factors and multiple genetic determinants. Each determinant or factor has modest effect but 
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when accumulated with others, results into the trait or disease (Figure 3.1.). Up to the 2000s, 
the common association study approach was the "candidate gene association study" where 
the tested SNPs were selected according to some a priori knowledge about the inquiry trait. 
Generally, the SNPs were located in a gene whose product was known to participate to the 
biological mechanisms underlying the studied phenotype. For example, this strategy has 
been used to show that the two prothrombin (F2) gene variants discussed in Chapter 2 
(page 27), rs1799963 and rs3136516, were influencing thrombin generation. 
 
Then the development of high-throughput genotyping technologies revolutionized the 
genetic research offering the possibility to study simultaneously hundreds of thousands of 
SNPs all over the genome without any restriction about their location within specific 
candidate gene or genes. This leads to the emergence of the Genome Wide Association 
Study (GWAS) era, still relying on the key concept of LD. In the last ten years, this strategy 
has become a standard method to identify novel susceptibility genes for common, but also 
rare, diseases and quantitative traits. Thanks to it more than 2000 robust associations within 
more than 300 complex diseases and traits have been identified in the past 7 years98, 
permitting also to create more than 2,000 genetic tests99. 
 
As part of my PhD project, I conducted the first GWAS on TGP biomarkers, the only one 
performed so far on such phenotypes, with the aim at identifying novel genes participating to 
the control of TGP. 
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Chapter 4. Genome-Wide Association Studies "for 
dummies": step-by-step analysis
 
 
The following chapters aim at exposing the general procedures for a good genome- 
wide association analysis (GWAS) (Figure 4.1.) I followed in my project, from the genotype 
determination of the samples up to the final interpretation of the results. 
 
Figure 4.1. Diagram of the steps to follow to 
perform a GWAS. 
 
4.1. Genotype Calling 
One of the essential elements for an association analysis is the genetic data of the 
samples under study. The genetic data most frequently used are polymorphisms, also called 
markers, which are known genome variations easy to determine (or to genotype). Among all 
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known polymorphisms, the mostly used in GWAS are the single nucleotide polymorphisms 
(SNP). 
The application of GWAS has been possible thanks to the development of DNA 
microarray techniques enabling to simultaneously genotype a huge number of SNPs. The 
latest generation of such arrays enables now to genotype ~5 Millions of SNPs on a single 
microarray. 
 
Figure 4.2. Representation of a microarray genotyping using as example 
Illumina images. 
 
The fundamentals of this technique are explained in Figure 4.2. using images of 
Illumina®100 as an example. This method consists in a multiple step procedure where the 
DNA sample is first amplified to increase the number of copies, and fragmented in small 
sequences. Then these short sequences are inserted in the array, where they hybridized to 
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their complementary probes. Those probes finish just before the SNP of interest. Then to 
determine those SNPs there is an amplification reaction to add just one nucleotide (the SNP 
itself). The nucleotides are bound to two different fluorochromes (or dyes): one for one allele 
(A1) and for the other (A2). Finally, the excited fluorochromes are read by a scanner or 
spectrophotometer and translated into a genotype. The possible results can be: 
- A high fluorescence of one of the dyes, and a very small of the other, 
corresponding to the homozygosis (A1A1, A2A2). 
- A combination of the two fluorochromes corresponding to heterozygosis (A1A2). 
The fluorochromes intensity can be represented more visually in a 2D graph (Figure 
4.3.): 
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A Allele 2 B Allele 2 C Allele 2 
Figure 4.3. Examples of genotype calling results of a SNP. The y axis represents the 
intensity of one of the fluorochromes marking the allele 1 and in the x axis the intensity of 
the other fluorochrome for the second allele. A is an example of a good result where it is 
possible to differentiate well the three genotypes: A1A1 (blue dots), A1A2 (green dots) and 
A2A2 (red dots) with some indeterminate individuals represented as grey pluses. B is an 
example of a difficult determination, but it still maintains two groups of dots with a high 
intensity of one fluorochrome and low for the other and a group of dots in the middle. On 
the contrary in C, one of the genotypes (the blue) is very ambiguous and has a high 
intensity for both dyes. 
 
4. 2. Data Quality Control  
Before embarking in the statistical analysis of the genetic data there are some important 
quality controls (QCs) to apply to avoid any bias in the subsequent analysis and to minimize 
the risk of false positive and false negative results. These quality controls are applied at both 
subject samples and SNPs101–104. Different software can be used to conduct these QCs on 
GWAS data, such as PLINK105, the R GenABEL package106 and EIGENSTRAT107. 
 
4.2.1. Quality controls at the individual sample level 
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Five criteria are often used to identify individuals with genotypic information of 
insufficient quality to ensure validity of the subsequent statistical analysis. 
Informative Missingness -When the percentage of SNPs with no assigned genotype 
for a given individual (a.k.a., missingness or genotype calling rate =1-missingness) is high, 
the individual is generally excluded from the GWAS analysis. This phenomenon may occur, 
for example, when the DNA quality is low. In general, a missingness threshold of 5% (or 
sometimes even 1%) is adopted, meaning that any individual with SNP call rate smaller than 
95% (or 99%) of the SNPs genotyped is excluded from further analysis. 
Gender Check- When the sex status reported in the clinical data file of an individual 
does not match the sex status inferred from the SNPs of X and Y chromosomes, the 
individual is usually excluded from the analysis. For example, males must generally not be 
heterozygous for SNPs on X chromosome (except the ones in the pseudoautosomal region). 
This may occur when there have been errors mislabeling the DNA samples or due to 
contamination (i.e., the DNA of two individuals have been mixed and genotyped together). 
Heterozygosity - This test is based on the proportion of heterozygous SNPs for each 
individual104 and is applied to detect those individuals with higher or smaller heterozigosity 
than expected according to Hardy Weinberg equilibrium (described afterwards). An excess 
of heterozygous SNPs could indicate a contamination of the samples whereas an excess of 
homozygosity (low heterozigosity) could indicate inbreeding (mating between relatives) or 
samples from other populations. Actually, a simple visual inspection of the distribution of 
heterozygosity across the whole genotyped individuals permits to detect "outlier" samples 
(Figure 4.4.). This heterozygosity parameter is also dependent on the missingness 
(discussed above), the kind of population under study and the genotyped SNPs available for 
that population. For that reason there is no standard threshold established to filter out 
heterozygosity. Every study applies the best threshold according to their data and it is 
indicated in the posterior report108. For example, The Wellcome Trust Case Control 
Consortium* established empirically a threshold for his reference work in GWAS109 in which 
all those individuals with > 30% or < 23% of heterozygosity were excluded. 
Other studies use an inbreeding coefficient instead101, which is calculated for each 
individual i, with the proportion of 1-heterozygosity (homozygosity) as following105: 
Inbreeding coeff  
     
     
 
O is the observed homozygotes, E the expected homozygotes relaying on Hardy-
Weinberg equilibrium, and T the total of genotyped autosomal polymorphisms. A positive 
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test suggests an excess of homozygotes and a negative test, an excess of heterozygotes. 
Then the test values near 0 suggest a proportion of homozygous/heterozygous as 
expected101. 
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A Mean heterozygosity B Mean heterozygosity 
Figure 4.4. Two plots representing the relation between missingness (y-axis) and 
mean heterozygosity in a GWAS sample (3C study samples). The graph A individuals 
are displayed before any quality control. Some outliers are detected (in the up-right corner) 
of this graph. In B, the inbreeding coefficient based on heterozygosity of the individuals 
after apply all quality controls. 
 
Relatedness - Although GWA studies have also been developed to analyze families110, 
generally, they are implemented in unrelated individuals using standard generalized linear 
models (see Page 46). Therefore, it is important to assess that the GWAS individuals are not 
related beforehand. For that purpose, the genome-wide genetic information available for 
each subject can be used to assess the relatedness. Two individuals have a locus Identical 
by State (IBS) when they share, at least, half of the alleles for that locus, and that apprise 
about the genetic information in common. The values obtained by pair of individuals are 
0,1/2 or 1 meaning 0,1 or 2 alleles in common, respectively. For the pair of individuals of a 
GWAS dataset, one can compute their average IBS as the addition of the IBS for each SNP 
divided by the total number of SNPs measured. 
     
            
           
 
Then, when a pair of individuals has an IBS> 0.95 or 0.98, the one with less call rate 
(less genetic information) is removed. 
Outliers and population stratification- Another relevant issue in a GWAS is the 
possible existence of an unknown stratification of the studied, i.e., a subgroup of individuals 
with different genetic background (alleles and frequencies). If it is not properly detected and 
taken into consideration, such phenomenon can produce significant false positives. Two 
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strategies are commonly used to detect population stratification: the multidimensional scaling 
and the principal components analysis. 
Multidimensional scaling (MDS) - MDS is a statistical method that represents graphically 
a group of samples based on a given distance matrix. In the GWAS context, the IBS value of 
a pair of individuals (above) is used, more exactly 1-IBS, to define the genetic distance 
between two individuals. The aim of this method is to observe the stratification of the 
samples and to detect atypical individuals that might come from a different population. The 
method distributes the individuals in a 2-dimension graphic, plotting together those who are 
homogenous or similar and drawing like a cloud of points (see Figure 4.5. C). It was 
considered as outliers those plotted outside the cloud with a distance of 3 times the standard 
deviation from the center (Figure 4.5. A and B, the red dots). Other works consider 2 or 4 
times. Once such individuals are excluded from the group, the process is repeated a couple 
more of times until obtain a stable "cloud", i.e., homogenous group of samples (Figure 4.5. 
C). 
 
A first MDS without filter B 2nd MDS after the first filtering C final MDS of homogenous samples 
Figure 4.5. Multidimensional scaling graphics to detect outliers in a group of samples 
from Three City Study: every point is and individual. Those in black are considered 
homogenous within the group and the red ones the outliers, who have a distance of 3 times 
the standard deviation from the center-the group of samples. For instance, in A) red points 
appear at the left bottom and on top in the middle (MDS from 3C individuals). 
 
Principal Components Analysis (PCA) -PCA is a method that explores and ranks the 
correlation structure of a sample under study. It is a dimension-reduction method widely 
used in biomedical research field. In the context of GWAS, the fundamental idea is to create 
components that can resume the general variability of the SNP data. Assuming n individuals 
genotyped for m SNPs, PCA distributes the SNPs in m-dimensions plan where each 
individual (with his/her m genotypes) are plotted (see an example Figure 4.6.). Individuals 
with similar genotypes would tend to be close to each other in this plot. Then, PCA creates 
"new" axis, called components, in which the genotypes will be projected characterizing a 
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hidden factor that explains part of the general variance of the SNP data. The first component 
is the one explaining the higher proportion of the variability of the data, the second 
component the one explaining the second higher proportion, and so on. Once the genotype 
data of an individual is projected into each m derived components, this individual can be 
characterized by his/her coordinates on each component. In an extreme case where the 
studied GWAS sample is composed of two populations with different genetic background, 
the coordinate of an individual on the first principal component can identify the subpopulation 
the individual belongs to. 
 
Figure 4.6. Graphic representation of a PCA111. In a), there is the 3-dimentional 
representation of a group of samples. Each axis can be a SNP that gives information about 
the samples. In b), 3 principal components have been created (the arrows) where the red 
one is the first principal component, the blue the second, and the green the 3rd principal 
component. In c), there is the distribution of the samples according to the 2 first principal 
components created that resume the information given by the 3 SNPs. 
 
Adjusting the statistical association analysis of each SNP with the phenotype for the first 
k components (page 58) is sufficient to handle any undetected stratification of the studied 
populations. However, the choice for the k value may depend on each GWAS study. Often, it 
is recommended, to identify the main components (k = 1,2, ...10) that are significantly 
associated with the phenotype of interest and to adjust for them in the subsequent SNP 
association analyses. 
4.2.2. Quality controls at the SNP level 
Three filtering steps are also recommended for pruning the SNPs of poor quality in order 
to obtain reliable results: 
SNP Missingness or call rate -Similar to what was described above for the informative 
missingness, any SNP that is correctly called (or genotyped) in less than 99% (sometimes 
95%) of the samples are excluded from the analysis. 
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Hardy-Weinberg equilibrium (HWE) - The Hardy-Weinberg law112 states that a 
population is in equilibrium when the individuals and their genes (and variants) have: a 
proper size to avoid genetic drift, no inbreeding but a randomly mating, no mutation events, 
no migration and no selection pressure. Under these ideal conditions, if the frequencies of 
two alleles A/a at a given locus are p and q respectively, after 1 generation of random mating 
the alleles shoud be in equilibrium and the genotype frequencies should be: AA=p2, Aa=2pq 
and aa=q2; in the case of only two alleles per locus: p+q = 1 and p2+2qp+q2=1. 
Deviation from HWE cannot only occur when the above conditions are not met but also 
when there are some genotyping errors113. Therefore, any SNP demonstrating strong 
deviation from HWE must be excluded from the subsequent GWAS analysis. HWE is often 
tested using a standard chi-square test with 1 degree114 of freedom comparing the observed 
genotype distribution of each SNP with the expected one under equilibrium hypothesis. This 
test is applied to all genotyped SNPs, and for that reason the statistical threshold of 0.05 is 
not used for declaring statistical deviation from HWE. Rather a more stringent threshold 
(e.g., p < 10-5), partially controlling for multiple testing issues, is advocated. When the GWAS 
sample is composed of cases and controls, HWE should be only tested in controls, as strong 
HWE deviation in cases samples may hide a true association with the disease which would 
be missed in the SNP had been excluded on the basis of HWE in cases or cases + controls). 
Minor Allele Frequency (MAF)- Finally, to avoid noise (random hybridization giving 
signal in the genotype calling) and poor quality in the general results, it is recommended to 
discard from the analysis any rare SNPs, i.e., with MAF as low as 5% (or 1% according to 
the study sample size). 
 
4.3. Statistical Testing for SNP - phenotype association 
Once data QCs have been correctly applied, it is time to test for the association of SNPs 
with the phenotype of interest. There are different methods to perform an association study. 
The choice depends on the kind of samples (family or unrelated individuals), the background 
information (Bayesian or not) and the studied trait114. Standard methods are those based on 
generalized linear model (GLM) that can easily incorporate confounding factors to adjust the 
relation between the phenotype and genotype. For instance: age, sex, smoking and the 
principal components (PCs) discussed in page 43. A logistic regression model is adopted for 
a binary trait and a linear one for a quantitative phenotype. 
By default, an additive allele effect is commonly used to test for the association of a 
SNP with a trait115. In the case of a linear model, this implies that the expected phenotypic 
Chapter 4. Genome-Wide Association Studies 
 
 
45 
mean is expressed as:                 . Where G is the variable denoting the tested 
genotype and takes values: 0,1 or 2 according to the number of rare or reference alleles 
carried by an individual, depending on the software. μ is the average phenotype mean, g 
represents the genotype and β is the additive effect. Other genetic models such as recessive 
and dominant can also be tested. In those cases, the G variable takes the values (0,0,1) and 
(0,1,1), respectively, instead of (0,1,2). 
For each tested SNP, the β coefficient and its standard error are generally obtained by a 
Maximum Likelihood procedure, which also provides the corresponding p-value for 
association between the SNP and the phenotype. 
Visualization of the GWAS results 
GWAS results are normally checked for possible false positives with a Quantile-Quantile 
(QQ) plot115, where the distribution of the observed p-values is compared to the expected 
under the null hypothesis of no SNP-phenotype association. The aim is to detect if there are 
more significant results than expected by chance. By definition, p-values under the null 
hypothesis follow a uniform distribution on the [0-1] interval. Then, the expected distribution 
of the m SNPs p-values can be obtained by computing for each j p-value the corresponding 
expected p-value Ej: 
   
 
     
 
The observed and expected p-value distributions are then transformed to -log10, ordered 
from the lowest to the highest, and plotted one against the other into a QQ plot. Under the 
null hypothesis, this should lead to a diagonal line "y = x". When there is deviation from this 
line only at the right tail of the distribution, it indicates that a true non-null association may lie 
in the results (Figure 4.7.). 
 
 
Figure 4.7. Example of QQplot 
of 3C study. In the Y axis the 
observed p-values and in the x 
axis the expected p-values. Both 
transformed: -log10 (p-values). In 
blue is shown the associated 95% 
confidence interval for the null 
hypothesis. 
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When the observed line deviates early from the straight line "y = x", there is a strong 
element in favor of spurious associations due to uncontrolled population structure, cryptic 
relatedness or other undetected phenomena, e.g., the applied test statistic is not correct115. 
This deviation can be measured by estimating the regression coefficient of the observed 
line "y = λ x ", also called the genomic inflation (GC) factor (Figure 4.8.). A λ value deviating 
from 1.00 (i.e., greater than 1.05 or lower than 0.95) indicates that something went "wrong" 
in the GWAS results. A Chi-Square statistic with 1 degree of freedom (df) is used to assess 
the SNP associations. The GC factor can also be obtained by computing the median of the 
observed Chi-square and dividing it by 0.455625 which corresponds to the median of a Chi-
square distribution with 1 df. 
A  B  
Figure 4.8. QQ plots showing deviation from what expected. In the case of A, 
there is a deviation showing lower p-values from what expected even though it is 
not too strong (λ=1.032). In the case of B, there is deviation under the diagonal, 
generally indicating over adjustment (λ=0.96). 
 
Finally, once we have validated that no strong inflation lies in our GWAS results, p-
values (-log10 (p-values), more precisely) are plotted in a graphic according to the genomic 
position of the associated SNP. This kind of graph is generally known as Manhattan (MH) 
plot (Figure 4.9.). 
 
Figure 4.9. Example of Manhatan plot or MHplot of MARTHA study. The 
Y-axis represents the observed -log10 (p-values) sorted by chromosome and 
position(x-axis). Each dot represents a SNP p-value. 
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4.4. Correction for Multiple Testing 
The use of a test statistic to assess a specific hypothesis can generate two different 
errors: The false positives (α) and false negatives (β). A common approach to control these 
errors is to reduce as much as possible the β, i.e., to increase the power of the test (1- β) 
while accepting arbitrarily a certain error α (normally α=0.05). However when the number of 
test increases, the probability that the test falsely declare significance increases 
proportionally with the number of tests (m): 
P(Type I Error)=1-(1-α)m 
Therefore, in a GWAS where association tests are repeated over thousands of millions 
of SNPs, it is very important to adopt a very low statistical threshold for declaring a SNP-
phenotype association significant while controlling for false positives. 
Several corrections have been proposed in the context of GWAS to handle the multiple 
testing issues and readers interested in this topic are invited to have a look at the 
references116–118 for more literature. Currently, the general recommendation is to use a 
genome-wide statistical threshold of 5 10-8 to declare genome-wide significance while 
controlling for a type I error of 5%. This threshold has been obtained by empirical and 
simulation studies estimating the number of independent common SNPs over the genome 
and then applying a standard Bonferroni correction on it119–121. 
The Bonferrroni correction is part of a group of test corrections called Family-wise Error 
Rate (FWER). It is defined as the probability to obtain at least one false positive in the case 
that all the tests result in the acceptation of the null hypothesis (H0). Bonferroni
122 proposed 
the following correction or threshold (α') considering the independence between N tests 
performed: 
       
This correction is optimal to avoid any false positive when replicating a finite number of 
tests. But in some cases such as GWAS, where there are enormous numbers of tests (one 
for each SNP), it is not possible to assure the total independence between those tests. Then 
the correction becomes too stringent increasing the risk of false negatives. 
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4.5. Meta-Analysis of GWAS datasets 
The Meta-analysis strategy is an effective approach that combines results obtained in 
different studies evaluating the same hypothesis when it is not possible to re-analyze all the 
data together at once (Mega-Analysis). This can occur when study designs are different, the 
confounding factors are not available in all studies, or the ethical and legal issues prevent 
from sharing the whole raw data. The combination of the GWAS results with meta-analysis 
method increases the power of the detection and, so far, this approach has provided 
numerous successes115. 
Generally, the combination or meta-analysis can be implemented by two different 
methods. One method combines the p-values obtained in each study to get an overall 
statistical evidence of the tested hypotheses. The other approach, widely used in the field of 
GWAS, provides a pooled estimate or a combined global coefficient characterizing the 
tested association (e.g., the regression coefficient described above in page 45) from each 
study-specific coefficient and its standard error. The method consists in: 
Let βi be the regression coefficient associated with a given SNP in the i
th study (i = 1, 
2,..., N), and SEi its standard error. The standard method consists in estimating a combined 
(or pooled) average for this SNP using the following formula: 
   
         
   
           
 
Then, it is possible to obtain a statistic that follows a Chi-Square distribution with 2 x N 
degrees of freedom. 
    
       
 
      
 
If the above statistic is significant, then a valid standard error for the resulting    is given 
by: 
        
 
     
  
 
The resulting coefficient is generally called the fixed-effect meta-analysis estimate. It is 
important to highlight that this method is valid when there is no heterogeneity between the 
individual regression coefficient (βi's) across the distinct studies. The absence of heterogeneity 
can be tested by the Cochran-Mantel-Haenzel Q or the Thomas and Higgins I2 test statistics. 
By defining 
Chapter 4. Genome-Wide Association Studies 
 
 
49 
   
 
      
   
then the Q test statistic is given by             
 
. Under the null hypothesis of no 
heterogeneity, Q follows a Chi-Square distribution with N-1 df. 
Related to the Q statistic is the Thomas and Higgins I2 defined as: 
I
2      
      
 
 
This criterion quantifies the degree of inconsistency/heterogeneity among the studies. It 
represents the percentage of total variation among the studies induced by their 
heterogeneity and not by chance123. I2 is generally positive (if not, it is fixed to 0) with 
evidence for heterogeneity and increasing together. When heterogeneity is suspected, the 
fixed-effect analysis is discarded in favor of a random-effect (RE) analysis. 
The RE analysis aims at incorporating an estimation of the inter-study variability into the 
estimation of the pooled β estimate. This estimation, , is given by: 
    
       
    
   
 
   
   if      
and      , if      . 
Defining   
     
       
  
, the RE estimate of     the     , and the SE is given by 
    
   
    
   
            
 
     
 
   
 
 
 
Once the combined     and its standard error are obtained, the statistical evidence for 
association is given by computing the p-value of the corresponding t (or Chi-square) test 
calculated as the ratio of     over its standard error (or the square of this ratio). When the 
meta-analysis p-values are obtained for all tested SNPs, the MH and QQ plots can be 
obtained together with the value of the genomic inflation factor (λ). 
The main limitation when trying to meta-analyze the results of several GWAS analyses 
on the same phenotype is that the genotyped SNPs are not necessarily the same in the 
different GWAS studies. This can occur when different DNA microarrays with different 
genetic content are used across studies and/or when some SNPs did pass the QCs in some 
but not all studies. However, this limitation has been solved with the development of novel 
statistical techniques relying on "imputation". 
2ˆ
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4.6. Imputation Analysis 
The Imputation technique is a method to infer polymorphisms, that have not been 
measured in the microarray. It uses the information of a reference panel of genotypes and 
haplotypes composed by a large number of genotyped SNPs. Sometimes it is called an in 
silico genotyping method124,125. The reference panel is constituted by a "model" group of 
individuals from whom extensive genetic sequence information is known. The most used 
reference panels are the HapMap126 and the 1000 Genome Project127. Both tools are 
essential in current human genetic research by providing access to the exact genetic 
sequence of a large number of individuals. 
The basis of the imputation method is as follows: let's assume for a moment that a 
known reference population has three particular SNPs (e.g., A1/G1, C2/A2 and G3/T3) that can 
only generate four haplotypes (H1, H2, H3 and H4), 
H1 ----A1 C2 G3---- with frequency f1 
H2 ----A1 A2 T3----with frequency f2 
H3 ----G1 C2 T3---- with frequency f3 
H4 ----G1 A2 T3----with frequency f4 
with haplotype frequencies (f1, f2, f3, f4) whose distribution satisfies HWE. Then, let's take a 
group of samples under study that have been genotyped only for the SNPs A1/G1 and G3/T3. 
If an individual has the following genotypes: A1A1 and T3T3, it can be deduce (or 
imputed) by observing the previous haplotypes that the non-genotyped C2/A2 SNP would be 
A2A2. Indeed, this individual carries two A1 and T3 alleles and this combination of alleles is 
only found in the H2 haplotype. Therefore, the individual is certainly homozygous for the H2 
haplotype and thus it carries two A2 alleles. 
Similarly, if an individual caries the A1A1 and T3G3 genotypes, it can be estimated (or 
imputed) that it carries one haplotype A1T3 (H2) and one A1G3 (H1) and therefore this 
individual is C2A2 for the non-genotyped C2/A2 - SNP. 
The situation becomes a bit tricky for an individual with genotypes A1G1 and T3T3. 
He/she can be either A2C2 (haplotype pair H2H3) or A2A2 (haplotype pair H2H4). If one has 
access to a precise estimate of the different haplotype frequencies in the reference 
population (the f1, f2, f3, f4), then it is possible to estimate that this individual has a genotype: 
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- A2C2 with a probability of P(A2C2 / A1G1& T3T3) 
  = P(A1A2T3& G1C2T3)/[ P(A1A2T3& G1C2T3) + P(A1A2T3& G1A2T3)] 
  = 2 f2f3/ (2 f2f3 + 2 f2f4) 
  = f3/ (f3+f4) 
or 
- A2 A2 with a probability of f4/ (f3+f4). 
And so on... 
 
As a consequence, when there is a reliable estimation of the haplotype structure derived 
from the reference population, including haplotype frequencies estimation, it is possible to 
infer (impute) non-genotyped SNPs. Always assuming that the reference population has 
similar genetic background as the sample under study. 
 
There are different software programs that can perform imputation analysis for unrelated 
samples, such as fastPHASE/BIMBAM128, BEAGLE129, IMPUTE130 and MACH125. Generally, 
these software programs compute, for each non genotyped SNP, the posterior genotype 
probability given the measured SNP data of an individual, and then assign to this individual 
an expected number of imputed alleles (often called imputed dose or dosage). For example, 
the imputation of an individual who lacks the SNP A/C can result AA, AC or CC with a 
posterior probability fAA, fAC and fCC. Then, his/her C allele imputed dose would be 2 x fCC + 
fAC. This dose can take values between 0 (e.g. for individuals of genotype AA with probability 
1) or 2 (e.g. for individuals of genotype CC with probability 1) and are used in regression 
models to test for the effect of the imputed SNP on the phenotype of interest. When the 
allele dose is very close to 0, 1 or 2, indicates slightly uncertainty about the inferred 
genotype, meaning homozygous for one allele, heterozygous and homozygous for the other 
allele respectively. The level of certainty in the allele dosage estimation can be quantified as 
the squared correlation coefficient, r2, between the expected allele count derived from the 
assumed known allele frequencies and the expected given the measured genotypes131. A r2 
value close to 1 indicates complete genotype determination of the non-measured SNPs. 
Conversely, a r2 value close to 0 indicates that the measured genotypes of the samples are 
not enough informative to bring the genotype of the missing SNP. The imputation of a SNP 
is considered acceptable when r2>0.3 and good when r2>0.8125,132. 
 
Before embarking into the imputation analysis per se, there are some additional controls 
necessary to guarantee a good procedure and expect the "highest" quality possible in the 
results. It is important to check if the genotyped data of the samples are accordingly to the 
annotations used in the reference panel. Approximately every year, a new annotation of the 
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human genome (list of polymorphism, their names, their genomic coordinates and their 
alleles) is updated. Since imputation techniques require the name of the SNPs (those 
measured and those to be imputed), their genomic position and their condition of reference 
/alternative alleles, it is very important to check whether the GWAS SNP data are annotated 
in the same way as the reference panel in use. 
 
4.7. Replication of the GWAS findings 
Once the GWAS analysis (or the meta-analysis of GWAS) is completed and the p-
values for all tested (genotyped and imputed) SNPs are available, it is time to bring the most 
significant associations for replication in independent samples and assess their robustness 
and validity to avoid claiming false-positive associations115. 
As described above, one usually assesses for replication the SNPs that have reached 
the pre-specified genome-wide significance threshold (~5·10-8). However, according to 
GWAS samples size and the unknown underlying genetic effects of the phenotype-
associated SNPs, genuine associations may hide under the heap of genome-wide significant 
signals. This is related to the power of the study. This is why it is not infrequent to reduce the 
stringency of the statistical threshold and to adopt a less stringent threshold (p <10-7 or even 
p<10-5) to increase the number of selected SNPs for replication. 
Then, the replication consists in investigate the association of the SNPs selected with 
the phenotype in another independent population. This association can be assessed by 1) 
wet-lab genotyping the SNP of interest, 2) wet-lab genotyping another SNP (referred to as a 
"proxy SNP") known to be in complete linkage disequilibrium (in particular from public 
reference panel database) with the candidate SNP when the latter is not technically 
"genotypable" using any standard protocol technique, 3) looking at the results of previously 
reported GWAS on the same phenotype where the SNP of interest has been measured or 
imputed (a.k.a in silico genotyping). 
When several SNPs are tested for replication in independent populations, the Bonferroni 
correction is commonly used to address the multiple testing issues and controls for the false 
positive rate at the replication stage (page 49). 
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Chapter 5. A "GWAS Study" on Thrombin Generation 
Potential
 
In this chapter, I describe the samples I used in my firsts analysis and I also specify the 
details I performed to achieve my GWAS according to the steps I exposed in the previous 
chapter. Then I present the results I obtained followed by the discussion. 
5.1. Discovery GWAS cohorts 
MARseille THrombosis Association (MARTHA) project28,133,134 coordinated by 
Professor Pierre-Emmanuel Morange, is composed of 1,592 unrelated Venous Thrombosis 
(VT) patients, mainly of French origin. Individuals were consecutively recruited at the 
Thrombophilia center of La Timone hospital (Marseille, France) between January 1994 and 
October 2005. All patients had a history of a first VT event documented by venography, 
Doppler ultrasound, angiography and/or ventilation/perfusion lung scan. They were all free of 
any chronic conditions and free of any well characterized genetic risk factors including anti-
thrombin, protein C or protein S deficiency, homozygosity for FV Leiden or FII 20210A, and 
lupus anticoagulant. 586 VT patients were typed with the Illumina Human 660W-Quad 
Beadchip and 1,011 patients were typed with the Illumina Human 610-Quad Beadchip. 
551,141 SNPs were in common between both arrays and available in the MARTHA patients. 
Thrombin generation potential was measured in a subgroup of 848 MARTHA patients 
using the method CAT (Chapter 2, page 22). 
The Three City Consortium Study (3C Study)135 is a population-based study carried 
out in 3 French cities: Bordeaux, Dijon, and Montpellier. The principal aim of the project is to 
find out if there are vascular factors that can account for the risk of dementia and loss of 
memory. It is composed of 8,707 non-institutionalized individuals aged over 65, randomly 
selected from the electoral rolls and free of any chronic diseases. Between March 1999 and 
April 2001 the 3C samples were recruited, examined and interviewed for general health 
information, lifestyle, cognitive tests, diagnosis of dementia and family history. For my PhD 
project I had access to a sample of 1,314 subjects with genome-wide genotype data typed 
with the Illumina Human610 DNA chips including 582,892 SNPs, and from those, 1,253 had 
Part I 
 54 
plasma available for TGP measurements. TGP measurements were obtained using the 
same CAT technique as in MARTHA. 
5.1.1. Genotyping Quality Controls and Imputation 
The application of genotype quality controls in MARTHA and 3C, separately (Figure 
5.1.), resulted in the final selection of 491,285 and 487,154 autosomal SNP, respectively. 
These SNPs were then used for imputing separately 11,572,501 SNPs reported in the 1,000 
Genome reference database (release 08/2010) using the MaCH program. After selecting the 
common SNPs with imputation quality r2>0.3 and minor allele frequency (MAF) greater than 
0.01, 6,652,054 were left for association analysis with TGP biomarkers. 
 
Figure 5.1. Diagram of the filters applied in MARTHA 
and 3C studies. 
 
Individuals with genotyping call rate <95% were discarded from the analysis, as well as 
individuals demonstrating close relatedness as suspected from pairwise clustering of IBS, 
and genetic outliers and substructure detected by multidimensional scaling and PCA107. 
Finally, 714 and 1253 individuals from the MARTHA and 3C study were left for association 
analyses respectively. 
 
5.1.2. Clinical and biological characteristics of the discovery cohorts 
Detailed description of the biological and clinical characteristics observed in the 
MARTHA and 3C are shown below in Table 5.1. extracted from my publication Rocanin-
Arjo et al. 201494. 
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In order to handle non-normal distributions, a log-transformation and a normal quantile 
transformation were applied to ETP and Lagtime values, respectively, separately in the 2 
cohorts (Figure 5.2.). 
   
  
Figure 5.2. Density distributions of TGP biomarkers. On top and from left to rigth: 
ETP, Peak and Lagtime raw data. On the bottom, the log transformed ETP (left) and the 
quantile transformed Lagtime (middle) distributions. MARTHA in purle, 3C in green. 
 
Table 5.1. Characteristics of the studied populations. 
 
MARTHA 
N = 714 
3C 
N = 1,253 
Age (SE)- yrs 46.84 (15.29) 75.05 (5.75) 
Sex (% Male) 32.1% 41.6% 
% VT patients 100% 0% 
BMI (SE) (kg/m2) 25.1 (4.55) 25.8 (4.22) 
FV Leiden 
(1)
 153 (21.4%) - 
F2 G20210A 
(1)
 83 (11.6%) - 
Oral coagulant - 52 (4.2%) 
ETP (nM/min)
 
[1
st
 - 3
rd
] 
1780 
[1554 -1958] 
1775 
[1586 - 1947] 
Peak (nM) 
[1
st
 - 3
rd
] 
333.0 
[293.5 - 372.0] 
332.8 
[307.0 - 364.3] 
Lagtime (min) 
[1
st
 - 3
rd
] 
3.229 
[2.830 - 3.500] 
1.382 
[1.000 - 1.670] 
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 Correlation between TGP markers 
(2)
 
ETP - Peak ρ= 0.78*** ρ= 0.77*** 
ETP - Lagtime ρ = 0.14* ρ = 0.06* 
Peak -Lagtime ρ = -0.05* ρ = -0.10*** 
(1)
 FV Leiden and F2 G20210A mutations were genotyped in MARTHA as part of the inclusion criteria. Homozygous 
carriers were not included in the study.  
 (2)
 Correlations were computed on transformed values (i.e., log-transformation on ETP and quantile normalization 
for Lagtime) adjusted for age, sex, oral coagulant therapy, F2 G20210A (when appropriate) and BMI. 
***<0.00001,**<0.0001,*<0.05 
 
ETP and Peak biomarkers have a strong positive correlation, ρ = 0.80, both in VT 
patients and healthy subjects. Conversely, Lagtime exhibited very low correlation with the 
other two TGP biomarkers (Table 5.1.). 
 
5.1.3. Statistical methods and adopted research strategy 
The association of imputed SNPs with each TGP biomarkers was conducted separately 
in MARTHA and 3C. A linear regression model was applied with the imputed allele dose as 
covariate characterizing the imputed SNPs effects (Figure 5.3.). Analyses were adjusted for 
age, sex, contraception and anticoagulant therapy and the first 4th principal components 
derived from the GWAS QC genotypes (page 40). Association analyses were conducted by 
use of the mach2qtl software125. A fixed-effect meta-analysis was then performed on 
MARTHA and 3C results altogether. Homogeneity of the results across studies was 
assessed using the I2 statistics136, derived from Mantel-Haenszel method137. The meta-
analysis was performed using the METAL software138. 
 
 
Figure 5.3. 
Diagram of the 
analysis 
procedure of the 
discovery step. 
 
In a first step of my research strategy, I focused on SNPs that reached the genome-wide 
significance level of 5 10-8 in the meta-analysis for each TGP biomarker. In a second step, I 
looked for SNPs that demonstrated association p-values <10-5 for at least two TGP 
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biomarkers. Such SNPs were then tested for replication in two additional French cohorts, 
MARTHA12 and FITENAT, where TGP markers were measured with the same technique. 
 
5.2. Replication cohorts 
MARTHA12 The MARTHA12 study is composed of 1,245 VT patients that have been 
recruited at the Thrombophilia center of La Timone hospital (Marseille, France) between 
2010 and 2012, following the same inclusion/exclusion criteria as those used for the 
MARTHA study (page 55).  
FITENAT139. The FITENAT study was designed in Health Examination Centers (HEC) 
selecting healthy individuals from the French Social Security of 11 regions distributed 
throughout France: Bordeaux (Aquitaine), Lille (Nord-Pas de Calais), Lyon (Rhône-Alpes), 
Marseilles (Provence C te d’Azur), Nancy (Lorraine), Nantes (Loire-Atlantique), Paris (Ile de 
France), Poitiers (Charente Poitou),  ennes (Bretagne), Strasbourg (Alsace) and Toulouse 
(Midi-Pyrénées). Each HEC recruited 600 individuals, 300 men and 300 women and they 
were grouped by age intervals of: 18–34, 35–49, 50–64, and >65 years. Other inclusion 
criteria were: a French origin for the individual and their parents, and European origin for 
grandparents. Individuals underwent a clinical examination where their personal and family 
history of chronic conditions was recorded, as well as details about lifestyle as: alcohol 
consumption, smoking habit, physical activity and medication (in case of women also 
contraception treatment). The FITENAT sample I used for my project was composed of 543 
healthy individuals with neither history of cardiovascular disease, diabetes, hypertension, 
renal nor hepatic failure; and those who were not under anticoagulant therapy. 
Detailed description of the biological and clinical characteristics observed in the 
MARTHA12 and FITENAT are shown below in Table 5.2. extracted from my publication94. 
In this case, both studies also present high correlation between ETP and Peak (ρ>0.7). 
However, they also present a small correlation between ETP and Lagtime, and just in the 
case of MARTHA12 also for Peak and Lagtime. 
 
5.2.1. Statistical methods and adopted research strategy 
Genotyping of the SNPs selected for replication was performed using allele-specific 
PCR in 733 MARTHA12 patients with available DNA. Association of genotyped SNPs with 
TGP biomarkers was assessed using a linear regression analysis under the assumption of 
additive allele effects. The same transformations on TGP phenotypes were applied as in the 
discovery GWAS cohorts to match the results. Analyses were adjusted for age, sex and oral 
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contraception therapy. A standard Bonferroni correction for the number of genotyped SNPs 
was applied to declare statistical evidence. 
 
 
Table 5.2. Characteristics of the MARTHA12 and FITENAT populations. 
 
MARTHA12 
N = 796 
FITENAT 
N = 543 
Age (SE)- yrs 49.74 (15.34) 47.81 (13.94) 
Sex (% Male) 42.9% 47.9% 
% VT patients 100% 0% 
BMI (SE) 
(kg/m2) 
26.0 (4.98) 24.2 (3.62) 
FV Leiden (1) 89 (11.2%) - 
F2 G20210A (1) 52 (6.5%) - 
Oral coagulant 24 (3.0%) - 
ETP (nM/min) 
[1st - 3rd] 
1892 
[1654 - 2124] 
1675 
[1456 - 1838] 
Peak (nM) 
[1st - 3rd] 
328.0 
[278.0 - 374.8] 
293.5 
[258.1 - 319.2] 
Lagtime (min) 
[1st - 3
rd] 
3.330 
[2.762 - 3.670] 
2.280 
[2.000 - 2.500] 
 
Correlation between TGP markers 
(2) 
ETP - Peak ρ = 0.73*** ρ = 0.78*** 
ETP - Lagtime ρ = 0.19*** ρ = 0.34*** 
Peak -Lagtime ρ = -0.18*** ρ = 0.04 
 
(1) FV Leiden and F2 G20210A mutations were genotyped in MARTHA12 as part of the inclusion criteria. 
Homozygous carriers were not included in the study.  
 (2) Correlations were computed on transformed values (e.g., log-transformation on ETP and quantile normalization 
for Lagtime) adjusted for age, sex, oral coagulant therapy, F2 G20210A (when appropriate) and BMI. 
***<0.00001,**<0.0001,*<0.05 
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SNPs that showed statistical significant association with TGP biomarkers in MARTHA12 
were further genotyped in 528 FITENAT subjects. The same statistical methods were 
employed in FITENAT. 
Finally, results obtained in the four available cohorts were combined into a fixed-effect 
meta-analysis. 
 
 
5.3. Main GWAS findings 
A total of 6,652,054 polymorphisms were tested for association with each TGP 
biomarkers, ETP, Peak height and Lagtime, in a meta-analysis of 1,967 individuals from 
MARTHA and 3C cohorts. Corresponding QQ plots for each biomarker are shown below in 
Figure 5.4. 
 
Figure 5.4. Quantile-Quantile plots of the meta-analysis p-values combining 
MARTHA and 3C: ETP (left), Peak height (middle) and Lag-time(right). 
 
The associated GC inflation factors ware 0.998, 0.997 and 1.000, for ETP, Peak height 
and Lagtime respectively. 
 
5.3.1. GWAS analysis on ETP 
The Manhattan plot representation of the meta-analyzed GWAS findings for ETP is 
shown in Figure 5.5. 
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Figure 5.5: Manhattan plot representing the p-values of the GWAS meta analysis on 
ETP.The horizontal dashed line corresponds to the statistical threshold of 5 10-8. 
 
Seventeen SNPs, all mapping to the chromosome 11p11 region, were genome-wide 
significantly associated with ETP. The compelling signal was observed for MYBPC3 
rs2856656 SNP (p = 4.62x10-22). This polymorphism had already been shown to be in strong 
LD with the F2 G20210A mutation (rs1799963)140, a variant well established to influence 
thrombin generation. In MARTHA, the rs1799963 was genotyped as part of the inclusion 
criteria. In the 3C study, the quality of its imputation was of borderline quality (r2 = 0.274 
<0.30). As a consequence, this variant was not included in my initial GWAS meta-analysis 
(that was restricted to imputed SNPs with r2> 0.3 in both cohorts). Nevertheless, I ran a 
second round of GWAS where I further adjusted the analysis on the rs1799963 (imputed in 
3C), separately in MARTHA and 3C, and meta-analyzed the results. Resulting Manhattan 
plot is shown in Figure 5.6. 
Fourteen SNPs were still significantly associated with ETP at p < 5·10-8. The strongest 
association was observed at the 11p11 region, but for another F2 polymorphism, rs3136516 
(p = 5.94·10-14). A third round of (GWAS) analysis further adjusted for rs3136516 did not 
reveal any other significant SNP. As a reminder, the F2 rs3136516 is another variant known 
to influence thrombin generation (page 27). 
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Figure 5.6. Manhattan plot representing the p-values of the meta-analyzed GWAS for 
ETP conditioning on the F2 rs1799963. The horizontal dashed line corresponds to the 
statistical threshold of 5 10-8. 
 
A multivariate analysis simultaneously incorporating the F2 rs1799963 and rs3136516 
variants demonstrated that their effects on ETP were independent. In the meta-analysis of 
our two cohorts, the rs1799963-A (β = + 0.225 ± 0.019, p = 2.66·10-31) and the rs3136516-G 
(β = + 0.040 ± 0.006, p = 5.89·10-11) alleles were both associated with increased ETP. These 
effects were homogeneous in MA THA (β = + 0.224 ± 0.019; β = + 0.042 ± 0.009, resp.) 
and in 3C (β = + 0.287 ± 0.135, β = + 0.039 ± 0.008, resp.), with no statistical difference 
(p>0.05) between studies. It's worth to note that, while the rs1799963-A allele was much 
more frequent in MARTHA patients than in 3C healthy subjects (0.058 vs 0.005), there was 
no difference for rs3136516-G allele frequencies (0.48 vs 0.47, resp.). 
 
5.3.2. GWAS analysis on Peak height 
The GWAS findings for Peak height (with MH plot shown in Figure 5.7.) paralleled those 
obtained for ETP. Twelve SNPs, all on the 11p11 region, were significantly associated with 
Peak height at p < 5 10-8. These were as those strongly associated with ETP. In particular, 
the second most significant SNP was rs2856656 (p = 8.29·10-11). After further adjusting for 
rs1799963, two F2 SNPs remained in complete association with Peak height, rs3136512 
and rs3136516 (both p = 2.91·10-8). No other SNP was genome-wide significant after a 
second adjustment for rs3136516. As for the ETP biomarker, the effects of the rs1799963-A 
and rs3136516-G alleles were independent, β = + 45.37 ± 7.45 (p = 1.10·10-9) and β =+ 9.79 
± 2.03 (p = 1.36·10-6), respectively. These effects were homogeneous between the 
MA THA (β = + 44.37 ± 7.58; β =+ 12.26 ± 3.56, resp.) and 3C (β =+ 73.22 ± 39.97; β = + 
8.62 ± 2.46, resp.) studies. 
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Figure 5.7. Manhattan plot representing the p-values of the GWAS meta analysis on 
Peak height. The horizontal dashed line corresponds to the statistical threshold of 5·10 -8. 
 
5.3.3. GWAS analysis on Lagtime 
As it can be observed on the MH plot summarizing the main GWAS findings for the 
Lagtime meta-analysis (Figure 5.8.), no SNP demonstrated strong evidence for association 
with the biomarker. Additionally, contrary to the previous results, Lagtime show no evidence 
for association with the two F2 SNPs, F2 rs1799963 and rs3136516 (p = 0.096 and p= 
0.451, respectively). 
 
Figure 5.8. Manhattan plot representing the p-values of the GWAS meta analysis on 
Lagtime. The horizontal dashed line corresponds to the statistical threshold of 5·10 -8. 
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5.3.4. Joint GWAS analysis on two TGP biomarkers  
In order to improve our detection of SNPs associated with TGP, I studied the 
polymorphisms with effects not strong enough to reach the pre-specified genome-wide 
significant threshold of 5·10-8 but showing association at p < 10-5 for two TGP biomarkers. 
Joint analysis of ETP-Peak height - After adjusting for the F2 rs1799963 and rs3136516, 
7 SNPs mapping to chromosome 19q13, at the RPL7AP69 locus, showed association at p < 
10-5 with both ETP and Peak height. The lowest p-value was observed for rs117368154 
whose minor A allele was associated with decreased ETP (β= -16.29 ± 3.48, p = 2.83·10-6) 
and decreased Peak height (β= -0.054 ± 0.011, p = 3.39·10-7). These effects were 
homogeneous in the MARTHA and 3C studies, β= -0.056 p =6.5 10-4 and β= -0.052 p =3.4 
10-4, respectively. After adjusting for the effect of the rs117368154, the associations at the 
other 6 RPL7AP69 SNPs completely vanished with p-values >0.0083 (threshold according to 
Bonferroni: 0.05/6). 
Joint analysis of ETP - Lagtime - Four SNPs, in the promoter and coding regions of the 
ORM1 gene, exhibited association at p < 10-5 with both ETP and Lagtime. The lowest p-
value was observed for rs150611042. Its minor A allele associated with lower ETP (β= -
0.068 ± 0.013, p = 3.36·10-7) and Lagtime (β= -0.338 ± 0.073, p = 4.10·10-7). Results were 
again very homogeneous between MARTHA and 3C (see Table 5.3.). The rs150611042 is 
located in the promoter region of the ORM1 gene and was in strong LD with other ORM1 
SNPs (minimum r2> 0.86) whose associations with Lagtime disappeared after adjusting for 
rs150611042 (p-values >0.013, threshold according to Bonferroni: 0.05/4) 
Joint analysis of Peak height -Lagtime - No SNP was associated at p < 10-5 with both 
Peak height and Lagtime.  
 
5.4. Replication of GWAS findings 
According to the results of the GWAS meta-analysis, I selected the RPL7AP69 
rs117368154 and ORM1 rs150611042 for replication in the MARTHA12 study. No evidence 
for association of rs117368154 with ETP or Peak Height was observed (Table 5.4.). 
Conversely, I observed strong association of ORM1 rs150611042 with Lagtime (p = 2.46 10-
7). As in the two discovery GWAS cohorts, the rs150611042-A was associated with 
decreased Lagtime (β= -0.439 ± 0.084) (Table 5.3), but not with ETP (p = 0.147). The 
rs150611042 was then further genotyped in the FITENAT study where its A allele was also 
associated with decreased Lagtime (β= -0.280 ± 0.099, p= 5.04x10-3). Again, no association 
was found with ETP and Peak biomarkers (Table 5.3.). 
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Table 5.3. Association of ORM1 rs150611042 with TGP biomarkers in four independent studies (Table extracted from Rocanin-Arjo 
et al. Blood 2014). 
ORM1 rs150611042 
C/A 
MARTHA 
(N = 714) 
3C 
(N =1,253) 
MARTHA12 
(N = 726) 
FITENAT 
(N =528 ) 
Combined (3) 
(N = 3,221) 
Minor Allele 
Frequencies (A) 
0.089 0.082 0.096 0.095  
Lagtime      
 β(1) (SE) -0.329 (0.086) -0.343 (0.096) -0.439 (0.084) -0.280 (0.099) -0.354 (0.045) 
 P(2) p = 1.53 10-4 p = 3.85 10-4 p = 2.46 10-7 p = 5.04 10-3 p = 7.11 10-15 
ETP       
 β (SE) -0.041 (0.016) -0.083 (0.018) -0.024 (0.017) -0.013 (0.017) -0.038 (0.009) 
 P p = 0.015 p = 9.31 10-6 p = 0.147 p = 0.449 p = 8.41 10-6 
Peak       
 β (SE) -8.379 (6.107) -6.557 (5.516) 8.730 (6.286) -0.984 (4.592) -2.013 (2.748) 
 P p = 0.171 p = 0.233 p = 0.165 p = 0.830 p = 0.464 
(1)
 Additive allele effects associated with the rs150611042-A allele. 
(2) Association testing was performed by use of a linear regression model where values were adjusted for age, sex, oral contraceptive therapy (except in 3C) and on first four 
principal components (in MARTHA and 3C). In 3C, as well in 25 MARTHA patients, imputed allele dosage was used. Otherwise, the exact allele count derived from wet-lab 
genotyping was used.  
(3)
 Combined results were derived from a meta-analysis of the four studies under the framework of a inverse-variance weighting fixed-effect model (page 49). No heterogeneity 
was observed across cohorts, I2 = 1.67 (p = 0.795), I2 = 8.59 (p = 0.072) and I2 = 4.74 (p =0.314) for Lagtime, ETP and Peak, respectively. 
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Table 5.4. Association of RPL7AP69 rs55724737 with TGP biomarkers (adapted from 
Rocanin-Arjo et al. Blood 2014). 
RPL7AP69rs55724737 MARTHA 
(N = 714) 
3C 
(N =1,253) 
MARTHA12 
(N = 733) 
Combined (3) 
(N = 2,700) 
Minor Allele 
Frequencies 
0.087 0.071 0.067  
ETP  
β (SE) 
P 
-0.063 (0.018) 
p = 5.91 10-4 
-0.075 (0.017) 
p = 7.23 10-6 
0.010 (0.020) 
p = 0.622 
-0.048 (0.010)(4) 
p = 5.25 10-6 
Peak  
β (SE) 
P 
-16.96 (6.675) 
p = 8.95 10-3 
-23.23 (4.841) 
p = 1.79 10-6 
-2.54 (7.494) 
p = 0.735 
-17.23 (3.473) 
p = 6.93 10-7 
Lagtime 
β (SE) 
P 
0.098 (0.096) 
p = 0.302 
0.140 (0.085) 
p = 0.101 
-0.003 (0.103) 
p = 0.974 
0.087 (0.054) 
p = 0.107 
It was technically not possible to genotype the RPL7AP69 rs117368154 that was then substituted by its proxy rs55724737 (r
2
 
0.99, p<10
-16
). 
(1)
 Additive allele effects associated with the rs55724737-C allele.  
(2)
 Association testing was performed by use of a linear regression model where values were adjusted for age, sex, oral 
contraceptive therapy (except in 3C) and on first four principal components (in MARTHA and 3C). Imputed allele dosage was 
used in MARTHA and 3C while the exact allele count derived from wet-lab genotyping was used in MARTHA12. 
(3)
 Combined results were derived from a meta-analysis of the three studies under the framework of an inverse-variance 
weighting fixed-effect model. 
(4)
 The association of rs55724737 with ETP showed significant heterogeneity (I
2
 = 11.71, p = 0.003) across the three studies. 
No such heterogeneity was observed (p > 0.05) with Peak and Lagtime. 
 
5.5. Further analyses at the identified ORM1 locus 
When the four cohorts typed for the ORM1 rs150611042 were combined into a fixed 
effect meta-analysis, the overall statistical for association with Lagtime was p= 7.11·10-15 
with no heterogeneity across studies (p=0.795) (Table 5.4.). In the combined samples 
totaling 3,221 subjects, the decreasing effect on Lagtime associated with the rs150611042-A 
allele was β= -0.354 ± 0.045. Using a standard linear regression analysis, I further tested for 
any interaction between rs150611042 and F2 rs3136516 but did not observe such 
phenomenon (p for interaction = 0.172_MARTHA, MARTHA12 and 3C). In the two combined 
MARTHA and MARTHA12 VT samples enriched for F2 rs1799963 variant, the rs150611042-
A effect on Lagtime was homogeneous in patients with (β= -0.300 ± 0.255) or without (β=-
0.385 ± 0.062) mutation. 
In the discovery GWAS cohorts, the imputation quality for ORM1 rs150611042 was r2= 
0.51 and r2=0.56 in MARTHA and 3C, respectively. We also genotyped the rs150611042 
SNP in 689 MARTHA with available DNA in order to get additional information about the 
obtained imputation quality. For this sample, I then compared the results of the association 
of rs150611042 with Lagtime obtained using the imputed or genotyped data. The imputed 
dose and the true allelic count derived from genotype data were highly correlated (Pearson 
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correlation ρ= 0.73). The association of rs150611042 with Lagtime was slightly stronger 
using true genotyped allele count (β= -0.338 ± 0.087, p = 1.11·10-4) compared with the 
imputed dose (β= -0.362 ± 0.127, p = 4.71·10-3). 
5.5.1. Influence of ORM1 rs150611042 on clinical manifestations of VT 
As shown in Table 5.3. the allele frequencies of the ORM1 rs150611042 were very 
similar in the two VT cohorts (MARTHA and MARTHA12) and the two healthy subject 
samples (3C and FITENAT). However, I was interested to test whether this SNP could be 
associated with the two different clinical manifestations of VT, deep vein thrombosis (DVT) 
and pulmonary embolism (PE). No difference in allele frequencies was observed between 
these two VT groups (Table 5.5.).  
Table 5.5. Genotype frequencies of ORM1 rs150611042 depending on the type of VT 
in MARTHA and MARTHA12. 
ORM1 rs150611042 
C/A 
MARTHA 
MAF(A) 
MARTHA12 
MAF(A) 
DVT 0.077 0.097 
PE 0.056 0.079 
DVT/PE 0.073 0.103 
P-value
1)
 0.846 0.9585 
 
(1)
P-value obtained by a Fisher test to analyze the differences between the types of VT 
 
5.5.2. In silico association with gene expression 
 
To get support in favor of a potential functional effect of the ORM1 rs150611042, I 
tested the association of this SNP with ORM1 gene expression in two large epidemiological 
samples where the rs150611042 were imputed from GWAS data and where ORM1 gene 
expression was also available. More precisely, I had access to monocyte and macrophage 
ORM1 gene expression in 745 individuals of the Cardiogenics Transcriptomic Study (CTS)141 
where the rs150611042 was previously imputed (imputation r2 = 0.64). I also had access to a 
second independent sample of 1,374 individuals part of the Gutenberg Health Study 
(GHS)142 correctly imputed for rs150611042 (r2 = 0.75) and measured for monocyte ORM1 
expression. In both studies, the rs150611042-A allele was significantly associated with 
decreased monocyte expression in a fairly additive manner (p = 8.70·10 -10 and p = 5.21·10-16 
in CTS and GHS, resp.). The ORM1 rs150611042 explained around the 5% of the variability 
of monocyte ORM1 gene expression. A similar pattern of association, even though less 
significant (p = 3.18·10-3), was observed in CTS on macrophage gene expression (Figure 
5.9.). 
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(1)
 Mean (SD) 
 (2)
 Association test was performed between ORM1 expression and the imputed allele dosage of rs150611042 while adjusting 
for age, sex and center (in CTS). 
Figure 5.9. Association of ORM1 rs150611042 with ORM1 monocyte and macrophage 
expression. 
 
5.5.3. In vitro functional studies 
To get further functional arguments for the observed ORM1 association with Lagtime, 
the group of Professor Morange (INSERM UMR_S 1062) set up some in vitro experimental 
works. TGP biomarkers were measured in 10 poor platelet plasma samples with different 
concentrations of added ORM1 (see Results described in Rocanin-Arjo et al. Blood 2014). 
We showed that supplementing poor platelet plasma with orosomucoid, the protein encoded 
by the ORM1 gene, was followed by a significant increase in Lagtime and significant 
decreases in ETP and Peak Height. These effects were dose-dependent. In these samples, 
the basal correlation between ORM1 levels and Lagtime was ρ = 0.646 (p = 0.049) (Figure 
5.10.). 
 
 
Figure 5.10. Correlation 
between ORM1 plasma 
levels and Lagtime in a 
sample of 10 healthy 
individuals. 
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5.6. Discussion 
The (Meta) GWA study I conducted on the TGP biomarkers resulted in strong relation 
with two main genes: F2, affecting the variability of ETP and Peak for the same SNPs, and 
ORM1, a novel determinant of the variability of Lagtime. 
 
5.6.1. The main associations with TGP 
 
The two most significant F2 SNPs I detected in the GWAS, rs1799963 and rs3136516 
were already known to influence thrombin generation by increasing the prothrombin levels. 
The first polymorphism, the rs1799963-A (G20210A) is located in the 3’ UT  region of F2 
and so far, the studies point out that this variation at the 3'-end might be more efficient 
increasing mRNA stability, increasing translation efficiency, or a combination of these 
mechanisms74,75,143. The other, the rs3136516-G, also referred as A19911G, is located within 
the 13th intron of the gene, and affects an intronic splicing enhancer motif69,70. Remarkably, 
while the rs1799963-A allele is a rare (~2% in the general population) variant associated 
with a strong risk of VT, the rs3136516-G allele is common (~0.47 in all populations I have 
studied) and its association with VT risk is still debated74,75,120,144. A recent work (Segers 
20106) have related these two SNPs with thrombin generation, concretely with ETP 
measured by CAT45 but in presence of activated protein C20, in individuals heterozygous for 
FV Leiden. 
The main original finding of this GWAS project is the identification of ORM1 gene as a 
new locus participating somehow in the biological mechanisms of the thrombin generation 
pathway, mainly through an influence on the Lagtime phenotype. We detected a common 
ORM1 SNP associated with both decreased Lagtime levels and monocyte ORM1 
expression, and in vitro functional experiments confirmed the association between the 
encoded protein and thrombin generation. This SNP is located in the promoter region of the 
orosomucoid gene (Figure 5.11.). 
As indicated in my first publication, ORM1, also called alpha 1 acid glycoprotein (alpha1- 
AGP), has been related to many processes and the most known is regulating the immune 
response as an acute phase protein145. It has also been related to dermatologic allergies 
such as dermatitis, psoriasis and sarcoidosis146. The most appealing works for this project 
are those who propose a possible implication of ORM1 in coagulation: as a transport protein 
of the blood stream, as a modulator of the synthesis of tissue factor, hence regulating the 
intrinsic pathway initiation. It has been associated with the normalization of platelet 
aggregation, coagulation factors and antithrombin activity147. Additionally, high doses of AGP 
inhibit a certain kind of stimulation of platelet aggregation (ADP and adrenaline)148. 
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Apparently it interacts with plasminogen activator inhibitor 1 (PAI-1) too, stabilizing their 
inhibitory activity on plasminogen activators149. On the contrary, it reduces the activated 
Partial Thromboplastin Time (aPTT)150 and stimulate the monocyte expression of tissue 
factor (TF)151. Lately, ORM1 has been proposed as a cardiometabolic biomarker related to 
BMI152. It is still unclear its exact role in all mentioned processes. 
 
 
Figure 5.11. Diagram of the position of the rs150611042 SNP, the red line, 
marks the exact position of the SNP and in the top-left corner the ORM1 gene. 
 
5.6.2. Limitations and comments 
 
Despite the findings, the presented GWAS analyses suffer from some limitations that 
have already been acknowledged in the discussion of my first publication A meta-analysis of 
genome-wide association studies identifies ORM1 as a novel gene controlling thrombin 
generation potential, page 74) 
One of the limitations is that the studies have different clinical and biological 
characteristics, leading to a possible lost of detection power in the statistical test. Then, the 
ORM1 SNP was selected for its suggestive associations in the discovery cohorts with ETP 
and Lagtime. Although the correlation between Lagtime and ETP is stronger in the 
replication cohorts, we could not replicate the results in the case of ETP. Neither we can 
exclude the first association as false. Also, I analyzed the association of ORM1 expression 
with the rs150611042 SNP, in monocytes and macrophages, which was highly correlated. 
However, it would be interesting to analyze also the expression of hepatocytes, where 
orosomucoid is expressed. Eventually, we confirmed that ORM1 plasma levels were 
positively related with Lagtime in in vitro experiments, but also was strongly associated to 
ETP and Peak. That could be due to the low percentage (5% aprox, page 68) of variability 
that is explained by the hit SNP. 
Additionally, another limitation of this study is the lack of association analysis of X 
chromosome genetic markers. I started the analysis just after conducting the autosomic one, 
but for different difficulties inherent to the properties of this chromosome, the work was 
paused. The chromosome X is particular compared with the other chromosomes153, and the 
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most evident is that females have 2 copies, as an autosomal, and males have just one copy. 
This first characteristic marks already differences at the statistic analysis level making 
necessary to separate the samples by gender and apply differently tests or quality controls. 
For instance HWE is not suitable in males and imputation analysis was, at the beginnings of 
my PhD, recommended to be preformed separately resulting in decreasing imputation 
quality. It is also a chromosome with a low mutation rate, thus, it presents high linkage 
disequilibrium between the genes, so the tests are less independent between them. 
Nevertheless, it is one of the lines of TGP study that I want to continue. 
 
Finally, aiming at complete the description of this first part studding TGP biomarkers I 
want to expose the following points: 
 As detailed above, I observed strong evidence for association (1) between ORM1 
rs150611042 and Lagtime, (2) ORM1 rs150611042 and ORM1 gene expression, and (3) 
between orosomucoid plasma levels and Lagtime in different samples. It would be 
interesting to study the association of the SNP and ORM1 plasma levels. For that purpose, 
ORM1 plasma levels are being measured in 798 individuals of the MARTHA12 study and we 
should soon be able to check whether they are influenced by the rs150611042 SNP I have 
identified. So far, there is no functional evidence that it could be the "causal" variant. 
Therefore, it would be of great importance to identify the plausible causal variant(s) by 
deeply sequencing and characterizing the whole spectrum of the genetic variability of the 
locus. This may be a non-trivial task, as this locus is known to be subject of duplication154. 
Claire Perret, molecular biologist at INSERM UMR_S 1166, is currently investigating this 
issue and designing protocols to detect those duplications. 
 The novel ORM1 finding was identified because I did not focus only on the association 
signals that attained the genome-wide significant threshold of 5 10-8 but widened my search 
to SNPs with p-values as low as 10-5. This emphasizes that some true associations may lie 
in the list of SNPs with less stringent p-values. This is why I have also undertaken a sort of 
candidate gene approach. I selected from all my meta-analysis GWAS results the most 
significant SNPs at VT candidate genes that showed association at p < 0.05 with any of the 
three TGP biomarkers (Annex, page 160). From these first lists, 11 SNPs were sent for 
genotyping replication in MARTHA12, which is currently under process and soon completed 
in Professor Pierre-Emmanuel Morange's laboratory. We should then be able to assess 
whether the 11 selected SNPs add to the list of SNPs that associate with thrombin 
generation, but with milder genetic effects than those observed at F2 and ORM1 loci. 
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Key Points
• Genetic variations at the
ORM1 locus and
concentrations of the
encoded protein associate
with thrombin generation.
• These findings may guide
the development of novel
antithrombotic treatments.
Thrombin, themajor enzyme of the hemostatic system, is involved in biological processes
associated with several human diseases. The capacity of a given individual to generate
thrombin, called the thrombin generation potential (TGP), can be robustly measured in
plasma and was shown to associate with thrombotic disorders. To investigate the genetic
architecture underlying the interindividual TGP variability, we conducted a genome-wide
association study in 2 discovery samples (N5 1967) phenotyped for 3 TGPbiomarkers, the
endogenous thrombin potential, the peak height, and the lag time, and replicated the main
findings in 2 independent studies (N 5 1254). We identified the ORM1 gene, coding for
orosomucoid, as a novel locus associated with lag time variability, reflecting the initiation
process of thrombin generation with a combined P value of P 5 7.1 3 10215 for the lead
single nucleotide polymorphism (SNP) (rs150611042). This SNP was also observed to
associate with ORM1 expression in monocytes (P 5 8.7 3 10210) and macrophages
(P 5 3.2 3 1023). In vitro functional experiments further demonstrated that supplementing normal plasma with increasing
orosomucoid concentrations was associated with impaired thrombin generation. These results pave the way for novel
mechanistic pathways and therapeutic perspectives in the etiology of thrombin-related disorders. (Blood. 2014;123(5):777-785)
Introduction
The enzyme thrombin (also called activated factor II) is a central
product of the response to vascular injury, displaying procoagulant,
anticoagulant, antiﬁbrinolytic, and cellular effects; the magnitude
and timing of these effects are critical to normal hemostasis.
The vast majority of thrombin is generated well after the
plasma (or blood) clot formation time, which is the traditional
endpoint for the activated partial thromboplastin time and pro-
thrombin time assays.1 These tests do not assess the whole co-
agulation system and also are insensitive to prothrombotic states.2
Thrombin generation assays have recently gained in popularity
and are considered useful to measure “global hemostasis,” that is,
capturing the complete dynamics of the coagulant response beyond
initial clot formation.3
Patients with high levels of thrombin generation are at risk for
thrombotic diseases such as acute ischemic stroke,4 venous throm-
boembolism (VTE),5-8 and myocardial infarction9 while bleeding
events are observed in presence of very low thrombin generation.10
In addition, the role of thrombin generation extends far beyond the
sole coagulation system. Several recent ﬁndings have emphasized
its key impact in atherosclerosis,11 diabetic nephropathy,12,13 and
inﬂammatory diseases such as sepsis,14 Crohn disease,15 and sickle
cell disease.16
Altogether these observations clearly emphasize the importance
of identifying factors controlling the interindividual variability of
thrombin generation. Known environmental and biological deter-
minants of thrombin generation are bodymass index, estrogen-based
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therapies, factor II, ﬁbrinogen, antithrombin, tissue factor pathway
inhibitor (TFPI) levels in plasma17-19 while 2 functional genetic
variants, both in the F2 gene coding for prothrombin, rs1799963
(G20210A), and rs3136516,20 have been robustly shown to as-
sociate with thrombin generation levels. The former is a well-
established genetic risk factor for VT21 where the rs1799963-A
allele is associated with a 2.5-fold increased risk.22 Conversely, the
association of the common rs13136516 with VT risk remains
questionable. It has been observed in 2 case-control studies23,24 but
was not detected in recent genome-wide association studies
(GWAS).25-29 Preliminary works also suggested that the rs3136516-G
allele could associatewith increased riskof systemic lupus erythematous
(SLE).30 If conﬁrmed, this association would add support for the role of
thrombin generation into inﬂammatory diseases.
We hypothesized that additional genetic factors, outside the F2
gene, could modulate the potential of a given individual to generate
thrombin. To test this hypothesis, we undertook a GWAS in 2 in-
dependent populations totaling 1967 subjects using 1000 Genomes
based imputation techniques which allowed us to test 6 652 054
single nucleotide polymorphisms (SNPs) for association with 3
thrombin generation parameters: endogenous thrombin potential
(ETP), lag time and peak thrombin generation using the calibrated
automated thrombography (CAT) method.31 The main ﬁndings
were tested for replication in 2 additional independent populations
gathering 1339 individuals and functional arguments derived from in
silico and in vitro experiments were obtained to support the identiﬁed
novel association.
Methods
Studied populations
Two independent cohorts with both GWAS data and thrombin generation
measurements were used for the discovery stage: MARTHA and the Three-
City (3C) Study. The main ﬁndings of the meta-analysis of these 2 GWAS
datasets were tested for replication in 2 additional independent studies,
MARTHA12 and FITENAT. Each individual study was approved by its
institutional ethics committee and informedwritten consent was obtained in
accordance with the Declaration of Helsinki. All subjects were of European
descent.
Discovery cohorts. TheMARTHA study has already been extensively
described.32,33 It is composed of 1542 patients with venous thrombosis (VT)
recruited from the thrombophilia center of La Timone hospital (Marseille,
France). All subjects, with a documented history of VT, were free of any
chronic conditions and free of any thrombophilia including anti-thrombin,
protein C and protein S deﬁciencies, and homozygosity for factor V Leiden
and factor II G20210A mutations. Patients under anticoagulant therapy were
also excluded. The 3C study34 is a population-based study carried out in 3
French cities composed of 8707 noninstitutionalized individuals aged over
65 randomly selected from the electoral rolls and free of any chronic diseases
and for which biological (DNA, plasma) samples could have been obtained.
Replication cohorts. The MARTHA12 study is composed of an
independent sample of 1245 VT patients that have been recruited between
2010 and 2012 according to the same criteria as the MARTHA patients. The
FITENAT sample35 consists of 543 French healthy individuals selected from
health examination centers of the French Social Security. These subjects had
no history of cardiovascular disease, diabetes, hypertension, renal nor hepatic
failure and were not under anticoagulant therapy.
Biological measurements
In all studies, thrombin generation potential (TGP) was measured in platelet-
poor plasma (PPP) using the CAT method36 as extensively described in
Lavigne-Lissalde et al.18 Three biological TGP parameters were derived
from the thrombogram analysis: the ETP (in nmol min21) which corre-
sponds to the area under the thrombogram curve, the peak thrombin
generation (peak in nmol L21) which represents the maximum amount of
thrombin produced after induction by 5pM tissue factor (TF), and the lag
time (LagT in minutes) which represents the time to the initial generation of
thrombin after induction.
In vitro functional studies
Plasma orosomucoid levels were determined using an automated turbidimet-
ric immunoassay based on the use of a polyclonal rabbit anti-human oro-
somucoid covalently attached to polystyrene microparticles resulting in
a ready to use immunoparticle reagent. All reagents were from Dako A/S and
all assays were performed on a Vitros 5.1 from Ortho Clinical Diagnostics.
Orosomucoid (Cell Science) was added at the concentrations of 0.2, 0.4,
0.8, 1.2 and 1.6mg/mL of plasma to 80mL of PPP dispensed into the wells of
round-bottom 96 well-microtiter plates (Immunolon microtiter 96-well solid
plates; Fischer Scientiﬁc). These concentrations were chosen for correspond-
ing to the normal range of orosomucoid in plasma (0.6-1.6 mg/mL). Throm-
bin generation was then initiated by adding 20 mL of PPP reagent (Stago)
containing 5 pMTF and 4mMphospholipidmixture, andmeasured using the
CAT method in a Fluoroskan Ascent ﬂuorometer (Thermolab Systems OY)
equipped with a dispenser. Fluorescence intensity was detected at wave-
lengths of 390 nm (excitation ﬁlter) and 460 nm (emission ﬁlter). The starting
reagent FLUCA Kit (Stago) containing ﬂuorogenic substrate and CaCl2 was
automatically dispensed by the ﬂuorometer (20 mL per well). A dedicated
software program, Thrombinoscope (Stago) was used to calculate thrombin
activity against the Calibrator (Stago) and display thrombin activity vs time.
ETP, peak, and lag time were calculated from the thrombogram. These
experiments were conducted on normal plasma samples from healthy random
individuals, Wilcoxon-paired test statistic was used to assess the association
of orosomucoid with TGP biomarkers.
Genotyping and imputation
Plasma were available for TGP measurements in 848 MARTHA patients and
1314 3C subjects with genome-wide genotype data typed with Illumina Hu-
man610 and Huma660W Quad beadchips.28 In each study, SNPs with
genotyping call rate,99%, minor allele frequency (MAF),1%, and showing
signiﬁcant (P, 1025) deviation from the Hardy-Weinberg equilibrium37 were
ﬁltered out. This led to 491 285 and 487 154 quality-control (QC) validated
autosomal SNPs inMARTHA and 3C, respectively. Individuals were excluded
according to the following criteria: genotyping rate,95%, close relatedness as
suspected from pairwise clustering of identity by state distances and multi-
dimensional scaling implemented in PLINK,38 and genetic outliers detected by
principal components analysis as implemented in the EIGENSTRAT
program.39 Finally, 714 and 1253 individuals from the MARTHA and 3C
study, respectively, were left for association analyses.
The 467 355QC-checked SNPs common to bothMARTHA and 3Cwere
then used for imputing 11 572 501 autosomal SNPs from the 1000 Genomes
2010-08 release reference dataset. For this, the MACH (version 1.0.18.c)
software was used.40 All SNPs with acceptable imputation quality (r2. 0.3)29,41
and MAF . 0.01 in both imputed GWAS datasets were kept for association
analysis.
In the replication cohorts, genotypingwas performed using allele-speciﬁc
PCR in 733MARTHA12 patients and 528 FITENAT subjects in which TGP
measurements and DNA were available.
Statistical analysis
Discovery analysis. In order to handle nonnormality distributions, a log-
transformation and a normal quantile transformation42 were applied to ETP
and lag time values, respectively, separately in the 2 cohorts (supplemental
Figure 1, available on the BloodWeb site). Association of imputed SNPs with
TGP markers were assessed independently in each cohort by a linear reg-
ression model implemented in the MACH2QTL (version 1.1.0)40 software. In
this model, the allele dosage, a real number ranging from 0 to 2 and equal to the
expected number of minor alleles computed from the posterior probabilities of
possible imputed genotypes, is used for assessing the imputed SNP effect.
778 ROCANIN-ARJO et al BLOOD, 30 JANUARY 2014 x VOLUME 123, NUMBER 5
 use only.
For personal at CRAI UNIVERSITAT DE BARCELONA on February 3, 2014. bloodjournal.hematologylibrary.orgFrom 
Analyses were adjusted for age, gender, oral contraception therapy (in
MARTHA), oral coagulant therapy (3C), and the ﬁrst 4 principal components.
Results obtained in the 2 GWAS cohorts were entered into a ﬁxed-effect meta-
analysis relying on the inverse-variance weighted method as implemented in
the METAL program.43 Homogeneity of associations across the 2 studies was
assessed using the Mantel-Haenszel method.44 A statistical threshold of
5 3 1028 was used to declare genome-wide signiﬁcance.41,45,46 In order
to increase the sensitivity of our discovery phase, we also considered of potential
interest any SNP that did not reach genome-wide signiﬁcance but were
nevertheless associated at P , 1025 with at least 2 TGP biomarkers.
Conditional analysis. A second round of GWAS analysis was perform-
ed where we further conditioned on the Prothrombin G20210A (rs1777963)
mutation, a known strong genetic determinants of TGP markers. Because the
rs1777963 has been genotyped in the MARTHA study as part of the inclusion
criteria, the true genotypeswere then used in the conditionalMARTHAGWAS
while, in the 3C study, the imputed allele dose were used.
Replication analysis. The same transformations as in the discovery co-
horts were applied to ETP and lag time values in MARTHA12 and FITENAT.
Association of tested SNPs with TGP markers was also assessed by a linear
regression model under the assumption of additive allele effects, adjusted for
age, sex, and oral contraception therapy.
In silico association with gene expression
The identiﬁed ORM1 hit SNP was investigated for association with the ex-
pression of its corresponding gene in monocytes and macrophages. Two
genome-wide expression studies were used, the Cardiogenics Transcriptom-
ics Study (CTS)47,48 and the Gutenberg Health Study.48,49
For this work, CTS individuals initially typed for the Illumina Sentrix
Human Custom 1.2M and human 610-Quad beadchips and GHS subjects
typed for Affymetrix Genome-Wide Human SNP Array 6.0 were separately
imputed by the MACH (version 1.0.18.c) software according to the 1000
Genomes February 2012 reference database. RNA genome-wide expression
from monocytes and macrophages was assessed in CTS using the Illumina
HumanRef 8 version 3 Beadchip. In GHS, the Illumina HT-12 version 3
expression array was used to assess monocyte expression. In both datasets,
ORM1 gene expression was characterized by the ILMN_1696584 probe.
Association of the hit SNP with gene expression was tested by use of
a linear regression model adjusted for age, sex, and center (in CTS).
Results
Characteristics of the 4 populations studied are given in Tables 1 and 2.
Discovery meta-analysis
A total of 6 652 054 imputed SNPs common to both GWAS cohorts
satisﬁed pre-speciﬁed imputation quality criteria and were then
tested through meta-analysis for association with the 3 TGP pheno-
types, ETP, peak, and lag time. Quantile-quantile (Q-Q) plots of the
association results did not reveal any inﬂation from what expected
under the null hypothesis of no association, except for the extreme
right tail distribution for ETP and peak (supplemental Figure 2)
Corresponding genomic inﬂation coefﬁcients were 0.998, 0.997,
and 1.000 for ETP, peak, and lag time, respectively. Manhattan
plot representation of the results are depicted in Figure 1.
ETP analysis. Seventeen SNPs, all mapping the chromosome
11p11 region, reached genome-wide signiﬁcance for association
with ETP (supplemental Table 1). The strongest signal was observed
forMYBPC3 rs2856656 (P5 4.623 10222). As we have previously
shown that this SNP tags for the F2 G20210A (rs1799963)
mutation,29 a further GWASmeta-analysis was conducted by condi-
tioning on the rs1799963. The imputation quality criteria of the
rs1799963 was r25 1 inMARTHA (see “Methods”) and r25 0.274
in 3C. The rare rs1799963-A allele was much more frequent in
MARTHA thus allowing better imputation. As a consequence, it was
not included in the initial set of imputed SNPs that entered theGWAS
analysis. After adjusting for rs1799963, 14 SNPs remained signi-
ﬁcantly associatedwith ETP. The strongest associationwas observed
for the F2 rs3136516 (P 5 5.94 3 10214). After a further round
of adjustment on the rs3136516 allele dosage, no association re-
mained genome-wide signiﬁcant. A 2-locus model incorporating the
rs1799963 and rs3136516 revealed that their effects on ETP were
independent and highly signiﬁcant (P 5 1.02 3 10229). The
rs1799963-A (b 5 10.225 6 0.019, P 5 2.66 3 10231) and the
rs3136516-G (b510.0406 0.006,P5 5.893 10211) alleles were
both associated with increased ETP. These effects were homoge-
neous in MARTHA (b 5 10.224 6 0.019; b 5 10.042 6 0.009,
respectively) and in 3C (b510.2876 0.135,b510.0396 0.008,
respectively), with no statistical difference (P . .05) between
studies. It is worthy of note that, while the rs1799963-A allele was
much more frequent in MARTHA patients than in 3C healthy
Table 1. Characteristics of the studied populations
Discovery Replication
MARTHA, N 5 714 3C, N 5 1253 MARTHA12, N 5 796 FITENAT, N 5 543
Age, y (SE) 46.84 (15.29) 75.05 (5.75) 49.74 (15.34) 47.81 (13.94)
Sex, % male 32.1 41.6 42.9 47.9
VT patients, % 100 0 100 0
BMI, kg/m2 (SE) 25.1 (4.55) 25.8 (4.22) 26.0 (4.98) 24.2 (3.62)
FV Leiden (%)* 153 (21.4) — 89 (11.2) —
F2 G20210A (%)* 83 (11.6) — 52 (6.5) —
Oral anticoagulant (%) — 52 (4.2) 24 (3.0) —
BMI, kg/m2 25.14 (4.55) 26.03 (4.98)
ETP, nM/min (1st-3rd) 1780 (1554-1958) 1775 (1586-1947) 1892 (1654-2124) 1675 (1456-1838)
Peak, nM (1st-3rd) 333.0 (293.5-372.0) 332.8 (307.0-364.3) 328.0 (278.0-374.8) 293.5 (258.1-319.2)
Lag time, min (1st-3rd) 3.229 (2.830-3.500) 1.382 (1.000-1.670) 3.330 (2.762-3.670) 2.280 (2.000-2.500)
BMI, body mass index; FV, factor V.
*FV Leiden and F2 G20210A mutations were genotyped in MARTHA and MARTHA12 as part of the inclusion criteria. Homozygous carriers were not included in the study.
Table 2. Correlation between TGP markers
MARTHA 3C MARTHA12 FITENAT
ETP 2 Peak, r 0.78 0.77 0.73 0.78
ETP 2 Lag time, r 0.14 0.06 0.19 0.34
Peak 2 Lag time, r 20.05 20.10 20.18 0.04
Correlations were computed on transformed values (ie, log-transformation on
ETP and quantile normalization for lag time) adjusted for age, sex, oral anticoagulant
therapy, F2 G20210A (when appropriate), and BMI.
Abbreviations are explained in Table 1.
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subjects (0.058 vs 0.005), there was no difference in the rs3136516-
G allele frequencies (0.48 vs 0.47, respectively)
Peak analysis. Twelve SNPs at the 11p11.2 locus were signi-
ﬁcantly associated with peak, the strongest signal being for the
rs138315285 (P 5 5.48 3 10211) and the second hit being the
rs2856656 (P 5 8.29 3 10211) (supplemental Table 2). After
adjusting for rs1799963, 2 associations, rs3136512 and rs3136516,
remained statistically signiﬁcant (both P 5 2.91 3 1028). These
2 SNPs were in perfect linkage disequilibrium (LD). In a joint
model, the rs1799963-A and rs3136516-G alleles were inde-
pendently associated with increased peak levels, b5145.376 7.45
(P 5 1.10 3 1029) and b 5 19.79 6 2.03 (P 5 1.36 3 1026),
Figure 1. Manhattan plots of the association results
from the meta-analysis of 2 discovery cohorts im-
puted for 6 652 054 SNPs on 3 TGP biomarkers. ETP
(A), peak (B), and lag time (C). The horizontal line
corresponds to the genome-wide significant threshold
taken at 5 3 1028.
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respectively. These effects were of similar amplitude in MARTHA
(b 5 144.37 6 7.58; b 5 112.26 6 3.56, respectively) and in 3C
(b 5173.226 39.97; b 518.626 2.46, respectively).
Lag time analysis. No SNP was genome-wide signiﬁcantly as-
sociated with lag time. Of note, the F2 rs1799963 and rs3136516 did
not associate with lag time (P5 .096 and P5 .451, respectively).
“Joint analysis” of TGP phenotypes. As the GWAS analyses
of TGP phenotypes did not reveal any genome-wide signiﬁcant
association signal independent of the known F2 variants (rs1799963
and rs3136516), we followed up additional SNPs that demonstrated
suggestive evidence for association (P, 1025) with at least 2 of the 3
studied TGP biomarkers.
Four SNPs, all mapping to the chromosome 9 ORM1 gene, de-
monstrated suggestive evidence for association with both ETP
and lag time (supplemental Table 3). The strongest association was
observed for rs150611042 whose A rare allele was associated with
lower ETP (b 5 20.068 6 0.013, P 5 3.36 3 1027) and lag time
(b 5 20.338 6 0.073, P 5 4.10 3 1027) with no evidence for
heterogeneity betweenMARTHA and 3C (P5 .729 and P5 .912,
respectively). After adjusting for rs150611042, the association at
the other ORM1 SNPs completely vanished conﬁrming that these
4 SNPs were in strong LD as initially anticipated from the similarity
in their allele frequencies and associated genetic effects.
Thirty-eight SNPs were suggestively associated with both ETP
and peak, most of them being located in the 11p11 region discussed
above. After adjusting for rs1799963 and rs3136516 F2 variants, we
observed suggestive association between a block of 7 SNPsmapping
to theRPL7AP69 locus on chromosome 19q13.43 and ETP and peak
(supplemental Table 4). All these SNPs were in nearly complete
association, the minor allele of the best associated SNP (rs117368154)
was associated with decreased ETP (b5216.296 3.48, P5 2.833
1026) and peak (b 520.0546 0.011, P5 3.393 1027).
No SNP exhibited association at P , 1025 with both peak and lag
time.
Replication studies
Following the main ﬁndings derived from the discovery meta-
analysis,ORM1 and RPL7AP69 hit SNPs were tested for association
with TGPphenotypes inMARTHA12.No associationwith anyTGP
biomarker was observed for the RPL7AP69 SNP (supplemental
Table 5). Conversely, the ORM1 rs150611042 demonstrated sig-
niﬁcant association (P 5 2.46 3 1027) with lag time but not
with ETP (P 5 .147). Consistent with the discovery results, the
rs150611042-A allele was associated with decreased lag time
(b 5 20.439 6 0.084). To provide additional support for this
association, the rs150611042 was genotyped in the FITENAT
study where its A allele was also associated with decreased lag
time (b5 20.280 6 0.099, P 5 5.04 3 1023) (Table 3).
rs150611042 was imputed in the discovery GWAS. As a con-
sequence, we de novo genotyped it in 689 patients of the MARTHA
GWAS where DNA was still available. In this sample, the Pearson
correlation between the imputed dose and the true genotype was
r5 0.73. The association of rs150611042 with lag time was slightly
stronger using true genotyped allele count (b 5 20.338 6 0.087,
P 5 1.11 3 1024) than that observed using imputed allele dose
(b 5 20.362 6 0.127, P 5 4.71 3 1023).
Finally, the meta-analysis of the 4 studies provide strong statisti-
cal evidence for the association of rs150611042 with lag time
(P 5 7.11 3 10215) with no evidence for heterogeneity across
studies (P 5 .795) (Table 3). In the combined samples totaling
3,221 subjects, the decreasing effect of the rs150611042-A allele
was b 5 20.354 6 0.045. No evidence for heterogeneity
according to the presence of the rs3136516-G allele was
observed (P 5 .172). Similarly, in the 2 combined VT samples
enriched for F2G20210Amutation, the rs150611042-A effect on
lag time was homogeneous (test for homogeneity P 5 .746) in
patients with (b520.30060.255) or without (b520.38560.062)
the rs1799963-A allele. Further adjustment of BMI did not alter the
detected association (b 5 20.343 6 0.044, P 5 1.08 3 10214)
No association of rs150611042 with peak nor ETP was observed
(Table 3).
In silico association with gene expression
In the CTS and GHS studies, the rs150611042 was correctly im-
puted, with r25 0.64 and r25 0.75, respectively. In both studies, the
rs150611042-A allele was signiﬁcantly (P 5 8.70 3 10210 and
P 5 5.21 3 10216 in CTS and GHS, respectively) associated with
decreased expression in monocytes in an additive manner (Table 4)
and explained ;5% of the variability of ORM1 monocyte gene ex-
pression. A similar pattern of association, although less signiﬁcant
(P 5 3.18 3 1023), was observed for ORM1 gene expression in
macrophages from CTS (Table 4).
In vitro functional studies
As illustrated in Figure 2, orosomucoid levels were positively cor-
related (r25 0.646, P5 .049) with lag time in a plasma sample of 10
Table 3. Association of ORM1 rs150611042 with biomarkers of thrombin generation in 4 independent studies
ORM1 rs150611042 C/A MARTHA, N 5 714 3C, N 5 1253 MARTHA12, N 5 726 FITENAT, N 5 528 Combined,* N 5 3221
Minor allele frequencies 0.089 0.082 0.096 0.095
Lag time
b† (SE) 20.329 (0.086) 20.343 (0.096) 20.439 (0.084) 20.280 (0.099) 20.354 (0.045)
P 1.53 3 1024 3.85 3 1024 2.46 3 1027 5.04 3 1023 7.11 3 10215
ETP
b (SE) 20.041 (0.016) 20.083 (0.018) 20.024 (0.017) 20.013 (0.017) 20.038 (0.009)
P .015 9.31 3 1026 .147 .449 8.41 3 1026
Peak
b (SE) 28.379 (6.107) 26.557 (5.516) 8.730 (6.286) 20.984 (4.592) 22.013 (2.748)
P .171 .233 .165 .830 .464
Abbreviations are explained in Table 1.
*Combined results were derived from a meta-analysis of the 4 studies under the framework of an inverse-variance weighting fixed-effect model. No heterogeneity was
observed across cohorts, I2 5 1.67 (P 5 .795), I2 5 8.59 (P 5 0.072), and I2 5 4.74 (P 5 .314) for lag time, ETP, and peak, respectively.
†Additive effects associated with the rs150611042-A allele, adjusted for age, sex, oral contraceptive therapy (except in 3C), and on first 4 principal components (in
MARTHA and 3C). In 3C, as well in 25 MARTHA patients, imputed allele dosage was used. Otherwise, the exact allele count derived from wet-laboratory genotyping was
used. Association was tested by use of a linear regression model.
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individuals. As shown in supplemental Figure 3, there was a positive
dose-dependent association between orosomucoid concentrations
and lag time. For instance, at the 1.6 mg/mL concentration, the
supplementation of orosomucoid to PPP was followed by a modiﬁ-
cation of the thrombin activity characterized by signiﬁcant increased
lag time (3.25 vs 4.50 miutesn, P 5 .0057) but also signiﬁcant
decreased ETP (1790 vs 1628 nmol L21, P5 .0020) and peak (266
vs 213 nmol L21 P5 .002) (Figure 3).
Discussion
Here, we reported the results of a GWAS study aimed at identifying
genetic variations associated with thrombin generation through a
comprehensive analysis of 3 complementary biomarkers, ETP, peak
and lag time.
For ETP and peak, associations were observed with rs1799963
and rs3136516, 2 F2 variants already known to associate with
thrombin generation and whose functionality has already been
discussed.20,50-54 Both rare alleles, rs1799963-A and rs3136516-G,
were associated independently from each other with increased
thrombin generation, the strongest effect being at rs1799963. These
2 mutations act on thrombin generation through increase in pro-
thrombin levels. Themechanism bywhich the rs1799963-A, located
in the 39 UTR region of F2, inﬂuences prothrombin levels has been
proposed to result from more efﬁcient 39-end formation, increased
mRNA stability, increased translation efﬁciency, or a combination of
these mechanisms.50,54 The rs3136516-G, located within the 13th
intron of the gene, is functional through its effect on an intronic
splicing enhancer motif.20 Of note, while the rs1799963-A allele is
a rare (;2% in the general population) variant associated with a
strong risk of VT, the rs3136516-G allele is common (;0.47 in all
populations studied here) and its association with VT risk still
warrants in-depth investigation.
The novelty of this work is the association ofORM1 rs150611042-
A allele with decreased lag time in 4 independent studies, with an
overall statistical evidence of P 5 7.11 3 10215. Although this
polymorphism explained ;2% of the lag time variability (1%,
1.7%, 3.4%, and 1.4% in MARTHA, 3C, MARTHA12 and
FITENAT, respectively), it was not associated with either ETP or
peak. No evidence for association with VT risk was suggested either,
the frequency of the rs150611042-A allele (Table 3) being homo-
geneous across the 2 cohorts of VT patients (0.089 and 0.096) and the
2 cohorts of healthy individuals (0.082 and 0.095). The rs150611042
is located in the promoter region of theORM1 gene and was in strong
LD with other ORM1 SNPs whose association with lag time
disappeared after adjusting for rs150611042. Using transcrip-
tomic data, we further observed that the rs150611042-A allele was
associated with decreased ORM1 expression in monocytes and
macrophages. Finally, in vitro functional studies revealed that plasma
orosomucoid levels correlate with lag time and that supplementing the
plasma of healthy individuals with orosomucoid resulted in impaired
thrombin activity as characterized by increased lag time; this obser-
vation being consistent with the concomitant associations of
rs150611042-A allele with both decreased lag time and decreased
ORM1 expression.
ORM1 encodes a key acute phase plasma protein, orosomucoid
also called a-1-acid glycoprotein 1 (a-1-AGP)55 whose speciﬁc
function has not yet been determined; it might function as a transport
protein in the blood stream, appears to modulate the immune system
during the acute-phase reaction and has been shown to associate
with allergic contact dermatitis, psoriasis, and sarcoidosis.56 Several
pieces of evidence support a role of a-1-AGP in coagulation. In an
experimental model of peritonitis in rats, high doses of a-1-AGP
normalized platelet aggregation, blood clotting parameters and
antithrombin activity.57 Increased amounts of a-1-AGP inhibit
platelet aggregation induced by ADP and adrenaline.58 a-1-AGP
was also found to interact with plasminogen activator inhibitor 1, a
member of the serine proteinase inhibitors (serpins) family, and to
stabilize its inhibitory activity toward plasminogen activators.59
One could speculate that a-1-AGP delays thrombin generation by
playing the same role with other coagulation inhibitors belonging
to the serpin family. Conversely, a-1-AGP has been observed to
shorten aPTT60 and to contribute to the cellular initiation of
coagulation by inducing monocyte expression of TF.61
Our study provides evidence of the role of a-1-AGP in thrombin
generation, in particularly on the initiation process evaluated through
the lag time biomarker. Several limitations must be acknowledged.
First, the 2 discovery cohorts as well as the 2 replication studies were
composed of samples of VT patients and healthy individuals ex-
hibiting different clinical and biological characteristics. This may then
have introduced heterogeneity between studied individuals resulting
in a decreased power for detecting genetic effects, in particular of
modest effect size. Conversely, the association of ORM1 SNPs with
lag time observed in these 4 different cohorts is a strong argument in
favor of a true association. The ORM1 locus was selected for further
investigation in the replication studies because of its suggestive
association (P , 1025) with both ETP and lag time in the combined
discovery cohorts. However, only the association with lag time
robustly replicated. As the correlation between ETP and lag time was
stronger in the replication studies than in the discovery cohorts, we
could have anticipated that the association with ETP would also hold
Table 4. Association of ORM1 rs150611042 with ORM1 monocyte
and macrophage expression
ORM1 rs150611042
CTS GHS
N Monocyte Macrophage N Monocyte
CC* 664 6.80 (0.57) 6.19 (0.21) 1175 6.81 (0.38)
CA* 79 6.45 (0.48) 6.12 (0.11) 196 6.62 (0.26)
AA* 2 5.99 (0.09) 6.10 (0.09) 3 6.36 (0.04)
R2, % 4.80 1.30 4.90
P† 8.70 3 10210 3.18 3 1023 5.21 3 10216
CTS, Cardiogenics Transcriptomics Study; GHS, Gutenberg Health Study.
*Mean (SD).
†Association testing was performed by regressing ORM1 expression on the
imputed allele dosage of rs150611042 while adjusting for age, sex, and center (in CTS).
Figure 2. Association of lag time with plasma ORM1 levels. In 10 normal plasma,
the correlation between ORM1 and lag time was 0.646 (P 5 .049).
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in the replication. Therefore, we cannot rule out that the original
association with ETP was spurious. We observed strong statistical
evidence for association of our hit SNP with ORM1 expression in
monocytes and macrophages, but its inﬂuence on gene expression
in other cell types would also be of great interest, in particular
in hepatocytes, the main source of orosomucoid. Finally, while our in
vitro experiments conﬁrmed the association of ORM1 with lag time,
they also strongly suggested some associations with both ETP and
peak biomarkers which were not robustly suspected from the GWAS
investigations. This discrepancy could be explained by the fact that
the identiﬁed SNP explains a modest part of the ORM1 variability
(eg, ;5% in monocytes) which could be only enough to detect an
inﬂuence on lag time, whereas our in vitro experiments were able to
reﬂect a more global and stronger effect of orosomucoid on all TGP
biomarkers. This would emphasize the need for an in-depth investi-
gation of all genetic and non-genetic (incl. epigenetic) factors in-
ﬂuencing ORM1 expression and their impact on thrombin generation.
In particular, based on our preliminary results, it would be highly
relevant to assess in larger populations the correlation between plasma
ORM1 and TGP biomarkers and whether this correlation could be
inﬂuenced by ORM1 SNPs.
Despite these limitations, our results strongly support a role of
ORM1 in thrombin generation-related mechanisms. The impact of
the identiﬁed SNP on thrombin generation is mild and does not seem
to be sufﬁcient to modify the risk of VT in the general population.
Orosomucoid is an acute phase reaction protein which increases in
concentration as much as 5-fold in acute inﬂammation and cancer.59
We can speculate that its direct inﬂuence on thrombin generation
might be higher during inﬂammation process and thus responsible
for coagulation disorders observed in such circumstances. Lastly, the
association of the identiﬁed ORM1 polymorphism with thrombin-
associated human diseases (eg, Crohn, SLE, diabetic nephropathy,
stroke) would warrant further investigations.
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1.6 mg/mL orosomucoid. Effect of supplementation of
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INVESTIGATIONS OF DNA METHYLATION 
MARKS ASSOCIATED TO THE THROMBIN 
GENERATION POTENTIAL. 
 
This second part describes the results related to the study of DNA methylation patterns 
regulating the inter-individual variability of Thrombin Generation Potential (TGP), another 
main objective of my PhD project.  
The strategy was very similar to the one I adopted in the previous Part I (Identification of 
novel genetic factors influencing TGP plasma variability). Using the data from a dedicated 
microarray, I conducted a methylome-wide scan for DNA methylation changes associated 
with the three TGP biomarkers in a subsample of the MARTHA study. Afterwards, I 
performed a replication analysis of the most significant findings in an independent study 
composed of French-Canadian pedigrees. Eventually, I analyzed the complete methylome-
wide scan in these pedigrees and combined with the results of MARTHA in a meta-analysis 
aiming to increase the statistical power to detect TGP associated methylation marks. 
The structure will mimic Part I, starting by basic notions of epigenetics and the main 
principles of methylation wide association studies (MWAS). Then I describe the studied 
populations and the results I obtained. The main findings are summarized in a manuscript 
currently under review in Thrombosis Research (pages 120-130) 
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Chapter 6. DNA methylation, an epigenetic mechanism 
 
 
Epigenetics is a branch of the genetics, which enclose the regulation activity not caused 
by genes. Arthur Riggs defined it as: "the study of mitotically and/or meiotically heritable 
changes in gene function that cannot be explained by changes in DNA sequence"155. As the 
name signs "epi" that in Greek means "over", they are all those marks and patterns upon or 
over the genes and genetic structural proteins that regulate the transcription and expression 
of them. These marks are stable: persist after cellular mitosis and meiosis so they can be 
inherited (imprinting, epigenetic memory) from one mother cell to daughter cell. However, 
additionally they can be modified by gene activity or environmental factors156,157 causing 
changes in cells physiology or state and even cell disorders as tumour cells158,159. These 
marks could be the explanation to the question why two cells with the same genetic material 
will express different proteins and become different cell types. While the organism cells have 
the same genetic content, the epigenetic pattern is tissue specific160. In relation to this, this 
epigenetic pattern play also a role in development of the organisms, like with HOX genes, 
which are used several times in the development stage, in different places. Their differential 
expression in time and space is regulated epigenetically156. 
 
There are two principal types of DNA epigenetic marks (Figure 6.1.): 
1. Histone code  
2. DNA methylation 
 
 
Figure 6.1. Image of the two main epigenetic types, 
the tails modification represented at the right of the 
image and the DNA methylation of C's at the left 
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6.1. Histone epigenetic code 
 
Histones are nuclear proteins bound to the DNA double helix to help with its stabilization 
and packaging161. Together, they form the so-called nucleosome (Figure 6.2.) The DNA 
fibber makes almost 2 turns (equivalent to 2 nm) around the histone core and another 
histone unit (H1) will fix this complex. The histone core is formed by 8 histone units: 2xH2A, 
2xH2B, 2xH3 and 2xH4. 
 
 
 
Figure 6.2. Scheme of histone 
cores
158
. (a) the DNA surrounds 
the core (formed by 8 histone 
units) and the histone H1 fix the 
proteic complex. All together form 
the basic unit named: 
Nucleosome. (b) Example of two 
histone tails (the sequence and 
line in red) modified by acetyl (Ac) 
and Methyl (Me) molecules. 
One of the most known histone 
modifications is the Histone 3 -
Lysine 4 (H3K4), which is 
dimethylated and trimethylated- in 
this case trimethylated. It appears 
all along the genome in promoter 
regions
161
. 
 
The tails of the polypeptides (N-terminals) of these histones stand out from the 
nucleosome and are subject to several modifications such as acetylation, mono-, di- or/and 
tri-methylation of the lysine amino acids, and phosphorylation of serine amino acids (Figure 
6.2.). The different combinations of these added-molecules are known as the histone code. 
According to this code the gene expression is enhanced (attracting i.e., transcription factors) 
or blocked (attracting i.e., packaging proteins). This kind of epigenetic mark is a short-term 
modification in the expression162. 
 
6.2. DNA methylation 
 
DNA methylation consists in an enzymatic addition of a methyl group (CH3, one carbon 
molecule and three of hydrogen) at the carbon 5 position of cytosine mainly in the context of 
the sequence 5'-cytosine-guanosine (CpG dinuclotide). This methyl group is transferred by a 
DNA methyltransferase from a molecule called S-adenylmethylcisteine (SAM), which 
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becomes a S-adenylhomocysteine (SAH) (Figure 6.3.). At the same time, the DNA 
methyltransferase attracts proteins to bind the DNA that will regulate the expression and the 
chromatin structure too161. 
 
Figure 6.3. Methylation process. 
Recent works have documented that DNA methylation could also occur, not only at CpG 
sites, but also at CpHpG sites where H can be any A, T or C nucleotide163. RNA methylation 
is also another recently observed epigenetic mechanisms164. 
The CpG dinucleotide is strongly under-represented in the human genome probably due 
to a mutational process in mammals that transforms the methylcytosines in thymines. 
Additionally, it is irregularly distributed over the genome presenting deserts interspersed by 
regions of high density of CpGs called CpG islands165. The proximal regions around those 
islands are called the island shores, and in turn, surrounding the shores, there are the 
shelves. The CpG islands contain the 7% of CpGs of the genome and they can be located 
either in the regulatory 5'-UTR ends or in the first exon of ~50% of human genes162,166,167. It 
has been estimated that about 70% of cytosines of CpG are subject to methylation in the 
human genome168. 
The unmethylated status of a 
cytosine is generally agreed as the 
standard state allowing the transcription 
of the downstream gene. Conversely, 
DNA methylation represses physically 
and chemically the transcription by 
attracting methyl-CpG binding proteins 
and other enzymes that modify the 
structure and the composition of 
chromatin. All these expression 
modifications lead to trait changes and also diseases. 
DNA methylation is more resistant than the histone modification, making possible its 
transmission from mother cells to daughter cells170,171. At the same time, these marks are 
 
Figure 6.4. DNA methylation tissue 
specificity169. The black dots are for methylated 
sites and white for unmethylated  
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reversible epigenetic marks as they can be modified by gene action or by environmental 
influence as diet, smoking or air pollution172. The methylation pattern is specific of each cell 
type; actually it contributes to the cell differentiation making possible the development of 
different cell types from stem cells with the same genome171,173 (Figure 6.4.). It can be even 
allele-specific, like Paternal/Maternal imprinting and X inactivation, which are two important 
biological mechanisms that are due to regulatory DNA methylation mechanisms160. 
 
6.3. DNA methylation and human diseases 
 
In the last decade, emerging evidences have support the role of DNA methylation in 
human diseases. First results were observed in the field of cancer but rapidly extended to 
other complex human diseases such as multiple sclerosis, diabetes, inflammatory and 
cardiovascular diseases174–179. 
Several elements support the implication of DNA methylation in the pathophysiology of 
thrombotic disorders. For instance, the F8 and VWF genes (two well-known quantitative 
biomarkers associated with VT) seem to be subject to epigenetic marks including DNA 
methylation180,181. They have also been observed regulating the expression of the 
methylenetetrahydrofolate reductase (MTHFR) gene182,183 which influences the plasma 
variability of homocystein levels, another risk factor for VT184. Interestingly, in this last 
example, methylation also has been proposed as SNP-sensitive being present only when a 
certain polymorphism in the MTHFR gene. 
6.4. Peripheral blood DNA methylation, a good epidemiological tool 
In the study of cancer, DNA methylation patterns were identified in free floating DNA 
released in serum from apoptotic or necrotic tumour cells. That lead to the idea of looking for 
DNA methylation marks in blood serum and plasma165. Thereafter, this DNA blood method 
was followed in other successful non-cancer DNA methylation studies185–187. 
Additionally, the peripheral blood DNA is preferable to study DNA methylation changes 
because is easy to obtain compared to other relevant cell types that are impractical at a large 
epidemiological scale. Although, DNA from peripheral blood is composed of a mixture of 
different cell types (mainly leukocytes), the underlying hypothesis is that those DNA 
methylation marks are reflective of much stronger changes in specific cell-types. 
A very recent but highly popular tool to measure peripheral blood DNA methylation is the 
Illumina HumanMethylation450K (HM450K) array, used in this project. The description of the 
underlying principles and of the bioinformatics and statistical analyses of the data produced 
are given in the following Chapter 7. 
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Chapter 7. How to perform a Methylation Wide Association 
step by step 
 
To conduct a Methylation Wide Association (MWAS), several steps similar to those I 
described for a GWAS strategy must be followed. They are briefly summarized in the 
diagram below: 
 
Figure 7.1. Methylation-wide association study 
step by step. 
 
7.1. Methylation determination 
Different methodologies are available to identify DNA methylation level: methylation-
sensitive restriction enzymes, bisulfite conversion treatment and Methylated DNA 
ImmunoPrecipitation (MEDIP). Once detected they are analyzed by either microarray or 
deep-sequencing technologies, which provide very similar and reproducible results188,189 
(Figure 7.2.). 
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Figure 7.2. Different methods 
of DNA methylation 
measurement depending on the 
identification and measure 
approaches190. 
The Methylation sensitive restriction enzyme treatment is a very specific method that 
uses enzymes that break DNA at points with a specific sequence. They are also sensible to 
the methylation, responding differently -break or no break-depending on the methylation 
state. However, the detection is limited to just the sites inside the target sequences. 
The immunoprecipiation method is a direct approach that doesn't need previous DNA 
treatment as the other two methods. That makes also skip treatment specific pruning and 
extra steps, making it easier to perform and analyze. It also can interrogate repetitive 
sequences and allow epigenetic states to be assigned to specific alleles. However it is not 
nucleotic specific as the bisulfite conversion. 
The bisulfite conversion treatment converts the cytosines in uraciles, while the 
methylated-cytosines remain cytosines allowing detecting methylation at the exact 
nucleotide. Reason why is considered the "gold standard for detecting changes in DNA 
methylation"190. 
In the present work we used the bisulfite conversion and posterior analysis through the 
Illumina HumanMethylation450 bead array. The deep sequencing requires more complex 
bioinformatics tools especially for alignment mapping and is very expensive to apply at the 
genome-wide scale. Bioinformatics and biostatistical tools required for such DNA methylation 
deep-sequenced data have not yet achieved sufficient maturity for genome-wide analysis 
and are mainly recommended for the analysis of local regions191. 
7.1.1. The Illumina HumanMethylation 450K array  
The Illumina HumanMethylation450 bead array (H450K) technique has recently gained 
large popularity as a robust and efficient tool for investigating, in epidemiological studies, 
methylation marks at CpG sites associated with environmental, genetic and biological 
data185,192. It covers 99% of RefSeq genes and all important known regions such CpG 
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islands, shores and shelves193,194. It surveys the DNA methylation levels at 482,421 CpG 
sites, with an average of 17 CpG sites per gene region. 
The first step consists in treating DNA samples with sodium bisulfite (C-> U and Methyl-
C->C) followed by an amplification step that coverts uraciles into thymines and cytosines 
remain as cytosines (Figure 7.3.). DNA samples are then hybridized on the H450K array 
using 485,577 allele specific probes, synthetic sequences of 50 base pairs that tag for the C 
or T of the CpG site. The hybridization needs to be perfect to permit the extension of one 
nucleotide that will be bound to a fluorochrome, which emits a signal. Finally a scanner 
measures that signal and transforms it into methylation intensity according to the used probe 
(see thereafter). Of note, 482,421 assessed sites correspond to true CpG sites, 3,091 
correspond to CNG (where N could be any base but G) and 65 sites measured a known C/X 
polymorphism. Each probe is bound to a bead of 3 μm of diameter (as in the previous part I) 
which is in turn bound to the microarray. Each probe is repeated 15 times. 
 
Figure 7.3. Methylation determination protocol. 
 
The array is composed of 2 kinds of probes, Infinium I derived from the first generation 
of DNA methylation HumanMethylation27 array (n = 135,501, i.e., 27,9%), and Infinium II (n 
=350,076, i.e., 72,1%), and it additional includes 614 negative control probes that do not 
complement to any genomic sequence and should not hybridize. Nevertheless, these last 
probes produce some fluorescence signals considered as background noise, which will be 
used for quality control and normalization procedures (described thereafter, page 94). The 
H450K array uses two kinds of fluorochromes, green (Cy3) bound to adenines and thymines 
and red (Cy5) bound to cytosines and guanines, which in combination determine the 
methylation levels. 
Infinium I probes. These probes use a method that consists in two different probes for 
the same CpG methylation site: one probe measures the methylated state (i.e., with the C 
nucleotide at the 50th position) and the other measures the unmethylated state (i.e., with the 
T nucleotide at the 50th position), and both bound to different beads. Each bead has a 
known pre-defined position on the array (Figure 7.4.). 
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Figure 7.4. Example of the Infinium I probes display on the 
microarray for 3 methylation sites. For each CpG site there are 
two probes the unmethylated (U) and the methylated (M) placed in 
different points. If the samples have the site 1 methylated, the DNA 
will bind to the site M, and the fluorescence signal (red or green) will 
be in this M site but not in U site. On the contrary, if the site 1 is 
unmethylated, the fluorecence will appear in the U. 
 
According to the methylation status at the target site (methylated or not), the treated 
DNA will bind to one of the two probes. If the hybridization is perfect, then the extension 
phase will be possible adding a nucleotide (i.e., the 51th nucleotide of the genomic 
sequence), which will produce a fluorescence signal. In this kind of probe, the Illumina 
strategy does not pay attention to the color of the fluorescence but to position on the array to 
discriminate between methylation and non-methylation (M or U, see Figure 7.4.). The signal 
is read by the scanner to declare whether it corresponds to a methylated or unmethylated 
site (Figure 7.5.). Then to quantify the intensity of the methylated or unmethlyated signal, 
only one of the two fluorescences (green or red) is used by the scanner according to the 
added nucleotide at the 51th nucleotide and some probe-specific information treated by the 
Illumina GenomeStudio program. 
 
Figure 7.5. Scheme of the functioning of Infinium I (Illumina images). 
 
Infinium II probes. For this technology, only one probe is used to assess the methylation 
status of a target CpG site. Each Infinium II probe is a sequence of 50 base pairs that 
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matches to the genomic sequence just before the position of the target CpG site. When the 
treated DNA perfectly hybridizes on the probe, the extension of the 51th nucleotide (that 
corresponds in that case) to the C or the T of the target site will produce a fluorescence 
signal, green (Cyanin 3) or red (Cyanin 5) according to the added nucleotide, characterizing 
the non-methylated and methylated states, respectively. Unlike Infinium I probe, the 
fluorochrome signal is the element for assessing the methylation status (Figure 7.6.).  
 
Figure 7.6. Scheme of the functioning of Infinium II (Illumina images). 
 
Compared to the Infinium I technology, the Infinium II technology allows to increase the 
number of investigated CpG sites but they are less precise and less reproducible.  
At the end of the H450K array process, different fluorescence signals are generated, 
some for methylated (Meth) and some for unmethylated (UnMeth) sites, each of them can be 
split according the underlying Infinium technology (I or II) (Figure 7.7.). In addition, some 
methylated and unmethylated signals are also produced by negative control probes. 
 
 
Figure 7.7. Density distribution of the intensity signals 
obtained from the Illumina methylation microarray 
(MARTHA and F5L samples). 
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7.1.2. Definition of the DNA methylation levels 
From the intensity values, two different parameters can be defined to quantify the 
DNA methylation levels at a given CpG site i: 
 The β value is a parameter that rangs from 0 to 1, calculated as  
   
  
           
 
where Mi is the intensity of methylated fluorescence at site i and Ui the intensity for the 
unmethylated signal. The two possible states are methylated or unmethylated for a same 
site, but, the DNA is extract of an individual is composed of several DNA molecules, 
differentially methylated for the same site. This is why the β values represent the methylated 
percentage of DNA molecules at a given site. The 0 value corresponds to complete 
unmethylated status and 1 to complete methylation. The distribution of all of the β is 
displayed in the Figure 7.8. where there are two main peaks, one near 0 and the other near 
1. 
 
Figure 7.8. Distribution of β values. At the left, the mean β and on the 
right all the β from MARHTA and F5L samples. 
 
 The M value is an alternative to β proposed by Du195, that is a log transformation of β. 
       
 
   
       
 
   
  
Additionally M formulation has been proposed in which an offset α or compensation is 
applied in both M (methylated signal) and U (non methylated signal). 
       
   
   
  
This parameter is more appreciated from a statistical point of view because the values 
are around 0 and the distribution is more similar to a Normal distribution when considering 
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methylation and non methylation separately (Figure 7.9.). It is used in some of the 
normalization steps. However β is more comprehensible in biological sense as a methylation 
percentage and a very recent work suggest that the use of β is more appropriate in the 
context of large epidemiological studies196 such the MARTHA study. 
 
Figure 7.9. Density distribution of M value. The left distribution is the mean M 
value for the 577 and the right distribution is M value for each individual (MARHTA 
and F5L samples). 
 
7.2 Data quality control 
Any statistical and bioinformatic analysis of high-throughput data requires quality 
controls procedures to assess the validity of the produced data and avoid any spurious 
results. MWAS does not escape to the rule and many quality controls (QCs), both at the 
probes and the individual levels, must be applied to H450K DNA methylation data before 
embarking into association testing with biological/clinical data. 
Most QC procedures used for H450K data analysis can be conducted using the minfi197 
or methylumi R packages198. All the QC steps, describes in the next paragraphs, have been 
performed by Dylan Aïssi (UMR_S 1166) and Jessica Dennis (Dalla Lana School of Public 
health, Toronto). 
7.2.1. Probes filters 
 
7.2.1.1. Control Probes 
Among the 485,577 probes, 850 are designed to check for the quality of the DNA 
preparation and the process of the H450K array (Table 7.1.): 
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Table 7.1. Types and number of control probes. 
Control Type Nº Probes 
Staining 6 
Extension 4 
Hybridization 3 
Target Removal 2 
Bisulfite Conversion 16 (12 +4) 
Specificity 15 (12 +3) 
Negatives 614 
Non-polymorphic 4 
Normalization 186 (32+61+32+61) 
Total 850 
 
Staining controls check the staining step from the microarray protocol, which is 
independent from the hybridization and extension. 
Extension controls test the nucleotide extension step using a hairpin sequence that does 
not need the hybridization or a template for the extension. 
Hybridization controls assess whether the probes hybridize correctly. For that purpose, 
synthetic oligonucleotides are construct that are perfectly complementary to this control 
probes and added instead of DNA sample. These oligonucleotides just use the green 
fluorochrome and they test also different concentrations of those oligonucleotides: low, 
medium and high. On the array sites where there are low oligonucleotide concentration there 
should be low intensity signal, where medium concentration-medium intensity and high 
concentration-high intensity (Figure 7.10.). 
Target removal aims to check the correct elimination of the DNA in excess after the 
extension step. 
Bisulfite conversion control consist in 16 probes, 12 for the Infinium I probes and 4 for 
the Infinium II, are used to assess whether the bisulfite treatment performed well. Infinium I 
probes contain a domain Hind III (5'...AAGCTT...3') for the 2 options: the complementary 
sequence Hind III converted with bisulfite (5'...AAGUTT...3') and the sequence 
(5'...AAGCTT...3'). Then synthetic oligonucleotides designed with the domain HindIII are 
treated with sodium bisulfite. Theoretically these oligonucleotides are not methylated, so they 
should be all converted to U and hybridize to the corresponding complementary probe (U/T) 
is emits fluorescence (Figure 7.10.). In the case of Infinium II probes, the emission of a red 
fluorochrome indicates that the bisulfite conversion has worked. On the contrary, the green 
fluorescence would indicate a problem in this step. 
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HYBRIDIZATION 
 
BISULFITE CONVERSION 
 
Figure 7. 10. Examples of probe controls of MARTHA and F5L samples. On the left the 
hybridization control probes, just tested with the green fluorochrome. It is observed how the 
intensities vary according to the concentrations, from the top to the bottom: medium, low, 
high. Also it also confirms there is no red fluorochrome signal or residual. On the right, the 
bisulfite conversion controls just for Infinium I. There are the six first lines, which correspond 
to the Unconverted status, where it should be no signal as showed, and the bottom lines, 
correspond to the Converted status which do show intensity. 
 
Specificity of the probes. There are 12 Infinium I and 3 Infinium II probes designed to 
control the non specific hybridization and extension. The probes correspond to sequences 
with non polymorphic T sites. 
Negative controls probes are designed to be 
complementary to none DNA fragment. Therefore, 
there should be neither hybridization nor extension 
and should not produce any fluorescence signal. 
However, there is always signal which is used as 
background noise. In the previous Figure 7.7. the 
intensity of this background was displayed. In 
Figure 7.11. the negative controls are represented 
alone, where it is remarkable that the methylation 
signal is more intense than the non methylation 
one. 
 
 
Figure 7.11. Density destribution of 
the Negative control probes for the 
577 individuals (MARTHA and F5L 
samples). 
Part II 
 
96 
Normalization probes are those complementary to housekeeping genes without CpG 
sites. One nucleotide is added. The extended nucleotide is an adenine, a cytosine, a guanine 
and a thymine for 32, 61, 32 and 62 probes, respectively. 
 
7.2.1.2. Detection P value 
Every β value has an associated p-value, which evaluates the probability that the 
intensity of the probe is distinguishable enough from the negative control probes intensity. A 
non significant pvalue (e.g., pvalue >0.05) means that the intensity of the associated probe is 
too low and not distinguishable from the background. This could be due to poor quality of the 
probe design, poor hybridization, or chromosome anomalies in the region (eg 
deletion/insertion). It is recommended to exclude those probes. 
The standard method for calculating the detection p-value and the one used in my 
project is the "m+u" method implemented in the minfi package. For each processed 
individual DNA sample, it computes:  
 The mean of the fluorescence of the background noise for every color red (medR) 
and green (medG) 
 The mean absolute deviation (MAD) of the background and also by color: madR and 
madG 
 The total intensity by probe: 
 Infinium I 
- Red: intensity of the allele 1 (methylation state) + allele 2 (unmethylation 
state) 
- Green: intensity of the allele 1 + allele 2 
 Infinium II: intensity red+ intensity green 
 From these values, it computes the probability p that a Normal variable with mean 
and standard deviation given below would be greater than the observed total intensity 
probe. 
 For Infinium I: mean = medG*2 or medR*2 
   Standard deviation = madG*2 or madR*2 
 For Infinium II: mean = medG+medR 
   Standard deviation = madG + madR 
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7.2.1.3. Nucleotide Polymorphism 
Probes that harbour a SNP in their 50 bp genomic sequence require great attention to 
avoid any artifactual results199. Hence, it is important to update the annotation of the probes, 
e.g. with the available data in 1000 genome project127 to identify the probes with possible 
SNP in their sequence. 
Chen et al. demonstrated that there are 66,877 probes on the array that contain a SNP 
at the methylation site of interest. A given DNA sample may then present a C or an X 
(another nucleotide) at the target site before the bisulfite conversion, which would turn into 
biased signals depending on X. These probes must be excluded from the analysis. 
The same research group identified 239,238 probes with at least one SNP, not at the 
methylation site but in their 50 bp sequence. Such SNP may produce hybridization problems 
and result in biased intensity signal. These probes represent almost half of the total number 
of probes. For that reason, they are not filtered out from the analysis but interpreted carefully 
when any association is observed at such probe. When GWAS data is available, it can be 
easily checked whether such associations are artifacts by testing the effect of the probe 
SNP(s) on DNA methylation levels. 
7.2.1.4. Cross-reaction 
Finally, there are probes that are not specific enough and can hybridize with more than 
one sequence in the genome. The produced signals are then not easily interpretable. This 
phenomenon was also pointed out by the group of Chen et al.199,200 identifying 16,532 
autosomal probes that react with the X chromosome and recommending to exclude them 
from the analysis. 
7.2.2. Individuals filters 
7.2.2.1. Detection P value 
Similar to the genotype missing data addressed in the GWAS context, individuals with 
too many probes whose intensity are not distinguishable from background noise are 
excluded. The strategy excludes any individual with more than 5% of their probes with a 
detection p-value > 0.05 (mentioned before). 
7.2.2.2. Outliers 
As in the GWAS QC protocol, it is important to check if there could exist some outliers in 
the studied samples. It is possible to apply the multidimensional scaling (MDS) method to 
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identify individuals that strongly differ from the others. For example, in Figure 7.12., 3 women 
grouped together with males and 1 man grouped together with women (see also next 
paragraph). 
 
 
Figure 7.12. MDS of 
the 577 individuals 
(MARTHA and F5L 
samples). The "F" in 
green represent the 
females and the "M" in 
orange the males. 
 
7.2.2.3. The X Chromosome 
Similar to the "Gender Check " QC (Chapter 4, page 40), DNA methylation data can be 
used to check for the consistency between the reported biological sex and the methylation-
derived sex. This relies on the analysis of the green fluorescence of the Y chromosome 
probes (Figure 7.13.). Compared to males, females should not present intensity signal above 
the background noise. Females presenting non negligible intensity must be excluded from 
the analysis. 
 
Figure 7.13. Green intensity of Y chromosome probes in females 
(left) and males (right). In this example, there are two females 
presenting intensity signal meaning a possible contamination (MARTHA 
and F5L samples). 
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7.3. Bias and corrections 
The bias is a systematic error due to a poor quality sampling that can make vary the 
results from what it is expected. Different kind of bias can be encountered in analyzing 
H450K data. These are described in the next section together with the generally advocated 
methods to correct for them.  
7.3.1. Background Bias 
This kind of bias is due to the non-specific hybridization between the probes and the 
DNA samples. It may happen that non-specific DNA fragments bind the designed probes and 
are used as templates in the extension step, producing not desired fluorescence called 
background noise. There are two types: 
 A general background that increases the general signal of all probes. 
 A structured background, meaning the increase is just produced locally, in a particular 
place of the array (also called spatial background). 
Since Illumina manufacturer have been placed the probes randomly on the array, this 
second kind of background is avoided. Only the general background noise must be 
corrected, and for that purpose, two popular methods have been proposed. 
 
7.3.1.1. Negative control probes method 
 
As previously mentioned, 614 negative control probes are available on the array, which 
should not hybridize to the treated DNA. However, there is always a degree of non specific 
fluorescence which is used to determine the background noise (Figure 7.11. of negative 
controls). The correction would consist in subtracting this background noise from the other 
measured signals. 
In the NormExp correction model proposed by Irizarry and improved by Silver201 the 
observed intensities X are modeled from a exponential S distribution with mean α. The 
background noise B is modeled as a normal distribution with mean μ and a standard 
deviation δ2. The background corrected values of X are then taken as the expected value of 
S given observed x 
             
           
  
             
 
 
where ϕ and   are the density and the cumulative distribution function of a Normal 
distribution, respectively, and μsx=x-μ-(δ
2/α).μ and δ2 can be directly estimated from the 
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negative controls and α by maximum likelihood. This correction is applied for each channel 
color separately (Cy3 et Cy5). 
 
7.3.1.2. Out-of-band method  
This second method takes advantage of the particularity of Infinium I that uses two 
probes for each tested methylation site. As mentioned above, the scanner only reads one of 
the two fluorochromes at each of the Infinium I, hence there are maximum 135,501 probes to 
quantify methylation and non methylation. These non-used intensities, for each color, serves 
as a surrogate for non specific nucleotide incorporation and fluorescence. Instead of using 
only 614 negative control probes into the NormExp model mentioned above, Triche et al.202 
proposed to use these 135,501 intensities in a similar NormExp model. This method is 
referred to as the Noob function implemented in the methylumi package and is the one used 
in this work. 
In Figure 7.14. the distribution of the negative controls is represented (the 614) probes 
compared to the out-of-band signals (from 135,501 sites) by each fluorochrome. 
 
 
Figure 7.14. Negative controls and out-of-band intensities from MARTHA and F5L 
samples distributions by fluorochrome (channel). 
 
7.3.2. Bias of two type of probes 
Checking and comparing between the signals derived from the H450K array and those 
obtained by a bisulfite pyrosequencing method (which is also based in bisulfite technique but 
followed by pyro-sequencing) has demonstrated that Infinium II probes are less reproducible 
and less sensitive to extreme values than Infinium I203. Because the technology underlying 
the Infinium I and II probes differ, the resulting β values are not directly comparable. Figure 
7.15. A displays the mean distribution of β overall all Infinium I and II probes (in black) which 
shows two peaks at the right tail of the distribution (i.e., close to 1). In blue (red) is shown the 
distribution for Infinium I (II) probes. While the blue and red distribution are very similar for 
low β values, the Infinium II distribution is shifted to the left for high β values. These 
Chapter 7. How to perform a Methylation Wide Association step by step 
 
101 
differences can be problematic when comparing probes measured by Infinium I and Infinium 
II. Different corrections have been proposed, the peak-based correction by Dedeurwaerder et 
al. 2011203, the SQN method by Touleimat et al.204, the Beta MIxture Quantile dilation method 
(BMIQ) by Teschendorff et al.205, and the Subset Quantile Within-Array method (SWAN)206. 
As part of his PhD project, Dylan Aissi, supervised also by David-Alexandre Tregoüet has 
shown that the SWAN method was the more consistent and reproducible between replicates 
in the MARTHA project. His results were in complete agreement with those obtained by other 
works that have adopted the SWAN method for correcting this bias. Briefly, the SWAN 
method implemented in the minfi package is based on the application of quantile correction 
for each type of probe and separately to the methylated and non-methylated intensities. The 
SWAN correction makes the β distribution nearly superposable between Infinium I and II 
probes (Figure 7.15 b). 
A         B  
Figure 7.15. Distribution of the mean β before (A) and after (B) correction with 
SWAN(MARTHA and F5L samples). In black is represented the β of all the probes (I and II), 
in blue just the probes Infinium I and in red the probes Infinium II. 
 
7.3.3. Bias due to the use of two fluorochromes 
The use of two different fluorochromes for the Infinium II technology at the same probe 
can also create another bias because these fluorochromes possess different chemical 
properties which can produce a shift in the two color intensities, one being more "intense" 
than the other.  
A total of 186 normalization control probes have been designed by Illumina to correct 
this bias. As previously described, these control probes are designed to match housekeeping 
genes and to be extended in the same region. These genes are present in all cells, always 
expressed in any individual without any kind of regulation and they do not have CpGs. 
Theoretically, the produced intensities should be equivalent, but they are not. The correction 
method is as follows: 
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1. For each individual, an average is calculated for each dye: green Grn.avg and red 
Red.avg using the normalization control probes. 
2. The mean of these two average is then computed: Grn-Red.avg 
3. From all the samples, one is chosen as reference. There are different methods 
depending on the software used. The Illumina GenomeStudio does not specify how 
the reference is selected. With minfi package, the user can choose the reference or 
by default will select the first individual. The methylumi package selects the sample 
with the (Gnd.avg/Red.aveg - 1) value closest to 0. 
4. For each individual, the dye averages, Grn.avg and Red.avg, are then divided by the 
reference values resulting into a factor value, one for the red and one for the green 
dyes,  
5. Finally the intensities are multiplied with the corresponding factor (depending on the 
color) in each individual for correcting the fluorochrome bias (Figure 7.16.). 
 
 
A                                                      B 
Figure 7.16. Distribution of M value of the Infinium II probe intensities before (A) and 
(B) after correction (MARTHA and F5L samples). The color green Cy3 corresponds to the 
methylated status (nucleotides C and G) and the red or Cy5 for non methylated (T and A). 
 
7.3.4. Plate effect Bias 
The Illumina plate technology permits to determine 96 individuals simultaneously: one 
plate containing 8 microarrays (or chips), each of them processing 12 individuals. The 
individuals of MARTHA and FVL families have been processed on 7 plates. As it is 
impossible to reproduce the exactly same technical conditions between plates, there are 
always sampling differences between plates, sometimes called batch effects. Figure 7.17. 
displays the β distribution over all probes across the 7 plates used in the MARTHA and FVL 
families project. To correct for potential plate (and chip) effects, the natural way is to adjust 
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for such variable(s) in the regression model used when testing the association of CpG levels 
and a given phenotype (see below).  
 
Figure 7.17. Distribution of β of each one of 
the 7 plates (MARTHA and F5L samples). 
 
7.3.5. GC content bias 
The GC content bias was initially reported by Kuan et al. 207 in the analysis of the first 
generation of Illumina DNA methylation array composed only of Infinium I probes. Kuan et al. 
observed that the intensity of the methylation signal was dependent on the probe GC content 
related different thermodynamic properties. The more enriched in GC the probe, the lower 
intensity. However, this bias has not been extensively studied in the context of the H450K 
array. No correction is then currently proposed. 
 
7.4. Statistical Testing for Methylation - phenotype associations 
For my MWAS project, I was interested in identifying CpG site whose levels could 
associate with TGP biomarkers. The standard way to address such question is to adopt a 
linear regression framework where the TGP biomarker is the outcome and the CpG site β 
value the covariate. This is similar to the GWAS strategy I used in Part I except that the 
genotype variable is replaced by the DNA methylation β variable (see Part II, Chapter 8, 
page 109). 
MWAS results can be described in terms of MH and QQ plots similarly to what I have 
explained for the GWAS results (see Chapter 4, page 46). The standard method for 
correcting multiple testing errors is also the Bonferroni method as 0.05 by the number of 
tested CpG sites. The replication and meta-analysis strategies described for a GWAS were 
also applied to the present MWAS.  
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Chapter 8. The MWAS strategy applied to TGP biomarkers 
 
8.1. Cohort studies 
The methylation-wide association study I conducted builds upon two different datasets, a 
subsample of the French MARTHA study and the French-Canadian F5L pedigree study. 
MARTHA 
For this analysis, I had access to a subsample of 350 VT patients from the MARTHA 
study were epigenetically-typed with the Illumina HumanMethylation450 array. These 
individuals were randomly selected from the 1,542 MARTHA patients that were typed for 
GWAS SNP data (Part I, page 55). 
French-Canadian F5L pedigrees 
The F5L pedigree study is composed of five extended French-Canadian pedigrees 
totaling 255 relatives. These pedigrees were ascertained through an idiopathic VT proband 
carrying the FV Leiden mutation and seen at the Thrombosis Clinic of the Ottawa Hospital. 
With the exception of harboring the FV Leiden mutation, the probands were free of inherited 
thrombophilia (AT, PC and PS deficiencies and homozygosity of FII G20210A and FV Leiden 
mutation) and without acquired VT risk factors such as cancer, myeloproliferative disease, 
pregnancy, puerperium, prolonged immobilization, trauma, surgery and antiphospholipid 
syndrome. Once the proband was identified, the size and structure (4-5 generations) of the 
family were recorded, and the five largest families were enrolled in the study whose detailed 
description can be found in Antoni G et al.28. A total of 255 individuals were then recruited 
and 214 with DNA available were epigenetically -typed for the same Illumina 
HumanMethylation450 array. 
8.1.1. Quality Controls of DNA methylation CpG probes  
The Methylation patterns of both MARTHA and F5L pedigree samples were analyzed at 
the Toronto Centre for Applied Genomics (TCAG, http://www.tcag.ca/) using the same 
protocol. The same quality control and normalization procedures as in section 7.2 (page 94), 
were simultaneously applied to both studies. Any probe with a detection p-value (as 
described in the "minfi" package) greater than 0.05 in more than 5% of the total processed 
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samples was excluded from further analyses. The consistency assessment between the 
"biological" sex phenotype and the methylation patterns on sexual chromosomes (page 102) 
led to the exclusion of 4 individuals in the F5L pedigrees study. 
The general filters and corrections applied are shown in Figure 8.1. A total of 388,120 
CpG sites were finally selected for further statistical associations with TGP biomarkers. 
 
Figure 8.1. Diagram of the filters used for the quality control of the probes. 
 
8.1.2. Clinical and biological characteristics of the discovery cohorts 
TGP biomarkers were measured in 238 MARTHA patients and 187 F5L pedigree 
members with DNA methylation data (Chapter 2, page 22). The same methods were applied 
to both samples and all measurements were done at the Laboratory of Hematology of the 
Timone Hospital (Marseille). The biological and clinical characteristics of studied samples are 
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shown in the following Table 8.1. extracted from my second manuscript (Rocanin-Arjo et al., 
page 120). 
Table 8.1. Population characteristics. 
 
MARTHA F5L-families 
 
N = 238 N = 187 
Mean age in yrs ± SD 43.9 ± 14.2 39.5 ± 16.8 
Males/Females 53/185 92/95 
VT patients (%) 238 (100%) 4 (2.1%) 
Heterozygote
+
F5 rs6025 68 (28.6%) 41 (21.9%) 
Heterozygote
+
F2 G20210A 35 (14.7%) - 
Contraception treatment 21/185 15/95 
log-vWF
1
 4.9 (0.37) 1.29 (0.48) 
BMI kg/m2 24.1 (5.4) 26.8 (5.9) 
ETP
2
 nM/min (1st-3rd) 1751.8 (1502- 1934) 1881.7 (1649-2068) 
Peak (nM) (1st-3rd) 320.5 (279.8-359.8) 339.3 (307.1-377.9) 
Lagtime (min) (1st-3rd) 3.09 (2.67-3.33) 3.16 (2.83-3.48) 
Correlations 
  
ETP*Peak 0.758* 0.809* 
ETP*Lagtime 0.036 -0.112 
Peak*Lagtime -0.107 -0.400* 
1
220 ind in MARTHA and 183 ind in FVL 
2
185 ind in FVL 
*p>0.05, VT, venous thrombosis; vWF, von Willebrand factor; BMI, body mass index. 
+ FV Leiden and F2 G20210A mutations were genotyped in MARTHA as part of the inclusion criteria. Homozygous carriers were not included in the 
study. 
 
 
 
8.1.3. Statistical methods and adopted research strategy 
For this MWAS project I adopted two research strategies: 
First, I performed a MWAS on each TGP biomarker in the MARTHA samples and 
selected for further replication in the F5L pedigree study any CpG sites that reached the 
genome-wide significant threshold of 1.29 10-7, which corresponds to the standard Bonferroni 
threshold for the number of tested CpGs (= 0.05 / 388,120). 
In a second step, I conducted a similar MWAS investigation in the F5L pedigrees and 
combined the results with those obtained in MARTHA through a random-effect meta-
analysis. The GWAMA program208 was used for the meta-analysis. 
Similar to the GWAS project (Chapter 5, page 55), ETP values were log-transformed 
before association analyses while a quantile normal transformation was applied to Lagtime, 
separately in each cohort (see Figure 8.2.). 
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Figure 8.2. Distribution of TGP biomarkers in MARTHA (purple) and F5L pedigree 
study (green). On top and from left to rigth: ETP, Peak and Lagtime raw data. On the 
bottom, the log transformed ETP (left) and the quantile transformed Lagtime (right) 
distributions. MARTHA in purle, 3C in green. 
 
 
In the MWA study, linear regression analyses were used to assess the influence of CpG 
site variability, as covariates, on each TGP biomarker, as the outcome. In the F5L pedigree 
study, a linear mixed-model accounting for the non-independence between family members 
was used. All analyses were adjusted for age, sex, contraception therapy, body mass index, 
and batch and chip effects. The two last variables correspond to microarray plate on which 
samples were processed and their position on the plate, respectively to account for 
experimental variability between position and plates209. Because DNA methylation levels 
measured in peripheral blood DNA reflect the average level of DNA methylation in different 
cell types including lymphocytes, monocytes, neutrophils, basophils and eosinophils, all 
analyses were also adjusted for cell type composition to avoid any contamination 
bias197,210,211. For MARTHA samples we used available specific biological counts of 
lymphocytes, monocytes, neutrophils, eosinophils and basophils to characterize their cell 
type composition. In F5L pedigrees the cell type counts were not available, however we 
handled adjustment for cell type composition using the method described in Koestler et al.212. 
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8.2. Strategy 1 MWAS findings 
Quantile-quantile (Q-Q) plots representing the results of the MARTHA MWAS performed 
on the three TGP biomarkers are shown in Figure 8.3. There was no observable deviation 
from what expected under the assumption of no association between CpG sites and TGP 
biomarkers. The corresponding genomic inflation coefficients were 1.004, 1.012, and 0.957 
for ETP, Peak, and Lagtime, respectively. Corresponding Manhattan plot representations of 
the 3 MWAS scan in MARTHA are shown in Figure 8.4. 
   
Figure 8.3. Quantile-Quantile graphics comparing the p-values resulted from the MWAS in 
MARTHA with the expected p-values. From left to right ETP. the second is Peak and the last 
Lagtime. 
 
None of the tested 388,120 CpG sites passed the Bonferroni correction threshold for 
declaring statistical significant association with ETP or Lagtime. The lowest p-values 
observed for these two phenotypes were p = 2.08·10-6 for CpG cg06613480 (SOX2OT locus) 
and p = 1.23·10-5 for CpG cg20240757 (PTH locus), respectively. On the other hand, 
genome-wide significance was reached for the association of CpG cg26285502 mapping to 
C15orf41 on chromosome 15 with Peak. A 1% increase in cg26285502 DNA methylation 
levels was associated with an 11.96 ± 2.12 nmol/L increase (p = 7.15 10-8) in Peak values. 
I then looked for replication of the cg26285502 association signal in the F5L pedigree 
study. Unfortunately, in this sample, a 1% increase in cg268285502 DNA methylation was 
associated with a non significant (p = 0.40) increase of 2.16 ± 2.57 nmol/Lin Peak values. 
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Figure 8.4. Manhattan plots from the MWAS results observed in MARTHA where 
388,120 CpG sites were tested for association with ETP (top), Peak (middle), and Lagtime 
(bottom). The horizontal line corresponds to the Bonferroni significant threshold taken at 
0.05/388120= 1.29 10-7. 
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Afterwards, following the "joint analysis" strategy I have applied for my GWAS project, I 
further focused on the CpG sites that demonstrated significant associations at p < 10-4 with at 
least two TGP biomarkers. There was no such CpG site sharing these features between 
Peak and Lagtime or between ETP and Lagtime. However, 7 CpG sites were associated at p 
< 10-4 with both ETP and Peak (Table 8.2.), and one was the C15orf41 cg26285502 probe 
discussed above. 
Table 8.2. CpG sites showing evidence for association at p <10-4 with both ETP 
and Peak in the MARTHA MWAS. 
     
ETP Peak 
CpG Chrom Position Strand Gene BETA (%) P BETA (%) P 
cg05970398 4 95129288 F SMARCAD1 0.054 (0.013) 8.62 10
-5
 19.53 (4.53) 2.71 10
-5
 
cg21583690 6 33385779 F CUTA 0.075 (0.018) 4.18 10
-5
 26.34 (5.99) 1.88 10
-5
 
cg24750156 12 58025315 F B4GALNT1 0.014 (0.003) 5.16 10
-5
 4.66 (1.10) 3.70 10
-5
 
cg24849736 1 201084428 F 
 
0.011 (0.002) 3.73 10
-6
 3.21 (0.76) 4.02 10
-5
 
cg25181043 20 47013841 R 
 
-0.007 (0.002) 1.63 10
-5
 -2.33 (0.53) 1.66 10
-5
 
cg26285502 15 36871420 R C15orf41 0.027 (0.007) 4.10 10
-5
 11.96(2.13) 7.15 10
-8 
 
cg26957150 7 50861739 R GRB10 0.015 (0.004) 3.01 10
-5
 4.85 (1.19) 6.99 10
-5 
 
I sought for replication of these additional promising signals in the F5L pedigree study. 
As illustrated in Table 8.3. below, but no signal was replicated. 
Table 8.3. Replication in the F5L pedigree study of the Table II.XX results observed 
in MARTHA. 
     
ETP Peak 
Sondes CHR Position Strand Gène BETA E(%) P BETA P(%) P 
cg05970398 4 95129288 F SMARCAD1 0.0054 (0.012) 0.6623 1.84 (4.27) 0.6672 
cg21583690 6 33385779 F CUTA -0.0120 (0.025) 0.6375 1.67 (8.87) 0.8510 
cg24750156 12 58025315 F B4GALNT1 -0.0037 (0.004) 0.2946 -1.15 (1.22) 0.3499 
cg24849736 1 201084428 F 
 
-0.0025 (0.003) 0.3300 -0.38 (0.89) 0.6684 
cg25181043 20 47013841 R 
 
0.0005 (0.002) 0.7964 1.01 (0.68) 0.1397 
cg26285502 15 36871420 R C15orf41 -0.0014 (0.007) 0.8530 2.16 (2.57) 0.4013 
cg26957150 7 50861739 R GRB10 -0.0080 (0.004) 0.0494 -3.04 (1.41) 0.0324 
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8.3. Strategy 2 MWAS findings 
In order to increase statistical power to detect CpG sites associated with any of the three 
studied TGP biomarkers, I further conducted a MWAS on each TGP phenotype in the F5L 
pedigree study and combined the results with those obtained in MARTHA in the framework 
of a random-effect meta-analysis. The resulting QQ plots and Manhattan plots are shown in 
the next two figures (Figure 8.5. and 8.6.). 
  
 
Figure 8.5. Quantile-Quantile graphics from the Meta analysis comparing the p-values 
resulted with the expected p-values. From left to right: ETP, Peak, and Lagtime. 
 
No novel CpG site associations genome-wide significants were revealed from the meta-
analysis of the two MWAS studies. The signal C15orf41 cg26285502 CpG discussed above 
(p = 2.51 10-8) was not observed. The best association with ETP was detected in the SDAD1 
cg27589582 probe with a p = 2.44 10-6 where a 1% increase in DNA methylation 
corresponded to a 0.087 ± 0.027 nmol min/L and a 0.086 ± 0.025 nmol min/L increase of 
ETP, in MARTHA and F5L pedigrees, respectively. For Peak, the probe with the lowest p-
value (p = 5.87 10-6) was the cg18197092 probe located in the chromosome 4, at the 
position 117,626,456 (a 1% increase in DNA methylation corresponded to 9.564 ± 3.3 
nmol/L and 12.147 ± 3.4 nmol/L decrease of Peak, in MARTHA and F5L, respectively). 
Finally, for Lagtime, the most significant result (p = 4.23 10-6) was observed with MITF 
cg06070625 CpG (a 1% increase in DNA methylation corresponded to 0.114 ± 0.049 min 
and a 0.127 ± 0.031 min increase of Lagtime, in MARTHA and F5L, respectively). 
 
8.4. Further analyses 
Given the known interplay between DNA methylation and sequence variants, I 
interrogated the results of my meta-GWAS project on TGP biomarkers (part I) to investigate 
whether there could exist some SNP at the C15orf41, SDAD1 and PTH loci with statistical 
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evidence for association with Peak, ETP and Lagtime, respectively. If such associations 
exist, this could provide additional support to my preliminary MWAS findings and guide us 
towards novel hypotheses of novel genetic factors. 
However, in my meta-analysis GWAS study for TGP biomarker performed in 1,967 
individuals, the strongest association of SNP at the C15orf41 locus (i.e., ±100kb from the 
CpG cg26285502) with Peak was rather modest, p = 1.63 10-3 at the rs34280623. The lowest 
p-value observed at the SDAD1 locus with respect to ETP was p = 0.026 for the 
rs112868025. Lastly, the rs147594032 was the SNP showing the strongest association with 
Lagtime at the MITFlocus (p = 0.036). 
To complete my MWAS investigations, I further looked into the results of the MWAS 
meta-analysis for CpG sites at the ORM1 and F2 loci, the main two loci identified in my 
GWAS project, with suggestive statistical evidence for association with TGP biomarkers. No 
probe mapping to ORM1 was available in the Illumina HumanMethylation450K array. 
Conversely, ten probes typed by this array mapped to the F2 locus. Unfortunately, none of 
them showed suggestive evidence for association with TGP biomarkers. The lowest p-values 
observed in the meta-MWAS analysis were p = 0.075, p = 0.118 and p = 0.061 for ETP, 
Peak and Lagtime, respectively. 
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Figure 8.6. Manhattan plots of the results from the meta-analysis of the MARTHA and 
F5L pedigree MWAS on ETP (top), Peak (middle), and Lagtime (bottom). The horizontal 
dashed line corresponds to the Bonferroni significant threshold taken at 0.05/388120= 1.29 
10-7. 
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8.5. Discussion 
The second part of my PhD project was to conduct a DNA methylome-wide scan to 
identify DNA methylation changes in relation to the plasma variability of three TGP 
biomarkers. Unlike my GWAS project, my MWAS strategy was less successful as I did not 
identify robust methylation signals associated with the studied phenotypes. Even after 
selecting probes by joint -analysis, the results were not significant. Several limitations can be 
addressed. 
- While extremely dense, the used Illumina array does not cover all sites of the genome 
that could be subject to DNA methylation. Therefore, we cannot exclude that some relevant 
methylation association were missed. 
- I restricted my MWAS investigations to single CpG site analysis. However, a multi site 
analysis of CpG located in the same region could be a more powerful approach. This could 
be particularly useful in presence of several correlated CpG sites, for example in promoter 
regions with high density of CpGs, similar to what is sometimes advocated in the context of 
association analyses of SNPs in LD. There are statistical methods for analyzing 
simultaneously several CpG sites in the context of MWAS: 
 Bump hunting213. 
 GAMP which a package designed to analyze of DNA methylation data including the 
combination of correlated p-values214. 
  Methods Comb-p combining p-values based on the Stouffer, S.A. approach 215 
 WGCNA to create networks based on the CpG sites obtaining functional related genes 
but far located from each other216 
However, they are not yet robust enough and have not standard methods to handle 
correctly this issue as it is done with haplotype analysis with SNP data. 
- According to an independent work performed by Dylan Aïssi217, another PhD student 
working under David-Alexandre Trégouët 's supervision, the sample size of the MARTHA 
MWAS is large enough to detect a 0.05 increase in DNA methylation β-value at the 
Bonferroni corrected threshold of 1.29 10-7. Whether an increase of smaller magnitude could 
be biologically relevant remains an open question, especially given that methylation was 
measured in peripheral blood DNA, which reflects the average DNA methylation level of 
different cell types. Therefore, the cell subtype and tissue specific methylation marks would 
show a weaker effect in whole blood compared to levels that could be observed in more 
effector cells relevant to thrombin generation.  
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- TGP technique was applied at the same laboratory for both MARTHA and F5L 
pedigree studies, and both were also typed for epigenetic patterns in another laboratory. 
Nevertheless, one cannot exclude heterogeneity caused by design differences between the 
two studies, decreasing our power to identify robust signals. 
In conclusion, as highlighted in my manuscript (page 120), it may be speculated that 1 - 
whole blood DNA may not be a good model for identifying differentially methylated regions 
associated with thrombin generation or 2- variability of DNA methylation levels measured in 
peripheral blood cells has weak effects on plasma levels of thrombin generation, effects that 
would require much larger sample size in order to be detected. 
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Introduction 
A complex cascade of coagulation proteins underlies hemostasis and prevents life-threatening blood 
loss from damaged blood vessels. Determining the inter-individual variability in plasma levels of the 
collective effect of these proteins is of great importance. In the last decade, agnostic genome-wide 
association studies have contributed to discovering novel genes and pathways associated with 
biomarkers of the coagulation cascade. However, the identified genetic factors account for a minor 
proportion of the heritability of these biomarkers, suggesting that other contributing factors remain 
to be identified. DNA methylation is one of the compelling sources that could contribute to the so-
called missing heritability of quantitative biological traits. DNA methylation is an epigenetic 
mechanism that participates in the regulation of gene expression, generally through gene silencing. 
Several key molecules participating in the coagulation pathway, such as von Willebrand Factor (1), 
factor VII (2) and factor VIII (3), have been shown to be under the influence of DNA methylation 
marks. While the former finding was observed in endothelial and kidney cells, the latter two were 
derived from the analysis of DNA methylation measured in blood. 
Intense discussions are emerging about the use of whole blood as a model tissue to discover 
methylation marks associated with biological phenotypes through methylation-wide association 
studies (MWAS)(4). In this context, we explored whether the whole blood DNA based MWAS strategy 
may help discover novel mechanisms associated with hemostasis regulation. We applied this strategy 
to quantitative biomarkers for thrombotic disorders characterizing the overall hemostatic status of 
individuals as evaluated by a global thrombin generation assay (5). 
 
Materials and Methods 
MARTHA study - We measured genome-wide DNA methylation in whole blood samples of 238 
individuals of the MARTHA study (6) using the dedicated Illumina HumanMethylation450 array. A 
detailed description of the quality controls and the normalization procedures applied to the 
methylation array data has previously been published (7). 
MARTHA subjects were assessed for a thrombin generation assay using the calibrated automated 
thrombography method (5) as extensively described in (8). Three biological biomarkers were derived 
from the thrombin generation potential (TGP) measurements produced by the assay: the 
endogenous thrombin potential (ETP),the lag time and peak height (Supplementary Table 1). 
A total of 388,120 CpG sites were then tested for association with three TGP biomarkers. For each 
TGP biomarker, association analyses were performed using a linear regression approach and 
adjusted for age, sex, oral contraception therapy, body-mass index, batch and chip effects (7) and cell 
type composition determined by specific biological counts of lymphocytes, monocytes, neutrophils, 
eosinophils and basophils. 
Any association that was genome-wide significant at the Bonferroni threshold of 1.29 10-7 
(=0.05/388,120) was sought for independent replication in the F5L pedigree study. 
 
F5L pedigree study - A total of 187 related individuals of the F5L pedigree study described in (9) were 
phenotyped for the three TGP biomarkers (Supplementary Table 1) with exactly the same protocol 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
3 
 
and by the same laboratory; and simultaneously processed for the DNA methylation array with the 
MARTHA samples. Association analysis of CpG sites with TGP phenotypes was performed using a 
linear mixed effect model accounting for the familial relatedness and adjusted for the same factors 
as in the MARTHA study. As cell counts were not available in the F5L pedigree study, we used the 
method described in (10) to adjust for cell type composition. 
Finally, a MWAS investigation was also carried out in the F5L pedigree study and the results were 
combined to those obtained in MARTHA through a random-effect meta-analysis using the GWAMA 
program (11). 
 
Results and Conclusions 
None of the tested 388,120 CpG sites was significantly associated with ETP or Lag Time at the 
Bonferroni threshold of 1.29 10-7. Conversely, one CpG, cg26285502, which mapped to C15orf41 on 
chromosome 15q14, reached genome-wide significance for association with Peak height (P=7.15 10-
8). A 1% increase in cg26285502 DNA methylation was associated with an 11.96±2.13nmol L-1 
increase (increase±SE) in adjusted Peak values. We sought to replicate this finding in an independent 
sample of 187 individuals of theF5L pedigree study. In F5L, a 1% increase in cg26285502 DNA 
methylation was associated with anon significant (P=0.40) increase of 2.16±2.57 nmol L-1increase in 
adjusted Peak values. 
In order to increase statistical power to detect variability in CpG sites associated with TGP 
biomarkers, we conducted a MWAS on each TGP biomarker in the F5L-pedigree study and combined 
the resultswith those obtained in MARTHA. A Manhattan plot representation of these results is 
shown in Figure 1. No novel CpG association signal emerged at the pre-specified genome-wide 
threshold. The smallest observed p-values were P=2.44 10-6 (SDAD1 cg27589582 ), P=5.87 10-6 
(cg18197092 mapping to a region with no gene on chromosome 4q26) and P=4.23 10-6 (MITF 
cg06070625) for ETP, Peak and Lag Time, respectively. 
Recently, it has been suggested that decreased levels of leukocyte DNA methylation at NOS3 and 
EDN1 genes could associate with higher ETP (12). We did not observe strong statistical support of 
these findings in our combined datasets. Indeed, the NOS3 CpG site showing the strongest 
association with ETP was the cg03469471 with combined p-value=0.165. For the EDN1 locus, the 
strongest association was observed with cg07714708 (p=0.031). However, this association was not 
consistent with the results observed in (12). In our samples, a 1% increase in cg03469471 DNA 
methylation was associated with a 5.42±2.50 increase in ETP (7.84±3.77 and 3.51±3.35 in MARTHA 
and F5L studies, respectively). 
To our knowledge, this work is the first large-scale epidemiological investigation of DNA methylation 
marks measured in whole blood in relation to quantitative traits of the coagulation cascade. Even 
though DNA methylation measured in blood reflects average DNA levels from different cell types, the 
application of the MWAS strategy in whole blood cells has been proposed to detect differentially 
methylated regions (DMRs). Coagulation-relevant DNA methylation marks detected in blood could 
reflect stronger effects from effector cells(7), such as hepatocytes and endothelial cells. Such an 
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approach may be particularly suited when access to relevant cell types/tissues is still not feasible at a 
large epidemiological scale. 
We observed a genome-wide significant association of DNA methylation levels at C15orf41 with Peak 
height variability in the MARTHA study but did not validate it in our replication study. C15orf41 was 
an interesting candidate as it has very recently been found mutated in patients with congenital 
dyserythropoietic anaemia (13). We investigated whether C15orf41 methylation levels could 
associate with biological criteria of anemia (red blood cells counts and hemoglobin levels)in MARTHA 
but did not observe any evidence for such associations (data not shown).Nevertheless, further 
investigations would be warranted to assess whether this original methylation signal was due to 
random fluctuations or could suggest unsuspected biological links between thrombin generation, 
C15orf41 methylation and anaemia. 
According to our previous work(14), our study was well powered to detect, at the statistical 
threshold of 1.29 10-7,any DNA methylation change explaining at least 6% of the variability of a 
quantitative trait. As a consequence, it may then be speculated that: 1- whole blood DNA may not be 
a good model for identifying DMRs associated with thrombin generation or 2- variability of DNA 
methylation levels measured in whole blood cells has weaker effects, if any, on plasma levels of 
thrombin generation, effects that would require a much larger sample size in order to be detected. In 
that perspective, the summary statistics derived from the meta-analysis of our two MWAS cohorts on 
TGP are available upon request for those who would like to combine their own results with ours. In 
addition, Illumina HumanMethylation450 array and TGP phenotype data from MARTHA participants 
used in this work are available in the ArrayExpress database (www.ebi.ac.uk/arrayexpress) under 
accession number E-MTAB-3127. 
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Figure Legend 
Meta MWAS results of MARTHA and F5L pedigrees. 
Manhattan plot representation of the results derived from the meta-analysis of 2 methylome-wide 
association studies assessing the influence of DNA methylation levels at 388,120 CpG sites on TGP 
biomarkersin 425 individuals. ETP (Top), peak height (Middle), and lag time (Bottom). The horizontal 
linecorresponds to the genome-wide significant threshold fixed at 1.29 10-7. 
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Chapter 9. General discussion, balance and perspectives 
 
My thesis project focused on the identification of new genetic factors and DNA 
methylation marks that could influence in Thrombin Generation Potential (TGP). TGP is a 
new promising test measuring the activation of thrombin during the coagulation process. This 
measurement is an appealing tool for investigating novel determinants of the thrombin 
activation cascade and of the physiopathological anomalies resulting from abnormal 
thrombin plasma levels. From a TGP measurement, a curve that displays the activation and 
production of thrombin throughout the time, it is possible to extract different biomarkers, the 
main ones being the endogenous thrombin potential (ETP), the total amount of thrombin 
produced after activation, the maximum amount of thrombin that can be produced at a given 
time (Peak); and the time that takes to start the thrombin production after activation 
(Lagtime). The objectives of my project were to identify new genetic and epigenetic factors 
contributing to modulate the inter-individual variability of these 3 biomarkers with the ultimate 
goals of better understanding the physiology of the thrombin activation cascade and, if 
possible, to bring new targets for diagnosis of coagulation/thrombotic disorders. 
My work was divided in two main parts according to my objectives. In the first part, I 
focused my research on screening the whole genome for finding novel common genetic 
polymorphisms associated with TGP biomarkers using a genome-wide association based 
strategy. Second, I sought for DNA methylation marks measured from peripheral blood DNA 
that could also influence TGP measurements using a methylome-wide association based 
strategy.  
My GWAS findings first confirmed that the main genetic factor controlling TGP 
measurements is the F2 gene coding for prothrombin with two SNPs, rs1799963 (G20210A) 
and rs3136516 (A19911G) independently influencing ETP and Peak plasma levels. The 
association of these two SNPs with TGP was already known before the start of my project. 
While the rs1799963 is also a well-established risk factor for venous thrombosis, the impact 
of rs3136516 on venous thrombosis is still debated even if some associations have been 
reported74,75. The most important finding of my GWAS project is the identification of the 
ORM1 gene as a new susceptibility locus contributing to Lagtime variability. This locus 
emerged from my GWAS not because it reached genome-wide significance but because it 
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exhibited strong association signal at p <10-5 with two TGP biomarkers, LagTime and ETP.  
But only the association with Lagtime robustly replicated in two additional independent 
studies. ORM1 codes for orosomucoid (also known as α-1-acid glycoprotein 1 or α-1-AGP) 
that is protein linked to inflammatory responses such as acute phase response or 
dermatitis145,146. However, it has also been studied in relation to the blood stream transporting 
proteins and may have a role in the initiation phase of coagulation as a transport protein147. 
Even though we demonstrated in vitro that increasing ORM1 levels in plasma is associated 
with increased Lagtime, there is a lot to be done to understand how ORM1 acts to influence 
Lagtime and which genetic variant(s) are the functional one(s) modulating Lagtime variability. 
Plasma orosomucoid levels are currently under measurement in the MARTHA12 study and, 
once completed, we will be able to assess whether the identified Lagtime associated ORM1 
SNP is associated with plasma orosomucoid levels. Of note, the allele frequency of the 
identified SNP was very homogeneous across the venous thrombosis patients and healthy 
individuals sample I studied suggesting that, even if influencing TGP measurement, the 
ORM1 SNP is not a candidate for venous thrombosis. The strategy I used and which led to 
the ORM1 findings clear illustrates the interest of widening the search for suggestive 
association signals among the SNPs that do not pass the genome wide significance 
threshold, pending the adoption of a clear and rational research strategy based on biological 
and/or statistical criteria. See for instance the project I initiated and that relies on a candidate 
genes strategy (Annex I, page 153). 
I have not fully exploited all the genetic information I had access to in my GWAS project 
and there are still some additional research paths to follow in order to detect novel genetic 
factors contributing to TGP variability. First, X chromosome SNPs were excluded from my 
GWAS project, as their analysis requires special care and methodologies153. This analysis 
could add novel insights since some key genes participating to the coagulation cascade (F8, 
F9) are located on the X chromosome. Second, it could be interesting to assess the 
existence of SNP x SNP interactions modulating TGP measurements. A large number of 
methodologies have been proposed to search for such interaction in the context of GWAS 
and none of them is considered as the panacea. Nevertheless, the strategy proposed by 
Deng218 to select for entering into pairwise interactions the SNPs exhibiting the strongest 
inter-genotype variability for a studied phenotype seems appealing. This strategy was the 
one that was successfully adopted by Nicolas Greliche, a former PhD student at INSERM 
UMR_S 1166, in the context of SNP x SNP interaction influencing monocyte gene 
expression219. 
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The second component of my PhD project was to conduct a methylome wide association 
study (MWAS) for TGP biomarkers on DNA methylation measured from peripheral blood 
DNA. This work was very original as such MWAS approach is just starting to emerge as a 
promising tool to identify epigenetic marks associated with complex traits. Unfortunately, this 
part of my work was not as successful as my GWAS project. I looked at both "methylome-
wide" significant results and suggestive associations with at least two TGP biomarkers, but 
was not able to detect any robust methylation signals in the two datasets I have access to. 
As already discussed in Part II, two main issues could explain why no such signal was found. 
This could be due to power considerations and additional samples with both TGP and 
methylome wide data similar to those I used in my project would be required to increase the 
size/power of the study. Second, while peripheral blood DNA has been shown to be a good 
model for studying human traits such as lipids and BMI, it may not be a good model for 
investigating DNA methylation marks associated with thrombin-related phenotypes. Studying 
DNA methylation in specific tissues or cell types with key roles in coagulation, such as 
hepatocytes or epithelial cells, would be likely more relevant. Conversely, it would much 
more difficult to have access to such data at a large-scale epidemiological level.  
The MWAS part of my work was partially independent of the GWAS component. Another 
strategy that deserves to be adopted would be to integrate the MWAS results to dig into the 
GWAS findings (or vice-versa) in order to improve the power to detect SNP associated with 
both methylation levels and TGP phenotypes. For example, the CpG - TGP association p-
values could be used as weight to prioritize the p-values of the SNP - TGP associations 
through stratified or weighted- false discovery rate approaches220,221.  
Finally, my GWAS and MWAS researches were conducted on three TGP biomarkers, 
ETP, Peak and Lagtime. From the global TGP measurement, it is also possible to extract 
other parameters such as velocity and time to peak (Chapter 2, page 26) that may bring 
additional information about the haemostasis dynamics of the coagulation response. It would 
then be interesting to apply the same GWAS and MWAS strategies to these two phenotypes 
or to multivariate phenotypes combining all 5 TGP biomarkers that could be derived for 
example through principal component analysis222. 
In conclusion, the study of thrombin physiology is not yet finished; new insights can be 
found thanks to thrombin generation potential that will help to understand its mechanisms, 
and hopefully, to better detect anomalies. 
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ANNEX 1 
 
 
Following the results of my metaGWAS analysis on TGP biomarkers, I further 
investigated whether SNPs located within some candidate genes showed suggestive 
evidence for statistical association with TGP biomarkers even if they have not reached 
genome-wide significance. Selected candidates were genes with strong support for 
association with venous thrombosis for which TGP phenotypes are risk factor. Nineteen 
genes derived from<sup>28,29,77,229</sup> were considered (Table A1.1). 
GENE CHR Start* End* 
FV 1 169431192 169605769 
AT_SERPINC1 1 173822938 173936516 
C4BPA 1 207227607 207368317 
PC 2 128125996 128236822 
PS 3 93541881 93742934 
KNG1 3 186385098 186512199 
FGG_FGA 4 155475286 155551897 
FXI 4 187137118 187250835 
HIVEP1 6 11962724 12215232 
BAI3 6 69295632 70149403 
STXBP5 6 147475494 147761612 
ABO 9 136080563 136200630 
FII 11 46690743 46811056 
vWF 12 6008040 6283836 
STAB2 12 103931069 104210502 
TC2N 14 92196266 92383880 
SERPINF2 17 1596130 1708559 
GP6 19 55475073 55599632 
PROCR 20 33709774 33815165 
Table A1.1 Candidate Genes list 
*Annotation corresponding to GRCh37/hg19 
 
At each candidate locus (± 50kb), I focused on SNPs with marginal association p-values 
(p < 0.05) with at least two TGP biomarkers and with consistent association between 
MARTHA and 3C. I further selected for replication in MARTHA12 the one with the lowest p-
values (Table A1.2). 
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Gene SNP ETP Peak LagTime 
     
BAI3 rs17691415 P = 1.59 10-4 P =0.0465  
     
C4BPA rs2012296 P = 0.014 P = 7.19 10-4  
     
F2 rs1799963 P < 10-16 P = 1.60 10-8 P = 0.034 
F2 rs3136516 P = 5.94 10-14 P = 2.92 10-8 P > 0.05 
     
F5 rs6015 P = 2.94 10-4 P = 4.05 10-7 P > 0.05 
F5 rs6025 P = 0.026 P = 3.46 10-4 P > 0.05 
     
FGG rs2066865 P = 2.46 10-4 P = 0.0212 P > 0.05 
     
PROS rs12629037 P > 0.05 P = 0.050 P = 1.52 10-3 
     
TC2N rs10138058 P = 0.040 P = 9.59 10-4 P = 0.012 
     
STAB2 rs2292687 P >0.05  P = 0.050 P = 2.04 10-3 
Table A1.2 Selected SNPs for replication 
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Abstract 
Thrombin Generation Potential (TGP) is a promising in vitro measurement that allows 
quantifying thrombin activity, in a close way to what happens in vivo. It is sensitive to coagulation 
factors deficiencies, anticoagulant proteins and is associated to thrombotic disorders. There 
exists two polymorphisms located in the F2 (prothrombin) gene known to influence TGP levels, 
and altogether they explain 11.3% of the TGP inter-individual variability. With the aims of 
identifying novel genetic and epigenetic factors that influence TGP variability, I have performed 
two different studies in the present work. First, I conducted the first genome-wide association 
study for the three TGP biomarkers (ETP, Peak and Lagtime) using imputation data from two 
French studies. The most significant single nucleotide polymorphisms (SNPs) were then 
replicated in two independent French studies. This analysis lead to the discovery of ORM1 as a 
new gene participating to the control of TGP. Second, I followed a similar strategy using this time 
whole blood DNA methylation levels at CpG sites to identify DNA methylation marks involved in 
TGP variability. I analyzed the association between methylation-wide patterns from a French 
study and a French-Canadian families measured for TGP. Unfortunately, I did not identify robust 
associations between whole DNA methylation levels and thrombin generation. 
Keywords: Thrombin Generation Potential, TGP, Meta-GWAS, ORM1, DNA Methylation, 
epidemiology.
 
Résumé 
Le potentiel de génération thrombine (TGP en anglais) est une nouvelle mesure qui permet 
de quantifier in vitro l'activité globale de la thrombine reflétant bien les mécanismes in vivo de la 
coagulation. Ce méthode de dosage est sensible aux déficits de facteurs de coagulation, à la 
prise d'anti-coagulants et à de nombreux troubles de la coagulation. Au moment où j'ai débuté 
ma thèse, seuls deux polymorphismes génétiques, tous les deux situés dans le gène F2 codant 
pour la prothrombine, étaient connus pour influencer la variabilité plasmatique du TGP. Mon 
projet de thèse avait pour objectifs d'identifier de nouveaux facteurs génétiques, mais également 
épigénétiques, pouvant influencer les taux plasmatiques de TGP. Dans une première partie, j'ai 
mené la toute première étude d'association génome-entier (GWAS pour Genome Wide 
Association Study en anglais) sur 3 biomarqueurs (temps de latence, quantité totale de 
thrombine produite et niveau maximal de thrombine produite) du TGP dans deux études 
françaises rassemblant 1267 sujets et j'ai répliqué les résultats les plus significatifs dans deux 
autres études françaises indépendantes de 1344 sujets. Cette stratégie a permis de mettre en 
évidence qu'un polymorphisme génétique du gène ORM1 était associé de manière robuste au 
temps de latence, biomarqueur caractérisant le temps nécessaire pour initier la coagulation 
après induction. Dans la seconde partie de ma thèse, en suivant une stratégie similaire mais 
cette fois-ci en étudiant non plus des polymorphismes génétiques mais des marques de 
méthylation d'ADN, j'ai recherché si des niveaux de méthylation de site CpG, mesurés à partir 
d'ADN sanguin et couvrant l'ensemble du génome, pouvaient être associés à la variabilité des 3 
mêmes biomarqueurs de TGP. Malheureusement, à partir de deux échantillons mis à ma 
disposition et rassemblant 425 sujets, je n'ai pas pu mettre en évidence d'association robuste 
entre des marques de méthylation sanguine et la génération trombine. 
Mots-clés: Potentiel Génération Thrombine, TGP, Meta-GWAS, ORM1, Methylation, 
épidémiologie.
 
